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ABSTRACT 
 
In recent years, a development of techniques and methods 
for detecting the presence of residues of substances with strong 
pharmacological actions in several animal matrices is carrying out. 
Additionally, an improvement of the analytical performances has 
allowed to achieve lower decision limits and capability of 
detection values, resulting in the ability to analyse the presence of 
analytes in extremely low concentrations (in the order of parts per 
trillion, ppt). 
The increase of the sensitivity permitted to detect the 
presence of substances that, under certain concentration levels, 
could be considered endogenous, even if they were defined only 
synthetically produced.  
Therefore, the analysis of substances that could be 
recognised as having a dual nature, both endogenous and 
exogenous, represents a challenge for researchers involved in the 
residue analysis. The presence of these substances in urine of 
animals (especially bovine, horses and pigs) could be a 
consequence of an illicit treatment, but also a result of endogenous 
production due to different factors, as stress, faecal contamination, 
ingestion of food containing precursors of the substances to be 
investigated. 
Currently, a debate on the origin in European of different 
analytes including, in particular, boldenone, prednisolone and the 
thiouracil, is ongoing. 
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The use of these substances in zootechnical field for illicit 
purposes of treatment in order to obtain an increase of the animal’s 
weight, is prohibited by European legislation because the presence 
of residues represent a risk for the consumers health. 
Despite the severe European regulations for the 
prohibition of the use of substances for fattening purposes in 
breeding, several cases of positive animals to these substances 
have been reported. However, considering the high number of non-
compliant samples, a hypothesis of abuse would be difficult to 
formulate. Consequently, the natural or endogenous origin was 
suggested for these substances. 
This thesis has the main aim to investigate the 
endogenous nature of two well-known semi-natural substances: 
boldenone, an anabolic steroid in urine of bovine, prednisolone in 
feedstuff for bovine and in urine and adrenal glands of pigs. These 
two steroids share a structurally analogy because both of them 
respectively differ from the most common steroid, testosterone and 
the corticosteroid cortisol for only one double bond in the first ring 
of the structure. 
The first work is focused on the development and 
validation of an analytical method for the direct determination of 
androstadienedione, free forms and conjugated forms of 
boldenone, whose is followed by a work performed in 
collaboration with the University of Torino (with the participation 
of the group of prof. Biolatti) to check the endogenous presence of 
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β-boldenone in urine of young bulls by the investigation of phase 
II metabolites (glucuronide and sulfate) under particular 
environmental conditions of stress. Surprisingly, no positive 
samples were detected in the most intense level of stress that was 
at the slaughterhouse. The study confirms the endogenous 
production of boldenone glucuronide and sulfate in the collection 
time corresponding to a low or zero level of stress (at the farm).  
The hypotheses that try to explain the presence of semi-
natural prednisolone in animals, as cattle, referring to an 
endogenous or a neo-formation ex vivo in urine of animals 
contaminated with faeces. However, the potential ingestion of feed 
containing prednisolone should be taken into account. Considering 
the limited literature, we wanted to analyse different commercially 
available complementary feedstuff for husbandry, stored in both 
farm and in controlled conditions in the laboratory to observe if 
the presence of the corticosteroid of our interest in the feed 
samples was due to environmental conditions of storage. Data 
obtained from our study confirm the crucial role of storage 
prednisolone was detected in almost all (95%) feedstuffs collected 
at the farm. 
The presence of prednisolone in urine, mainly due to 
stress, has been demonstrated in cattle, in horses and humans, but 
only one paper is available regarding pig. The fourth study of the 
present thesis has the purpose to detect the presence of 
prednisolone in urine of pigs collected at the farm and at the 
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slaughterhouse, where the adrenal glands were also sampled. 
Additionally, the presence of prednisolone was considered related 
to particular condition of stress for the animals. A second objective 
of the work was to verify a possible illegal treatment due to the 
presence of corticosteroids. The trial, funded by Regione 
Lombardia, has provided for the evaluation of the difference in the 
frequency of detection and concentration of corticosteroids in 
urine of animals at the farm compared to the urine of the same 
animals at the slaughterhouse. 
The work confirmed the presence of endogenous 
prednisolone in pigs, since found in most of the adrenal glands. 
Moreover, there was a relationship between the presence of 
prednisolone and cortisol in urine directly related to the intensity 
of the stress. In fact, the highest percentage of positivity to 
prednisolone in urine was collected at the time of slaughter. In the 
study, only one sample was considered suspicious for abuse 
prednisolone, given the high concentration in the urine sample. 
A further problem discussed in European laboratories 
regards the determination of cut-off levels of thyreostatic 
substances in urine and thyroids of bovine in order to define the 
natural origin.  
The analysis of thyreostats both in the thyroid and urine 
of bovine and the comparison of the results obtained in the two 
matrices could be a good way to satisfy this need. Therefore, the 
last part of the thesis concerns the development of a method for the 
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determination of five thyreostats: thiouracil, methylthiouracil, 
propylthiouracil phenylthiouracil and tapazole. 
Several methods have been published regarding the 
extraction procedures for thyreostats, but a derivatisation of the 
analytes prior to extraction, resulting in a possible loss of analytes, 
is generally performed. The methods developed and proposed in 
this thesis, allows the direct extraction of thyreostats without a 
derivatisation step and, since the extraction methods for the two 
matrices are very similar, allow a comparison between the results 
obtained in urine and thyroid glands. Therefore, the work carried 
out could be a great tool useful not only in the context of 
monitoring study, but also for research studies concerning the 
natural production of thyreostats. 
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RIASSUNTO 
 
Negli ultimi anni si è osservato uno sviluppo delle 
tecniche e metodologie per la ricerca di residui di sostanze ad 
azione farmacologica in diverse matrici animali. Il miglioramento 
delle performances analitiche ha permesso di raggiungere bassi 
livelli di rivelazione, quindi la possibilità di analizzare la presenza 
di analiti a concentrazioni estremamente basse (nell’ordine di parti 
per trilione, ppt). L’abbassamento dei limiti di sensibilità ha 
permesso di evidenziare la presenza di sostanze che sotto 
determinati livelli di concentrazione possono essere considerate 
endogene. Una sfida per coloro che si occupano di analisi di residui 
è quindi la ricerca di sostanze che possiedono una duplice natura 
e, che sotto certe condizioni, possono essere ritenute endogene o 
possono essere considerate semi-naturali perché prodotte 
dall’animale in seguito a vari fattori come ingestione di alimenti 
contenenti precursori delle sostanze da indagare.  
Attualmente, è in corso un dibattito a livello europeo 
sull’origine di diversi analiti, tra i quali, in particolare, il 
boldenone, il prednisolone e il tiouracile. L’uso di tali sostanze in 
campo zootecnico per scopi illeciti di trattamento, al fine di 
ottenere un aumento del peso degli animali, è vietato dalla 
legislazione europea poiché i residui, presenti nei prodotti di 
origine animali, rappresentano un rischio per la salute del 
consumatore. Nonostante la ferrea regolamentazione europea per 
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il divieto in allevamento dell’uso di sostanze a scopi auxinici, 
diversi casi di animali positivi a tali sostanze sono stati riportati 
ma, considerato l’elevato numero di positività tale da non poter 
collegare la presenza della sostanza a un abuso, è stata proposta 
l’ipotesi di origine endogena o semi-naturale.  
La presente tesi vuole andare ad indagare la natura 
endogena o semi-naturale di due note sostanze: il boldenone, 
steroide anabolizzante, nell’nell’urina di vitellone da carne; il 
prednisolone nell’urina e ghiandole surrenali del suini. entrambi 
steroidi che differiscono dai più noti testosterone e cortisolo per la 
presenza di un solo doppio legame nel primo anello della loro 
struttura. 
Il primo lavoro verte sullo sviluppo e validazione di un 
metodo analitico per la diretta determinazione di boldenone 
coniugato e libero e androstadienedione, a cui segue un lavoro 
realizzato in collaborazione con l’università di Torino con la 
partecipazione del gruppo del prof. Biolatti, per verificare la 
produzione endogena di β-boldenone attraverso la determinazione 
dei metaboliti di II fase, glucuronato e solfato, in urina di vitelloni 
sottoposti a particolari condizioni ambientali di stress. Lo studio 
condotto ha confermato la presenza endogena dei coniugati del 
boldenone in condizioni di assente o relativamente basso stress, 
mentre non è stata osservata alcuna positività al boldenone solfato 
e glucuronato nei campioni prelevati al macello, quando gli 
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animali sono sottoposti ad elevati livelli di stress dovuto alle 
diverse procedure che anticipano la macellazione. 
Le ipotesi che cercano di spiegare la presenza semi-
naturale di prednisolone in animali come i bovini, fanno 
riferimento ad una produzione endogena o una neo-formazione ex 
vivo nelle urine di animali contaminate dalle feci. Tuttavia, anche 
la possibile ingestione di mangime contenente prednisolone 
dovrebbe essere considerata. Considerate le scarse informazioni al 
riguardo, abbiamo voluto analizzare diversi mangimi 
complementari disponibili in commercio e conservati sia in 
azienda agricola che in condizioni controllate in laboratorio per 
verificare se l’eventuale presenza di steroide nel mangime fosse 
dovuta alle condizioni ambientali di conservazione I dati ottenuti 
confermano il ruolo determinante delle modalità di conservazione 
poiché la quasi totalità di campioni risultata positiva al 
prednisolone è stata campionata in azienda. 
Ad oggi, la presenza di prednisolone nelle urine come 
esito di produzione endogena o correlata a una condizione di 
stress, è stata dimostrata nel bovino, nel cavallo e nell’uomo, ma 
scarse informazioni si hanno relativamente al suino. Il quarto 
lavoro della presente tesi riguarda la determinazione della 
presenza di prednisolone in urine di suino prelevate in allevamento 
ed in urine e ghiandole surrenali campionate in macello e di 
stabilire se la presenza di prednisolone fosse correlata a condizioni 
di stress per l’animale o a un trattamento illecito. Un secondo 
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obiettivo del lavoro svolto è stato quello di verificare un possibile 
trattamento illecito dovuto a presenza di corticosteroidi. La 
sperimentazione, finanziata dalla Regione Lombardia, ha previsto 
la valutazione della differenza nella frequenza di ritrovamento e 
nella concentrazione del corticosteroide nelle urine di animali in 
allevamento rispetto alle urine degli stessi animali al macello. Il 
lavoro ha confermato la presenza endogena di prednisolone nel 
suino, in quanto riscontrato nella maggioranza delle ghiandole 
surrenali. Inoltre, è stata osservata una relazione fra presenza di 
prednisolone e cortisolo in urina direttamente correlata alla 
intensità della stress. Infatti, la percentuale maggiore di positività 
al prednisolone nelle urine è stata verificata in sede di macello. 
Nello studio, il sospetto di un eventuale abuso prednisolone è  stato 
avanzato solo per un animale a causa dell’elevata concentrazione 
dell’analita nel campione di urina. 
Un ulteriore problema dibattuto nei laboratori europei 
riguarda la determinazione di un livello di cut-off del tiouracile in 
urina e tiroidi per definirne l’origine naturale. Verificare la 
presenza di tireostatici nella tiroide dei bovini e confrontare i 
risultati ottenuti mediante l’analisi delle urine, potrebbe essere un 
buon metodo per rispondere a questa esigenza. Pertanto, l’ultima 
parte della tesi riguarda lo sviluppo di una metodica per la 
determinazione di cinque tireostatici, tiouracile, propiltiouracile, 
metiltiouracile, feniltiouracile e tapazolo. 
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Diversi metodi sono stati pubblicati riguardo le modalità 
di estrazione dei tireostatici, ma è pratica comune eseguire una 
derivatizzazione degli analiti prima della loro estrazione, 
comportando una possibile perdita degli analiti stessi. Il metodo 
che è stato sviluppato e inserito nella presente tesi, permette 
l’estrazione diretta di tireostatici senza condurre una 
derivatizzazione e permette un confronto fra i risultati ottenuti con 
i due metodi. Quindi, il lavoro condotto potrebbe essere un ottimo 
strumento non solo in un contesto di monitoraggio, ma anche per 
le ricerche incentrate sull'origine naturale di tireostatici. 
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CHAPTER 1 
Introduction 
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1.1 Food Safety in livestock 
News on the quality of the meat on the market seem to 
confirm a negative role of the globalisation on several production 
fields, and a condition of risk for the consumer’s health. The public 
awareness regarding problems of food, breeding and treatment of 
the animals is now arising; therefore, when on March 17, 2015 
several Italian newspapers have reported the following news, no 
one was surprised: “from early morning hours, an operation of 
N.A.S. (Nucleo Anti Sofisticazione) in various intensive farming 
of dairy cows of Northern Italy is ongoing. People under 
investigation are considered responsible for the illegal trade and 
use for animal breeding of veterinary drugs. A total amount of 55 
kg of illegal drugs was found. In 2014, a first investigation had 
already thrown light on a spread illicit trading of bovine growth 
hormone or, best known as somatotropin, from non-European 
countries and sold to breeders of dairy cattle along with other 
veterinary drugs derived from the illegal market and illegally 
introduced in Italy. The aim to use this kind of substances was to 
obtain an increase of 20% in milk production. Consequently, it 
means a prosecution for falsification and sale of adulterated food 
substances. The Financial Police raided the stables where doping 
substances were administered, seizing 845 veal calves, mainly of 
the Belgian Blue breed. The Financial Police found bottles 
containing 17-oestradiol benzoate, an anabolic and substance 
 19 
with carcinogenic activity. Bovine urine samples analysed resulted 
non-compliant for the presence of the anabolic compound above 
cited. After slaughter, histological analyses were also performed. 
The results showed the presence of metaplasia in the sexual glands. 
Finally, drugs without the obligatory approval were found. The 
payment of a penalty of 109 000 € for violation of regulations 
relating to pharmacovigilance has been imposed to the farmers” [1]. 
Despite the cited news, according to the report published in June 
25, 2015 by the Italian Ministry of Health, almost all bovine 
samples analysed for the routine control were compliant. Out of 40 
806 samples tested according the requirement of the NRP 
(National Residual Plan), only 44 samples showed irregularities. 
16 276 out of 40 806 samples were analysed for the detection of 
residues of unauthorized substances and only a percentage of 
0.11% resulted non-compliant. Of these, 15 are resulted non-
compliant for the presence of residues of category A of 
unauthorized compounds (34.1 %) and 29 for the detection of 
residues of substances in category B of Veterinary drugs and 
contaminants (65.9%) [2].  
However, the Italian husbandry should not be 
criminalized in total, because the conditions of foreign breeding 
are often more extreme than the Italian ones. In the United States, 
for example, the use of growth promoters is allowed and the 
treatment are commonly made [3, 4]. It is well known the elevated 
costs for breeding could cause difficulties to the farmers, who do 
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not consider the animal as only a machine producing milk and 
meat, and they do not want to give “junk food” to the consumers. 
In order to guarantee the farmers, the animal’s heath and, 
in particular, the consumer’s health, it is necessary to apply a 
sophisticated system of Food Safety, because the research of 
chemicals and hormones in meat or in another matrices, as the 
substances identified in the trafficking reported, are very difficult 
due to the number and differences of active compounds to 
investigate. Today, questions of Food Safety are at the centre of 
the International and Community scientific debate, because 
substances, such as veterinary drugs, are ones of the most 
important chemicals hazard in food of animal origin. Veterinary 
drugs, as other chemicals, are potentially dangerous based on their 
degree of pharmacological activity and capability of remain in 
foods as residue. The possible accumulation of these drugs or their 
metabolites in edible tissues may establish and increase the risk of 
exposure for consumers [5].  
De Brabander has given a clearer, but generic explanation 
of residue in a detailed review, “a residue is a trace of a substance, 
present in a matrix after some kind of administration” [6]. More 
precisely, Codex Alimentarius Commission defined the residue as 
following: “Residues of veterinary drugs include the parent 
compounds and/or their metabolites in any edible portion of the 
animal product, and include residues of associated impurities of 
the veterinary drug concerned” [7].  
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Nevertheless, there are some endogenous substances with 
a threshold level due to their natural origin, as the corticosteroids, 
and other molecules, whose exogenous origin is now into question 
and are complicated challenge for the Health Authorities [8].  
As established by the famous sociologist Ulrich Beck, the 
modern society is a risk society that contributes to the development 
and making of a global risk. The role of every Member States and, 
particularly of Health Authorities, is to manage and, possibly, 
decrease the risks existing at the various levels [9, 10].  
In this context, the Food Safety is becoming one of the 
most important questions to be addressed. It can be divided into to 
the categories of Food Safety and Food Security, on a matter of 
supplying and food self-sufficiency of the company or of national 
communities that invoke. Food Safety is an umbrella term that 
encompasses many facets of handling, preparation and storage of 
food to prevent illness and injury. Included under the umbrella are 
chemical, microphysical and microbiological aspects of Food 
Safety. Food Security has been defined by the Food and 
Agriculture Organization (FAO, 2003) of the United Nations (UN) 
as; "Food security exists when all people, at all times, have 
physical, social and economic access to sufficient, safe and 
nutritious food which meets their dietary needs and food 
preferences for an active and healthy life. Household food security 
is the application of this concept to the family level, with 
individuals within households as the focus of concern" [11].  
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In its turn, Food Safety can be subdivided into many 
different levels, whose one of the most important is the Risk 
Analysis, defined for the purposes of the Codex Alimentarius 
Commission as "A process consisting of three components: risk 
management, risk assessment and risk communication" [12-15] .  
The use of hormonal growth promoters in food-producing 
animals evokes fears and is dangerous for human health. More 
information and a better knowledge on human health risks are 
essential and necessary to establish regulation on the use of drugs 
and control programs. Risk assessments and management, with 
their plethora of levels and components, as hazard identifications, 
hazard characterizations, exposure assessments, and risk 
characterizations, play a major role in order to guarantee of Food 
Security and Food Safety and, at the end, to protect and preserve 
public health [5].  
A new challenge for the scientist is to evaluate the so-
called pseudoendogenous or semi-natural substances or the “grey-
area substances” that have double nature of endogenous but also 
exogenous substances. The task of the scientist is to detect the 
abuse of these substances, known to be endogenous in certain 
conditions. One difficulty arises from the fact that when they are 
defined as products naturally in a particular type of animal, a 
simple qualitative evidence of their presence does not necessarily 
prove the abuse.  
Furthermore, a threshold of these compounds should be 
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established with the aim to distinguish a condition of illicit 
treatment from a natural production, depending on the sensibility 
and specificity of the instruments by which the analyses are 
performed [8].  
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1.2 Anabolic Androgenic Steroids 
The term anabolism originates from Greek ἀνά "upward" 
and βάλλειν "to throw" and it is a metabolic pathway by which the 
formation of the molecules is achieved. More specifically, the 
anabolism is chemically defined as any state in which nitrogen is 
differentially taken in slender body mass by stimulation of protein 
synthesis or decreased breakdown of protein in several parts of the 
body [1,2] . 
Testosterone (T) is the principal steroid hormone 
expressing anabolic proprieties and all substances having steroidal 
structure, similar for its anabolic features and derived from T are 
known as Anabolic Steroids [2]. The ability to influence the 
development of secondary sexual characteristics permits to define 
them also as Anabolic Androgenic Steroids (AAS) [3]. 
“Play true” is the motto adopted by the World Anti-
Doping Agency (WADA) for the awareness campaign against the 
using of doping of banned athletic performance-enhancing drugs 
in sports. However, the abuse of these drugs is widely and covertly 
spread and it is not only a prerogative for the ironman athletes in 
any disciplines of top-class sports, but it also common in the 
smallest gym, widespread from young people to seniors. Among 
the prohibited chemicals substances, included in the WADA 
Prohibited List 2015, the AAS, collectively classified as 
“appearance and performance enhancing drugs” (APEDs) are in 
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the main position by relevance [4,5].  
1.2.1. Chemistry and biosynthesis  
The AAS have lipophilic characteristics and low-
molecular weight. Steroids share a basic structure, consisting of a 
skeleton nucleus, cyclopentenoperhydrophenanthrene that derived 
by the fusion of four rings from the parental compound cholesterol, 
as reported in Figure 1. 
 
Figure I-1. Chemical structure of cyclopentanoperhydrophenanthrene (A) and 
cholesterol (B). 
In males, T is the main circulating androgen hormone and 
it is mostly produced by the Leydig cells of the testis, and less than 
10% is synthesized in the zona reticularis of the adrenal cortex. In 
female, the course of production of T is principally achieved in the 
cells of the adrenal cortex and less in ovaries and placenta. T is a 
C19 steroid with an –OH group in the 17 position; its chemical 
structure is shown in Figure 2 [3]. 
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Figure I-2. Chemical structure of testosterone. 
In blood, T is reversibly bound to two plasma proteins, 
the sex hormone–binding globulin (SHBG), wherewith has a high-
affinity steroid-specific interaction (65%), and with low affinity to 
the albumin. About 2% of T remains free and available for the 
interaction with receptor cells.  
The biosynthetic pathway of T (Figure 3), as the other 
steroid hormones, required cholesterol whose side chain is cleaved 
by 11- and 21- hydroxylases of inner membrane, i.e. the 
mitochondrial cytochrome P450 enzyme (CYP11A), in order to 
form pregnenolone with the loss of six carbon atoms. Then, 
pregnenolone is hydroxylated in its 17 position and the cleavage 
of the side chain gives dehydroepiandrosterone (DHEA). DHEA 
can be peripherally converted to androstenedione (AED) 
(oxidation of 3-OH), T, and dihydrotestosterone (DHT), and 
aromatized to oestrogen. [3].  
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Figure I-3. Pathway of testicular testosterone synthesis. 
1.2.2. Hypothalamus-Pituitary-Gonadal Axis 
The control and the regulation of the production and 
secretion of T is carried out through an active feedback interaction 
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among the hypothalamus, pituitary, and testis, called 
Hypothalamus-Pituitary-Gonadal Axis, reported in Figure 4. 
 
Figure I-4. Steroids regulation pathway. 
The gonadotropin-releasing hormone (GnRH), 
synthesized by the hypothalamus, is released in a pulsatile way 
into the hypothalamic-pituitary portal system and stimulates the 
release of the pituitary gonadotropins luteinizing hormone (LH) 
and follicle-stimulating hormone (FSH). These gonadotropins, 
henceforth, influence the cells of the testicles to regulate T 
synthesis and spermatogenesis, respectively. A negative feedback 
is carried out at both the hypothalamic and the pituitary levels 
when there is an increase of T levels in serum. In this circumstance, 
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the T is converted to DHT and aromatized into oestradiol in the 
hypothalamus. Therefore, both androgens and oestrogens steroids 
can influence and modulate the release of the GnRH at the two 
levels, both at the hypothalamus and at the pituitary levels. 
Particularly in testis, another protein hormone, known as inhibin, 
is produced. This protein modulates in a negative manner the FSH 
secretion and it is present in ovarian follicles of female. In female, 
LH stimulates, together with prolactin, ovulation and the 
conversion of the ovarian follicle into the corpus luteum. Indeed, 
during the development of the follicle, LH stimulates T and it is 
inhibited by the oestradiol and progesterone secretion [3]. 
1.2.3. Mechanism of Action 
T exerts its action by the binding to an intracellular 
receptor. This complex binds to specific site of sequence of DNA 
in the nucleus, enabling the transcription of androgen-responsive 
genes; then a 5α-reductase converts T to DHT in target cells. 
There is also DHT circulating in the blood that is about 10% of 
the T level. After the conversion to DHT, the hormone binds to a 
receptor protein in the nucleus and this complex is activated and 
binds receptor on the nuclear matrix, causing a chain of reactions 
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as protein synthesis and cellular metabolism [3, 6].  
1.2.4. Metabolism, degradation and excretion of 
androgens 
The metabolism of AAS occurs in two phases, I and II in 
order to convert them into more polar molecules and to simplify 
their elimination. In the Phase I reactions, steroids are changed into 
more polar compounds from the body by enzymatically catalysed 
reactions (e.g., oxidation, reduction, or hydroxylation), while 
Phase II reactions or conjugation reactions, involve the addiction 
to the anabolic steroid or its metabolite of glucuronic acid or 
sulfate moiety [7]. The elimination of plasma T occurs principally 
in the liver, where it is rapidly metabolised into androstenedione 
(AED) and dehydroepiandrosterone (DHEA) and conjugated as 
water-soluble compounds either glucuronides or sulfates 
(glucuronides, particularly) and then excreted by the kidney as the 
urinary 17-ketosteroids or into the gut by way of the liver and bile 
[3].  
1.2.5. Anabolic androgen steroid actions  
T and other androgen steroids mainly exert two effects on 
the organism, the anabolic and the virilising effects, but they also 
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exert an inhibitory feedback effect on pituitary LH secretion. The 
AAS actions are below summarised (Figure 5): 
 Androgenic effects - Androgens permits 
the formation of secondary sex characteristics, including 
changes in hair distribution, body configuration, and 
genital size that develop in boys at puberty. 
 Anabolic Effects - Androgens cause 
masculinising and increase of muscle mass trough an 
increase of the protein anabolism, and increased bone 
density and strength, and stimulation of linear growth and 
bone maturation. Secondary to their anabolic effects, 
androgens cause modest electrolyte retention [7].  
 
Figure I-5. Effects of anabolic androgenic steroids. 
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1.2.6. Anabolic steroid in livestock and legislation 
aspects 
A leitmotiv of the Food Safety is to guarantee the 
consumer’s heath through a monitoring “from the farm to fork”, or 
the entire food chain. However, socio-economic reasons, 
correlated to the high costs of the livestock management, could 
contribute to enlarge the use of additives, as vitamins, antibiotics 
or steroids, added to animal food in order to improve breeding 
efficiency, and guarantee a production in concordance with the 
market requirements. Moreover, it is true that the abuse of these 
substances in the black market might not be excluded. Residues of 
chemicals might be present in edible matrices and exert dangerous 
actions of different levels of toxicity, hence representing a health 
hazard. 
In 1977, breast augmentation in young girls and boys in 
an Italian school was reported as consequence of contaminated 
meals with oestrogens. This event put attention on the health 
hazards correlated to the residues of drugs in products of animal 
origins and generated interest for the drafting of severe rules 
concerning the regulatory and, consequently, prohibition of the 
treatment with anabolic substances [8]. 
In 1980, an amount of 30 000 jars of baby food was found 
positive for the presence of diethylstilboestrol due to the treatment 
of French veal calves. At the beginning of the 80s, the EC 
Commission proposed strictly stance concerning the hormones, 
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which should have been completely forbidden, except for these 
compounds used for therapeutic aims [9].  
Therefore, with the purpose to ensure the health of the 
consumer, in conformity with the Directive 81/602/EEC, the 
European Union fixed the prohibition of the use of any growth 
promoter compounds, i.e. anabolic steroids from meat production 
in 1981 with a “zero tolerance” limit [10]. Among the substances are 
including 17β-oestradiol, T and esters, progesterone, zeranol, 
trenbolone, trenbolone acetate and melengestrol acetate. In 
compliance with the directive, the treatment of farm animals with 
substances express anti-thyroid activity and oestrogenic, 
androgenic or gestagenic action, the marketing of meat from 
treated animals and their slaughter are forbidden.  
The Directive 81/851/EEC has laid down common 
requirements for manufacturing and marketing authorisation, 
based on the evaluation of the quality, safety and efficacy of the 
product. Moreover, it required that only official veterinarian could 
administrate drugs for therapeutic treatments that have to be 
registered by the veterinarian responsible [11].  
The prohibitions on the use of such substances, on the 
trade of treated animals within the EU, and on the import from 
third countries was set in 1988 and then spread out to all EU 
member States, and to meat imported from other States [12, 13]. 
Directive 96/22/EC of 29 April 1996 (concerning the prohibition 
on the use in stockfarming of certain substances having a hormonal 
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or thyreostatic action and of ß-agonists) confirmed the ban use of 
steroidal hormones with promoting growth purpose in animal 
husbandry. The Council Directive 96/23/EC of 29 April 1996 (on 
measures to monitor certain substances and residues thereof in live 
animals and animal products) completely prohibited steroidal 
hormones as anabolic androgenic substances, including them into 
the into the A3 section (Anabolic Androgenic Steroids) as regards 
the production of animal origin and the livestock. The Category A 
includes substances with anabolic effect and unauthorized 
substances for the treatment of the animals in order to induce an 
increase animal weight and the group involves the “no maximum 
residue limit (MRL)” substances. In the Group A, substances are 
divided into four major groups: anabolic steroids, thyreostats, β-
agonists or repartitioning agents and Annex IV substances. Group 
B encloses the veterinary drugs or veterinary medicinal products: 
antibacterial substances, anthelmintics, coccidiostats, carbamates 
and pyrethroids, sedatives, non-steroidal anti-inflammatory drugs 
and other pharmacologically active substances [14, 15]. 
In 2003, the European Communities amended the 
Directive 96/22/EC, approving the Directive 2003/74/EC 
regarding the definitely prohibition of the use of hormones in 
livestock [16].  
Regarding the individual States, already before 1981, the 
use of hormones had been banned. In Italy, the legislation 
forbidden their use since 1961, in Denmark since 1963, while 
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Belgium and Greece had never permitted the use of hormones for 
fattening aims. Otherwise, countries outside Europe, as the in the 
United States, Canada, New Zeland, Australia, in some states of 
South America and Africa, substances having the effects to 
improve weight gain and feed efficiency in livestock farming are 
allowed. Particularly, United States, permit the use of steroid 
hormones, as testosterone, 17ß-oestradiol and progesterone, and 
synthetic hormone-like trenbolone, zeranol and melengestrol 
acetate. In United States breeding is approved their use as active 
component of solid ear implants (17ß-oestradiol in the ester form 
of benzoate, testosterone - as propionate, progesterone, trenbolone 
acetate and zeranol) and as feed additives, melengestrol acetate 
(MGA) for feedlot heifers [9, 17]. 
1.2.7. Administration of hormones in cattle 
The hormones are characterized by low bioavailability when 
administered orally; then in the body, they are rapidly conjugated 
and undergo to metabolic transformation in the liver. Generally, 
hormones are administered by subcutaneous implantation near 
the ears (that are discarded in slaughter), which permit to avoid 
the possibility of the presence of their residues in edible tissues. 
The subcutaneous implantation is consisting of continuously 
releasing steroid pellets in the ear (or less frequently, the dewlap) 
in order to guarantee a gradual and slow release of a fixed dose of 
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drug. The treatment can be carried out by using either free form 
or esters forms of steroids; in particular, steroids are usually 
administered as synthetic ester, mostly as propionic or benzoic 
acid, but also undecanoate or undecylenate. Esterification 
normally determines an increase of the half-life of the steroids by 
40 to 50% [9, 18]. 
A problem in the detection of the synthetic steroid is that they are 
quickly hydrolysed in vivo into natural steroids, and in urine, the 
detectable metabolites of synthetic steroid are the same of the 
natural ones [19]. In cattle, the use of hormones is done to veal 
calves and beef (steers and heifers). The treatment with steroids 
could be performed with a single steroid or in combination with 
other hormones in order to improve the efficiency of the steroid 
[9].  
1.2.8. Boldenone: endogenous or exogenous? This is the 
problem 
In the European Union, the use of steroid hormones as 
growth promoters for animals is strictly prohibited, as mentioned 
above. Since the early 80s, several methods have been developed 
in order to detect the presence of residues of these substances in 
meat and other matrices with particular attention to the xenobiotic 
drugs and to anabolic substances having a urinary threshold level 
due to their natural origin or to drugs permitted only for 
 39 
therapeutically treatment, as corticosteroids. This plethora of 
substances poses a challenge for researches and casts doubt on the 
origin of different substances that Wim Van Thuyne defined in his 
Ph.D. thesis as “grey-zone substances” [20]. This concept was well 
defined in a clear review published in 2009 by Scarth et al., where 
the Authors explained that the task is to identify the illicit abuse of 
exogenous hormones, synthetically produced, that “are also 
known to be endogenous under certain conditions, dubbed 
“pseudo-endogenous” or “grey-zone substances” due to their 
dual synthetic/endogenous nature”. Based on these considerations, 
certain elements of discussion on the existence of natural 
compounds, previously considered as only xenobiotic substances, 
could be laid. As indicated by the Authors, most of the steroid 
preparations consist in esters of endogenous steroids that are 
quickly hydrolysed in urine or plasma to the free endogenous 
forms and only for few exceptions (hair and injection/implant 
sites), the direct detection as proof of abuse of these esters 
compound is possible and can confirm an illicit treatment. 
However, “Where particular steroids are believed not to be 
endogenous in an animal at a particular limit of detection (LOD), 
who is to say that as analytical limits decrease, they will not be 
discovered as endogenous at a lower concentration?” [21]. The 
case of boldenone, as well as other 1-dehydro steroids (i.e. 17β-
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19-nortestosterone or nandrolone, prednisolone) are perfect 
examples of this problem.  
1.2.9. Chemistry of boldenone 
Boldenone (1-dehydrotestosterone or (17β)-17-
Hydroxyandrosta-1,4-dien-3-one) or 17β-boldenone (β-bold) is 
one of the most famous anabolic steroid on the market, known for 
its anabolic properties, is common used in different preparations 
as ester forms by athletes to increase muscle mass and improve 
sports performance, but it is prohibited in sports [22, 23].  
β-bold is structurally different from T (androsta-4-ene-
17β-ol-3-one) for the dehydrogenation of the carbon in the first 
position. The chemical structure of the analyte, including the 
structure of its epimer, 17α-boldenone (or -bold,) are shown in 
Figure 6 [23]. 
 
Figure I-6. Chemical structure of α -and β-boldenone. 
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β -bold was synthesised for the first time in 1956 by the 
dehydrogenation of T using selenium dioxide [24]. It is 
commercially available as ready-to-use anabolic preparations 
either for human, horse or cattle particularly by injection as ester 
forms, whose the principal is the undecylenate (or undecanoate), 
but also orally as boldione or Androstadienedione (androsta-1,4-
diene-3,17-dione, ADD), the oxidised precursor of boldenone. 
Examples of boldenone undecylenate used in medical treatments 
for veterinary use are the following: the Equipoise for horses 
(Equipoise®), cattle and dogs for Ganabol® Venobol® [25]. 
Like the other androgenic steroids, β-bold is classified by 
the International Agency for Research on Cancer (IARC) as a 
probable human carcinogen, with a carcinogenicity index higher 
than that of other androgens, such as nandrolone, stanozolol, T [26]. 
A recent study has also demonstrated the role of -bold in the 
development of human prostate carcinomas implanted in mice [27]. 
1.2.10. Endogenous presence of boldenone  
Despite the European legislation avoids the use of 
anabolic steroids as boldenone, an illicit administration in order to 
increase live weight gain, reduce the feed conversion ratio and the 
trade in the black market of the drugs, results difficult to control, 
and prevent. Samples positive for the presence of boldenone were 
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considered as a proof of illicit treatment for a long time because of 
the only exogenous deemed identity. 
Nevertheless, a gradual increase in the findings of 
samples containing boldenone in different States of the European 
Union doubted the purely exogenous origin of the drug and gave 
rise to the question concerning a possible endogenous production 
or natural presence in urine of boldenone [23].  
In 1996, the endogenous nature of -bold was reported 
by Arts et al. The Authors found a percentage of 25% out of a total 
of 50 urine samples of untreated veal calves, characterised by the 
natural presence of α-bold at levels exceeded 1 ng mL-1 (between 
0.1 and 2.7 ng mL-1), while β-bold were always found at a 
concentration lower than 0.1 ng mL-1 [28].  
Since then, a scientific debate about the origin of 
boldenone is ongoing. Several studies were performed not only to 
explain the presence of boldenone in urine of untreated cattle, but 
also to define possible metabolites that could be helpful markers 
to identify an abuse of β-bold and establish a threshold or a 
concentration limit by which a condition of unauthorized use of 
the anabolic hormone could be excluded [23, 21].  
Significant information regarding the metabolism of 
boldenone was acquired in 1983 by the experiments on the horses 
performed by Dumasia et al. The Authors shown that after the 
intramuscular administration of radioactive-labelled β-bold to 
castrated male horses, the metabolites were mainly excreted as 
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glucu- and sulfo-conjugated compounds. Particularly, the 
metabolites of boldenone were principally excreted as glucuronic 
acid conjugated, identified by capillary GC-MS. In the research, 
the Author expressed the difficulties to hydrolysed the sulfate 
conjugates with Helix Pomatia, and secondly that the epimer of 
boldenone tends to be conjugated with the glucuronic acid, while 
β-bold with sulfate moiety [29, 30].  
Studies in vivo were firstly performed by Galletti et al. 
and, then, by Cartoni at al., who illustrated the elimination of β-
bold metabolites in human urine as β-bold metabolite as β-bold 
free form, consequently the administration of β-bold [23].  
Van Puymbroek et al carried out studies both in vitro and 
in vivo in order to observe the metabolism of boldenone in cattle. 
The experiments in vitro were performed on microsomal liver 
preparations and isolated hepatocytes, while the in vivo experiment 
were done on urine and faeces samples of animal treated with 700 
mg of β-bold via intramuscular injection and an animal treated 
with boldenone undecanoate. The most visible metabolite found in 
vitro was the oxidised metabolite of β-bold, the ADD in the 
microsomal preparation, whereas incubations with isolated 
hepatocytes showed several 6-hydroxylated metabolites of both β-
bold (the epimer of bold, α-bold) and ADD. In the experiment in 
vivo, the Authors observed a similar metabolic profile in the urine 
and faeces form both of the animals treated. Particularly, they 
mainly found α-bold and “an unidentified reduction product (5ξ-
 44 
AEVI)” in the samples of the animal treated with boldenone 
undecanoate and “two reduced metabolites, 5 ξ -AEVI and 5 ξ –
AEVII “, in the samples of bovine treated with intramuscular 
boldenone. A smaller amount of 6-HO-17 β -boldenone was found 
in urine, but no traces on faeces, as well for 5β-AED [31].  
Similar studies were performed on urine and faeces 
samples of a male calf and a mature cow. The metabolite profile 
resulted comparable, in fact α-bold e 5 AED were found as 
principal metabolites [22, 33]. 
The endogenous production of β-bold in pigs was 
confirmed by the detection of the steroid in testicles. Unlike 17 β-
19-nortestosterone, the production of β bold in pigs is related to 
the gender, in fact β-bold was not detect in female even if a very 
low concentration in urine where the steroid could be present as a 
result of faecal contamination [34]. Regarding the horse, boldenone 
undecylenate, well known with the commercial name of 
Equipoise®, is illegally used for treating racehorse. Ho et al. 
reported the direct evidence of the natural presence of boldenone 
and its main metabolite, the sulfate conjugate in urine of horse with 
a concentration lower than 5 ng mL-1 [23, 35]. Also in humans 
endogenous production of boldenone is reported [36, 37].  
Recently, Le Bizec and Destrez, achieved studies on β-
bold with the purpose of have a clearer overview on its metabolism 
and to define a criteria to distinguish endogenous production of the 
steroid from illegal abuse. They suggested sulfo-conjugated form 
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of β-bold in urine as biomarker useful to define a condition of illicit 
treatment of the compound, while Blokland et al in 2007 proposed 
6β-hydroxy-boldenone. Also in human field, β-bold sulfate was 
found as tool for fraudulent administration [38-40].  
1.2.11. Origin of endogenous boldenone in urine  
Several hypothesis on the origin of endogenous 
boldenone in urine and in the faeces were assumed. Studies were 
performed both in vitro and in vivo in order to better understand 
the metabolism involved in the production of boldenone and to 
recognize metabolites that could be useful marker of illicit 
treatment. Since 80s, studies concerning the microbial 
biotransformation were principally focused on the ability of 
certain microorganisms of expressing selective dehydrogenase 
enzyme activity, which are able to transform dehydrogenated 
steroids from certain precursors and substrates. In particular, an 
interesting alternative of the precursors of steroids used as 
substrate for the dehydrogenase microorganisms activity are the 
phytosterols, which are sterols structurally related to cholesterol, 
but differ from cholesterol in the structure of the side chain [41].  
Barthakur et al. described the conversion of β-sitosterol 
to ADD via dehydrogenase activity of Mycobacterium sp. NRRL 
B-3683 [42].  
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Other several microbial enzymatic reduction activities 
were found using different mycobacterium extracts and fungi, the 
ability to cleave the sterol side chain in order to obtain AED from 
sitosterol and in river sediment was also found due, probably, to 
the presence of phytosterols in plants [23].  
In order to give more explanations to the problem related 
the origin of boldenone, other models were studied. invertebrate 
Neomysis integer is commonly used for in vitro instead of animal 
tissues. In a study where invertebrate Neomysis integer was 
exposed to β-testosterone and stanazolol, presence of β-bold was 
found. In 2003, Poelmans showed the ability of Neomysis integer 
to convert β-T to AED and, in its turn to β-T and ADD. When the 
invertebrate was exposed to ADD, a production of β-bold was 
revealed [23]. The possibility of an origin from maggot and mould 
on the feed was not excluded. [43, 44]. The results achieved by 
Poelmans in 2005 shown the presence of β-bold in the testicles of 
entire male pig, probably due to aromatisation of oestrogens [34]. 
Precursors of β-bold can be detected in the faeces of rats fed with 
phytosterols [45].  
The conversion of boldenone from phytosterols, for 
instance β-sitosterol in vegetable fat, was also considered. The β- 
sitosterol is commonly used as an additive to animal feed in 
response to the crises caused by bovine spongiform 
encephalopathy and is shown through an invertebrate model 
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capable to converted phytosterols to ADD, and then into bold and 
T [23]. 
Gastro-intestinal tract hosts a complex and miscellaneous 
microbial community, capable to convert precursor of steroids or 
phytosterols into dehydrogenated steroids [44]. Several studies 
focused the attention on the role of microorganism from faeces and 
examine the bacteria activity of the gastrointestinal tract of the 
bovine cable to convert steroids in urine when inadequately stored 
[46]. 
In 2004, Sgoifo Rossi et al. evidenced the possibility that 
a faecal contamination of urine could provide wrong results 
because the presence of faeces made urine non-compliant for the 
presence of α-bold and occasionally for β-bold. Until 2004, in Italy 
urine sampling was commonly performed by using a zootechnical 
apron. However, it could be reason of faecal contamination. The 
Authors suggested to collect urine using a kettle, kept under the 
body of the animal, after cleaning and trimming of the animal’s 
coat, thus avoiding any faecal contamination of sheath area. These 
samples and urine collected by a zoonotechnical apron were 
analysed and the results obtained could confirm the necessity of a 
clean collection of the urine, as shown in Figure 7 [47]. 
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Figure I- 7. Urine samples collected with a zootechnical apron and those 
collected by kettle upon cleaning and trimming of animal sheath area. 
In 2006,with the purpose to better understand the role of 
faecal contamination of urine, Pompa et al evaluated the eventual 
presence and variability in concentration of steroids (β-bold, α-
bold, ADD, AED, T, epiT) on the basis of the effect of drying the 
faeces, in the urine, skin swabs and faeces of ten Friesian calves. 
β-bold, α-bold and ADD were never detected in urine samples, 
whereas AED, T and ET were constantly found. β-bold was 
detected in all samples of  rectal faeces that were directly collected 
from the rectum (28-89 ng g-1). The epimer of bold was detected 
in only four animals in faeces rectal (2.6-5.6 ng g-1). Only one calf 
showed ADD in faeces rectal at 21 ng g-1. A variably increase of 
the concentrations of the analytes was found in faeces scraped 
from the skin, faeces taken from the stall floor and faeces stored 
for up to 13 days at room temperature in a cowshed. The Authors 
referred to a de novo synthesis of α-bold and metabolites that could 
take place naturally in bovine faeces. Due to the possibility to find 
α-bold and its metabolites in faeces, the Authors confirmed the 
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necessity to avoid faecal contamination of urine during the 
sampling and suggested to analyse urine samples rapidly after 
collection [48]. 
In 2008, the same group tried to explain the reason of the 
presence of the analyte boldenone in faeces. An in vitro 
experiment performing an incubation with several steroids of 
faecal matter suspended in 0.9% saline was carried out. The 
Authors showed that the transformation of steroids could occur in 
faeces, particularly after faecal expulsion and suggested a possible 
pathway for the neo-formation of boldenone from the endogenous 
AED. (Figure 8). They designed AED as key precursor for 
boldenone synthesis. AED can be converted to the epimer of 
testosterone (ET) but also T.  
The conversion of AED can also result in ADD, which 
could be an intermediate compound in the production of β-bold, α-
bold. However, the mechanism is to be investigated yet [49].  
 
 
Figure I-8. Potential neoformation and interconversions of steroids in bovine 
faeces (both before and after their emission) and in faeces-contaminated urine. 
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Van de Kerkhof in 1999 performed a study in order to 
demonstrate the suggestion of Shӓnzer (1994) who hypnotized the 
endogenous nature of boldenone in human urine due to the 
conversion of ADD. According to the Authors, boldenone could 
derive from testosterone glucuronide (TG) metabolized in bile and 
the converted by the intestinal bacteria in the ADD. Then ADD 
could be transported in liver through the enterohepatic circulation 
and the secreted in urine where it could be interconverted in 
boldenone. An experiment in vitro carried out by Van de Kerkhof 
showed that in fractions of faeces incubated in a medium with a 
Δ1-dehydrogenase and a precursor as testosterone glucuronide, 
could be found positive for the presence of ADD, while in urine 
collected from an athlete, boldenone was found but a very low 
concentration. In Figure 9 is shown the pathway suggested [50].  
 
Figure I-9. A hypothesis of pathway for the endogenous production of boldenone 
in urine. 
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Other different hypothesis on the possible origin of 
boldenone in bovine urine were assumed. It was reported that some 
types of wooden crate in which veal calves are housed might 
contain precursors to boldenone [51].  
However, the debate on the origin of boldenone in urine 
is still open and the knowledge regarding the mechanism involved 
in boldenone production is lacking.  
At the meeting placed in Brussels in 2003, the main 
experts in the residue fields representing the Member States made 
certain recommendations to address the problem of 
endogenous/exogenous boldenone. The conclusions of the 
meeting were reported in a review published by De Brabander in 
2004 and they are summarized in the following table. Moreover, 
the passage of more than ten years, the following guidelines are 
still valid [23, 52].  
Table I-1. Natural occurring situation of boldenone and the strategy for the 
control of the use of boldenone in cattle. 
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1.2.12. Legislation aspect regarding boldenone in bovine  
In Italy, as in the other Member States of the European 
Union, the presence of β-bold conjugated at any concentration in 
urine of calves and bulls is to consider as an evidence of illegal 
treatment (zero tolerance). Based on the scientific information 
obtainable, α-bold is considered as endogenous production in 
bovine urine if it is detected at a concentration lower than 2 ng mL-
1 in bovine urine, while there is no evidence today for the 
endogenous origin of β-bold [52-54]. Regarding the sampling 
procedure, it is required a “clear” collection of the urine sample, 
without faecal contamination in order to avoid false positive 
results and then, the samples have to be immediately frozen. The 
laboratory must to specify the form of boldenone investigated and 
define it as free or conjugated form, giving information of the 
animal species, including breed, gender and age of the animal. A 
Minimum Required Performance Levels (MRPL) for the 
analytical methods for the detection of β-bold and α-bold in urine 
of veal calves is now set at 1 ng mL-1. The analytical methods 
provided by the NRP are both screening methods (ELISA) and 
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confirmatory methods using liquid chromatography coupled to 
mass spectrometry (LC-MS/MS) [54]. 
1.2.13. Analytical methods for the detection of boldenone  
The analysis for the detection of β-bold and its 
metabolites may be carry out using both LC-MSn and GC-MSn, 
following appropriate extraction and purification methods [23]. 
Particularly, several studies conducted on urine of calves treated 
with different preparations of boldenone, esters and/or precursors 
by the use of GC-MS analysis techniques have shown that β-bold 
is excreted glucuronide and less as sulphate [25,26]. Biddle et al. 
indicated two possible markers of treatment as glucuronic 
metabolites, which are present independently of the route of 
administration: 6β-hydroxy-17α-boldenone and 5z-androst-1-ene-
3z-ol-17-one (a due to the lack of reference standard, have used 
the "z" to indicate either the α or β configuration). The researchers 
emphasized the importance of a sensitive method of analysis in 
order to define the conditions of treatment and were not able to test 
the limit of 2 ng mL-1 defined by European legislation due to lack 
of reference standards of α-boldenone glucuronide [55].  
Nielen et al. showed the importance of investigating the 
metabolism of II phase of boldenone, asserting that the presence 
of β-bold conjugates in urine of calves was the evidence of an 
illegal treatment [56]. 
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In further work, metabolism of β-bold in calves was 
studied after intramuscular and oral administration with 
boldenone, esters of boldenone and ADD. The Authors have 
shown by GC-MS analysis that the majority of metabolites were 
glucuronide (α-boldenone form) and that β-bold sulphate was 
present only in urine samples obtained from treated animals (this 
last result was obtained with LC analysis -MS) [38]. 
β-bold sulfate is proposed as a marker of abuse because it 
was detected only in treated cattle. However, the study was 
conducted on a small number of animals (5 calves treated) in a 
qualitative analysis and analytical performance values for LC-MS 
analysis were not reported. Destrez in 2009 conducted a study with 
three male calves treated for oral administration of ADD and by 
intramuscular injection of boldenone undecylenate. The analytical 
limits for metabolite sulfate were obtained either by analysis LC-
MS / MS (ESI negative acquisition SRM, triple quadrupole) that 
by LC-HRMS (ESI negative, Resolution 30,000, OrbitrapTM). 
The analytical limits detected by the two techniques of analysis are 
here reported: the limits of decision (CCα) 0.2 and 0.1 ng mL-1 and 
the detection capability (CCβ) 0.4 and 0.2 ng mL-1, respectively. 
The Authors stated that β-bold sulfate may be a good marker of 
treatment. The use of high-resolution instrumentation has not 
improved significantly the performances; the high cost and the low 
scanning speed of 'OrbitrapTM are reasons to favour the use of an 
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instrument of detection triple quadrupole. It is therefore to be 
noted, once again the insignificant number of calves studied [39]. 
At present, the current official analytical methods to 
identify β‐bold conjugated in calf urine require a preliminary 
deconjugation step in order to obtain the free form of the steroids, 
following by LC-MSn or GC-MSn analysis.  
The hydrolysis of glucuronic acid and sulfate conjugates 
is usually performed as the first step of the analytical 
determination of steroids in urine, and the hydrolysis is mainly 
achieved by enzymatic methods (rather than chemical methods) 
that involve the cleavage activity by β-glucuronidase and 
arylsulfatase. These enzymes can be extract from different 
sources, including bovine liver, bacteria (Escherichia coli) or 
gasteropoda (Helix pomatia) and arylsulfatase originates from 
bacterial sources (Aerobacter aerogenes), molluscs or limpets 
(Patella vulgata). The digestive juice of Helix pomatia, which 
contains both β-glucuronidase and arylsulfatase activities, is the 
most commonly used enzymatic preparation, and it leads to a total 
deconjugation of urinary steroids. For the determination of steroid 
hormones that are naturally present in bovine urine in free, 
glucuronic acid and sulfate forms, the use of a suitable enzyme 
preparation and optimization of the hydrolysis conditions were 
necessary. However, the step of deconjugation entails 
disadvantages, which must be taken into account and may be 
potential factors, which may lead to misinterpretation. The 
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enzymatic hydrolysis of the conjugates may be incomplete. The 
incubation, in particular with Helix pomatia, can lead not only to 
incomplete hydrolysis, but also to the conversion of steroids or 
degradation [57]. Based on these considerations, analytical 
strategies performed bypassing hydrolysis step, may be properly 
developed for the direct detection of phase II metabolites of AAS. 
The LC techniques allows a broad-spectrum of applications 
because it allows performing direct analysis of hydrophobic 
substances without a previous derivatisation and the direct analysis 
of conjugated metabolites without a prior hydrolysis. The 
conjugation increases solubility, converting the steroids into more 
polar compounds and facilitating kidney excretion. Because of 
polarity, the separation of the conjugated steroids from the other 
polar substances that are in urine, results difficult and requires 
many steps of concentration and purification [58, 59]. Recently, an 
alternative method to the indirect detection of conjugated 
boldenone in bovine urine was carried out and permitted to 
distinguish the different conjugated forms. The method, validated 
according to the European Commission Decision 2002/657/EC, 
allowed specific and sensitive analysis of conjugated and free 
forms of α‐ and β‐bold and ADD by a unique step of extraction 
and purification performing by the use of ImmunoAffinity 
Columns. The good and satisfactory results in terms of decision 
limits and detection capabilities may ensure this as an appreciable 
method to evaluate a condition of illicit treatment from natural 
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production of boldenone [60,61]. The latest studies cited are reported 
in Chapter 3.1. and 3.2.  
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1.3 Glucocorticosteroids 
World Anti-Doping Agency (WADA) prohibits the use 
of corticosteroids when administered by oral, intravenous, 
intramuscular or rectal routes in sport competition, but the 
treatments are permitted (only by obtaining the permission of the 
authorities) out-of-competition or in particular routes before or 
during competition [1, 2]. In an attempt to discriminate between 
permitted and forbidden administrations, WADA established a 
reporting level of 30 ng mL-1 for glucocorticosteroids and their 
metabolite [3]. 
The improper use of glucocorticosteroids in sports is 
exploited to the relaxing effects that these chemicals cause on the 
respiratory tract and, at higher doses, to their analgesic effects. The 
dilation of the airways and the raised pain threshold enable athletes 
to achieve better performance both in training and in competition. 
In veterinary practice, they are frequently used as 
therapeutic drugs for treatment of bovine ketosis, inflammatory 
diseases, and induction of parturition, but also illegally used both 
in the endogenous for in the form of artificial compound as growth 
promoters [4]. Glucocorticosteroids play significant roles in 
carbohydrate, protein, and lipid metabolism, the immune response, 
and the response to stress. Natural glucocorticosteroids have a few 
mineralocorticoid activity and therefore affect fluid and electrolyte 
balance. While corticosteroids can be highly effective in 
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suppressing or preventing inflammation, their physiologic and 
pharmacologic mechanisms of action are mediated by the same 
receptors. This explains why their pharmacologic and physiologic 
effects are inherently linked, and why physiologic exposure to 
corticoids is potentially detrimental to several metabolic, 
hormonal, and immunologic functions. 
1.3.1. Adrenal glands 
The adrenal glands are endocrine organs at the superior 
pole of the kidney and they are the source of the corticosteroids 
hormones. The adrenal cortex secretes mineralocorticosteroids, 
glucocorticosteroids, and sex hormones, and it is composed by 3 
distinct layers (Figure 10): 
 The outer layer is the zona glomerulosa 
where the production of the 
mineralocorticoid aldosterone occurs. 
This hormone is responsible for 
increasing sodium absorption and 
stimulating potassium excretion by the 
kidneys and thereby indirectly 
regulating extracellular fluid volume. 
 The zona fasciculata occupies about 
70% of the cortex and it is responsible 
of the production of 
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glucocorticosteroids with well-known 
effects on the metabolism of 
carbohydrate and protein. 
 The zona reticularis, the innermost 
layer, produces glucocorticosteroids 
and small amounts of sex androgens, 
oestrogens and progestins, involving in 
reproductive function [5]. 
 
 
Figure I-10. Structure of adrenal gland. 
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1.3.2. Synthesis of glucocorticosteroids  
All the metabolic pathways in the biosynthesis of steroid 
hormones derive from the common precursor cholesterol and they 
share a cyclopentenoperhydrophenanthrene nucleus. The basic 
chemical structure of the corticosteroids is shown in the Figure 11. 
Based on the number of the atoms of carbon, the 
corticosteroids are divided in three groups [6]: 
 Glucocorticosteroids or C21 steroids, 
which have a two-carbon side chain at 
position 17. i.e. cortisol and 
corticosterone. The 
glucocorticosteroids are the main 
steroids synthesised and they show a 
hydroxyl group at the 17 position, for 
this reason they are also defined as 17-
hydroxycorticoids or 17-
hydroxycorticosteroids. All secreted C 
21 steroids, classified using Selyes 
terminology, have both 
mineralocorticoid and glucocorticoid 
activity.  
 Androgenic steroid, C19 steroids, 
which have a keto or hydroxyl group at 
position 17 
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 Oestrogens, C18 steroids, which, in 
addition to a 17-keto or hydroxyl 
group, have no angular methyl group 
attached to position 10 
 
 
Figure I-11. Synthesis of glucocorticosteroids. 
The principally precursor of the corticosteroids, the 
cholesterol arises from the circulating Low Density Lipoproteins 
(LDL), which receptors are highly expressed in adrenocortical 
cells and less is synthesized from acetate. The release of the 
esterified cholesterol from lipid droplets occurs through the 
catalytic action of the cholesterol ester hydrolase enzyme. Then, a 
carrier protein transports the cholesterol to mitochondria where a 
member of the cytochrome P450 (or CYP11A1 known cholesterol 
desmolase or side-chain cleavage enzyme) converts it to 
pregnenolone. Pregnenolone is dehydrogenated in the smooth 
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endoplasmic reticulum to form progesterone by 3β-hydroxysteroid 
dehydrogenase, which also catalyses the conversion of 17α-
hydroxypregnenolone to 17α-hydroxyprogesterone, and 
dehydroepiandrosterone to androstenedione. A 17,20-lyase region 
of the same enzyme cuts the 17,20 bond, converting 17α-
pregnenolone and 17α-progesterone to the C19 steroids 
dehydroepiandrosterone and androstenedione. The hydroxylation 
of progesterone to 11-deoxycorticosterone and of 17α-
hydroxyprogesterone to 11-deoxycortisol are catalysed by 21β-
hydroxylase, a cytochrome P450 that is also known as P450c21 or 
CYP21A2. The production of corticosterone and cortisol takes 
place in the mitochondria of the zona fasciculate from 11-
deoxycorticosterone and the 11-deoxycortisol that are 11-
hydroxylated by 11β-hydroxylase a cytochrome P450 also known 
as P450c11 or CYP11B1. Cortisol is produced in greater amounts 
compared to corticosterone in these species and represents 
approximately 80% of the glucocorticoid production (Figure 12) 
[6]. 
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Figure I-12. Pathway of corticosteroids synthesis. 
1.3.3. Transport of glucocorticosteroids 
Glucocorticosteroids are secreted into the systemic 
circulation, reversibly bound to a specific α globulin 
(approximately 80% of human cortisol), called transcortin or 
corticosteroid-binding globulin (CBG), while 10% is bound to 
serum albumin and the remaining 10% is the biologically active 
unbound hormone [6]. 
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1.3.4. The regulation of the synthesis of the 
glucocorticosteroids: The Hypothalamus-Pituitary-
Adrenal Axis 
The release of glucocorticosteroids is stimulated by the 
adrenocorticotropic hormone (ACTH, also called corticotropin), a 
linear peptide consisting of 39 amino acids, that binds to high-
affinity receptors on the plasma membrane of adrenocortical cells. 
At the physiological level, under conditions of stress (i.e. exercise, 
fear) or hypoglycemia, the hypothalamus secretes corticotropin-
releasing factor that induces the pituitary prior to the production of 
the hormone ACTH, which in turn, stimulates the release of 
glucocorticoids in the adrenal glands. This bounding is necessary 
to activate an adenylyl cyclase, resulting to a formation of 
pregnenolone and its derivatives. The hypothalamus releases the 
corticotropin releasing factor or CRH that stimulates the anterior 
pituitary gland to release the hormone ACTH, adrenocorticotropic 
hormone. The mutual aid of the three glands is defined as 
Hypothalamus-Pituitary-Adrenal axis (HPA) (Figure 13). Free 
glucocorticosteroids inhibit ACTH secretion, and the degree of 
pituitary inhibition is proportional to the circulating glucocorticoid 
level [6].  
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Figure I-13. The Hypothalamus-Pituitary-Adrenal Axis. 
1.3.5. Metabolism and excretion of glucocorticosteroids  
Corticosteroids are metabolised mainly in the liver, which 
is the principal site of glucocorticoid catabolism but also in kidney 
and mammary glands, giving rise to inactive, water-soluble 
conjugates excreted in urine (75%) and faeces (25%). Most of the 
cortisol is reduced to dihydrocortisol and then to 
tetrahydrocortisol, which is conjugated to glucuronic acid [6]. 
Cortisol (CL) can be interconverted to the non-active 
hormone, cortisone (CN) through the activity of 11β-
hydroxysteroid dehydrogenases (11β-HSD). The enzyme 11β-
HSD presents two isoforms: type I catalyses the conversion of CL 
into CN (Figure 14), while type II controls the catalysis of the 
conversion of CN into CL. Tetrahydrocortisol (THF), allo-
tetrahydrocortisol (ATHF) and tetrahydrocortisone (THE) are the 
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metabolites of respectively cortisol and cortisone, produced by a 
two-step  reduction of the C4-5 double bond catalysed by 5alfa- or 
5beta-reductase (Figure 15), followed by the reduction of 3-keto 
group catalysed by 3-oxoreductase, which is conjugated to 
glucuronic acid. THF, allo-THF and THE are made more water-
soluble by conjugation with glucuronic acid through a glucuronyl-
transferase system responsible for this conversion and the 
formation of the glucuronides of bilirubin and hormones and 
drugs. Then, the metabolites are excreted in the urine. 
Downstream, cleavage of THF and THE to C19 steroids 11-
hydroxy or 11-oxo-androsterone or etiocholanolone can occur. 
Alternatively, reduction of the 20-oxo group by 20α- or 20β-
hydroxysteroid dehydrogenase yields α and β-cortols and 
cortolones, respectively, with subsequent oxidation at the C21 
position to form the polar metabolites, cortolic, and cortolonic 
acids. Hydroxylation at C6 to form 6-β-hydroxycortisol is 
described, as is reduction of the C20 position, which may occur 
without A ring reduction giving rise to 20 α-and 20 β-
hydroxycortisol. Approximately 50% of secreted cortisol appears 
in the urine as THF, allo-THF, and THE; 25% appears as 
cortols/cortolones. Ten percent appears as C19 steroids, and 10% 
appears as cortolic/cortolonic acids. The remaining metabolites are 
free, unconjugated steroids (CL, CN, and 6 β- and 20 α/20 β-
metabolites of CL and CN) [6-8]. 
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Figure I-14. Interconversion of cortisol/cortisone by 11β -hydroxysteroid 
dehydrogenases. 
 
 
Figure I-15. Pathway of synthesis of cortisol ad cortisone reduced metabolites: 
tetrahydrocortisol allo-tetrahydrocortisol and tetrahydrocortisone. 
 
1.3.6. Glucocorticoid metabolism in farm animals  
The published studies on glucocorticoid metabolism in 
farm animals, particularly in cattle, are mostly focused to evaluate 
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animal welfare, which possible indicator of the stress that is 
influenced by several factors as transport, courtship, copulation 
and hunting and any physiological stressors associated with 
invasive procedures. Circulating CL is released depending on the 
intensity of the stressors, metabolized (conjugated) in the liver and 
excreted in urine and faeces, and in saliva. However, the 
monitoring of the adrenocortical activity should be made without 
induce stress to the animals and the non-invasive techniques in 
order to analyse of faeces and, recently, of saliva are the most 
suitable [9,11].  
Moreover, several Authors have proved that 
corticosteroid concentrations in saliva are directly related to those 
in plasma in humans, dogs, pigs, and domestic ruminants [12, 13]. 
Antignac et al. performed a study on the phase II 
metabolism of corticosteroids, determining the relative 
proportions of free, glucuronide, and sulfate metabolites, in bovine 
urine with the purpose of improving the efficiency and the 
specificity of their control in cattle in 2002. Two animals were 
treated with different dexamethasone esters by intra-muscular 
injection. The results illustrated an evident difference of the total 
proportion of conjugated forms between endogenous THF (40–
65%, mainly as glucuronide form) and endogenous CL (2–8%) or 
exogenous dexamethasone (4–27%), showing that cortisol is 
excreted mostly as free form [14]. 
 80 
1.3.7. Therapeutic of corticosteroids in breeding  
Prednisolone, methylprednisolone, dexamethasone and 
betamethasone are synthetic corticosteroids only approved for 
therapeutic uses. They are widely prescribed in human and 
veterinary medicine for their anti-inflammatory and anti-allergic 
properties [15, 16]. 
Synthetic glucocorticoids, with a 21-carbon steroid 
skeleton, are chemical derivatives synthesized from cholic acid 
obtained from cattle or steroidal saponins in plants. Synthetic 
corticosteroids show a chemical structure of these drugs is very 
similar to that of natural glucocorticoids with slightly alterations 
to cortisol skeleton and selectively alter the degree of anti-
inflammatory activity. The effects of their resulting anti-
inflammatory activity can be even more potent than naturally 
occurring steroids. The levels of efficacy, potency and 
pharmacological activity of synthetic hormones are determined by 
their pharmacokinetic properties. Potency and plasma half-life of 
natural and synthetic glucocorticoids are shown in Table 2 [16-19]. 
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Table I-2. Relative potencies of corticosteroids used in veterinary practice. 
The main changes to the cortisol skeleton in order to 
increase the corticosteroid activity are the following: 
 Introduction of an additional double bond 
between C1 and C2 (increase of glucocorticoid 
and anti-inflammatory activity). For example, 
prednisolone is ~3 to 4-fold more selective than 
cortisol. 
 Additional of hydroxyl group at carbon 11. 
 Additional fluorination at the C9 position 
enhances both glucocorticoid and 
mineralocorticoid activity.  
 Addiction of a group at the position 16.[19] 
Corticosteroids formulations are available for oral, 
parenteral, and topical use. Prednisone, prednisolone, 
methylprednisolone, and dexamethasone are well absorbed with 
oral preparations [19].  
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1.3.8. Glucocorticosteroids and legislation 
European Union banned the use of corticosteroids as 
growth promoters, allowing their use only for therapeutic aims [20]. 
The strong pharmacological activity of corticosteroids used in 
animal breeding makes the residues of these molecules potentially 
dangerous to meat products consumers [21]. Consequently, the 
monitoring of the use of corticosteroids is mandatory. The 
Commission Regulation (EEC) n° 37/2010 of 22 December 2009 
(on pharmacologically active substances and their classification 
regarding maximum residue limits in foodstuffs of animal origin) 
establishes Maximum Residue Limits (MRLs) for edible matrices 
(muscle, kidney, liver and milk from different species ) with a 
withdrawal period  between treatment and slaughter, as indicated 
in the Annex and reported in Table 3 [15,22].  
The monitoring control for the presence of corticosteroids 
is performed by collecting samples at the slaughterhouse on tissues 
for which MRLs are set, and at farm through the analysis of urine. 
For this matrix, no MRL has been fixed.  
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Table I-3. MRLs of Betamethasone, Dexamethasone, Methylprednisolone and 
Prednisolone, as specified by the Commission Regulation (EU) No 37/2010. 
Synthetic corticosteroids might be used particularly at 
low dosages and via oral administration, as growth promoters 
either alone or in a cocktail with other active principles, always 
banned, including β-agonists or steroid [5]. Dexamethasone, which 
is the most frequently corticosteroid illegally used [23], could 
ameliorate the overall carcass quality traits through the significant 
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increase of serum insulin, resulting in a fat deposition and protein 
catabolism [5]. Tarantola et al. reported that the use of 
dexamethasone at low dosage, both orally and intramuscularly, 
was found to have no positive effect on performance but it 
positively influenced meat tenderness and colour [21]. Moreover, it 
was observed that dexamethasone could influence the regulation 
of β2-receptors, so enhancing the repartitioning effects of β2-
agonists. 
Among the glucocorticosteroids used in illicit treatment, 
prednisolone is one of the most debated and differs from CL 
through Δ1,2, hydroxylation, by which improves its potency and 
their glucocorticoid effects [24-26]. 
In Italy, from 1988 National Residues Plan (NRP) 
provides for the surveillance and the monitoring of residues of 
chemical substances in foods with animal origin. Council 
Directive 96/23/EC “on measures to monitor certain substances 
and residues thereof in live animals and animal products” demands 
to each Member States to implement a National Residues Plan 
(NRP) [27]. This document has to be drafted in order to monitor the 
process of farming and primary processing of animal products for 
the detection of residues and of certain substances in live animals, 
their excrement and liquids biological tissue, animal products, feed 
and drinking water. The official control system carried out by the 
competent authorities. 
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The NRP is designed taking into account the 
requirements of the legislative decree 16 March 2006, n. 158, 
implementing Directive 96/22 /EC and 96/23 /EC and its 
subsequent amendments and decisions 97/747/EC and 98/179/EC, 
as regards the levels and frequencies of sampling and procedures 
for the official taking and the management of the samples. It 
defines the species and categories animals to be sampled, the 
category of residues or substances to be investigated, the sampling 
strategies, levels and frequencies sampling, according to the 
legislation and the directions of the Commission European. The 
NRP is yearly drawn by the Ministry of Health-Directorate 
General for Health and Food Safety and Nutrition (the Ministry) 
that collaborates with the Regions and Autonomous Provinces, 
National Laboratories reference and Istituti Zooprofilattici 
Sperimentali [28]. 
According to Legislative Decree of August 4th 1999 n. 
336 with a transposition of EC Directives 96/22/EC and 96/23/EC 
(concerning the prohibition on the use of certain hormonal 
substances, thyrostatic and of β-agonists and measures to monitor 
certain substances and their residues in live animals and their 
products), the NRP is prepared for the investigation of certain 
molecules that fall into two categories established by the European 
Community. 
The substances to be investigated and controlled are 
included into two categories, as established by EU: 
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 The Category A includes substances 
with anabolic effects and forbidden substances for the 
treatment of livestock. 
 The Category B includes veterinary 
drugs, drugs authorized for the treatment of livestock, for 
which the European Union defines a maximum residue 
limit that cannot be exceeded in consumer products; 
environmental contaminants, such as heavy metals and 
substances that may be absorbed by environment and 
enter in food chain. 
Some Member States include these substances in group 
A3 (steroids), whereas others allocate them to the group B2f 
(veterinary drugs and contaminants-other pharmacologically 
active substances). As regards Italy, corticosteroids belong to B2f, 
following the suggestion of the European Commission. However, 
the use of corticosteroids without any kind of control, is considered 
as illicit treatment [29 30]. 
 
1.3.9. Prednisolone: a corticosteroid under magnifying 
glass 
Prednisolone (Δ1,4-pregnadiene-11β,17α,21-triol-3,20-
dione) (PL) , is one of the most important and debated 
glucocorticosteroid having gluconeogenetic and anti-
 87 
inflammatory activities, which structurally differs from CL only 
by the presence of the double bound at the position C1-C2 (Figure 
16), an adding modification in structure similar to the that of 
boldenone regarding testosterone. This feature gives an anti-
inflammatory activity to the steroid that is 3–4 times higher than 
that of CL [19]. 
The use of PL in livestock is allowed only for 
therapeutically purpose, while it is forbidden as growth promoter. 
Because the presence of residual traces of PL, as the others 
corticosteroids, in meat and meat products could be a risk for 
consumers [8], the use of PL is allowed only for therapeutic 
purposes in bovine and is regulated by Commission Regulation 
(EU) N°37/2010 [23], which sets maximum residue limits (MRLs) 
for milk and the edible tissues (Table 3). 
Nevertheless, based on scientific evidence currently 
available, on 22nd May 2012, the Italian Ministry of Health, 
recommended a cut-off level 5 of µg L-1 for bovine urine, above 
which a response of non-compliance could be set and, thus, 
indicating the potential endogenous origin of PL in urine [31]. 
 
Figure I-16. Chemical structure of prednisolone, cortisol and cortisone. 
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In June 2012, the European Medicines Agency for 
Veterinary Use (Committee for Medicinal Products for Veterinary 
Use) recommended to place PL in the Commission Regulation No. 
37/2010/EC as substance allowed in horse [32]. 
Until the first ten years of the XXI century, PL was 
considered only of exogenous origin, however an increased 
frequency of urine bovine samples positives for PL at slaughtering 
put in doubt the hypothesis of illegal treatment. A research carried 
out in Lombardy (Northern Italy) during the years 2008-2009 on 
196 bovine urine liver samples taken at the slaughterhouse, 
reported 72%  non-compliant urine samples for the presence of PL, 
while all liver samples resulted to be negative for this 
corticosteroid. Considering the high number of positive samples, 
the hypothesis of an illicit treatment was excluded and other 
possible explanations were taken into account, as mainly the role 
of the stress transport and pre-slaughter on the production and 
release of corticosteroids. The Authors indicated a possible 
relationship between stress condition and the detection of PL in 
urine, collected directly from bladder of three treated Holstein 
Friesian cows with adrenocorticotropic hormone (ACTH) via 
intramuscular at two and six hours after treatment. The presence 
of PL after ACTH treatment seems to suggest the possibility that 
this molecule could be physiologically produced [33]. It was also 
noted that the prednisolone could occasionally be found even if 
animals are apparently not submitted stress [24]. The metabolic 
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pathway that would lead to the production of endogenous 
prednisolone has not yet been clarified. Bertocchi et al. performed 
a comparative study on cow urine samples collected at the farm 
and urine and adrenal glands (of cattle positive for corticosteroid 
in breeding) taken at the slaughterhouse from the same animals, 
assuming a conversion of endogenous CL to PL. The adrenal 
glands were positive for the presence of PL and could therefore be 
the seat of endogenous synthesis of PL obtained as an intermediate 
metabolite in the synthesis of endogenous corticosteroids, 
although data shown showed that the involvement of the adrenal 
glands seem to play a minor role in the endogenous production of 
PL. Moreover, the Authors hypothesized that presence of trace 
amounts of the corticosteroid in urine could be a result of intestinal 
dehydrogenation of cortisol operated by bacterial conversion in the 
gut and then transported in the liver by the hepatic portal vein, and 
thus secreted via the urine [15,25]. 
Furthermore, the formation of PL may also be the result 
of a poor preservation of the sample. However, the bacterial 
dehydrogenation does not explain the positive to the 
slaughterhouse, where urine samples are taken directly from the 
bladder and thus, theoretically, free of faecal material [34]. The 
formation of PL from CL could be also a result of microbiological 
contamination of soil bacteria. Bredehoft et al published in vitro 
experiments by which the Author demonstrated that urine positive 
for the presence could be obtained by Δ1-dehydrogenase activity 
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of bacteria as Rhodococcus erythropolis that were able to convert 
cortisol into PL [35]. 
Additionally, a possible presence of PL in urine due to the 
involuntary administration of prednisolone with complementary 
feed is also conceivable. In 2014, the detection of PL in samples 
of feedstuff under poor storage, thus indicating a determinant role 
of the environmental conditions in the possibility of PL neo-
formation in feedstuff and, consequently, in urine of animals fed 
with non-compliant feed [36] This study is reported in Chapter 3.3.  
The possibility of the endogenous origin of PL has also 
been described for equine and human urine [37, 38]. Finally, 
Delahaut et al. (2014) reported that the Belgian Federal Agency 
for the Safety on the Food Chain (FASFC) found PL at a mean 
concentration of 0.96 µg L−1 in 73% of 393 samples of porcine 
urine collected at the slaughterhouse. The same Authors described 
the results of a preliminary study concerning the presence of PL in 
sows before and after intramuscular administration of PL or 
tetracosactide hexaacetate. The urine collection was performed at 
the farm before and after the treatment and at the slaughterhouse, 
where the liver was collected as well. The presence of PL in 
porcine urine was confirmed in all samples prior to the treatment 
and in most of them after the treatment, but, in liver, PL was only 
found after administration of prednisolone or tetracosactide 
hexaacetate. The Authors proposed the PL/CL ratio in liver 
samples as an indicator for detecting illicit PL administration to 
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pigs and suggested confirming these observations in a study on a 
larger number of animals [39]. The endogenous production of PL in 
pigs seemed also confirmed in a recent study on 80 pigs, whose 
urine both at the farm and at the slaughterhouse, and adrenal glands 
were object of analysis for the presence of the corticosteroids. PL 
was detected in 89% of the samples. The possibility that PL is 
endogenously produced in pigs was directly demonstrated by its 
presence in the adrenal glands, the organ in which CL is produced 
[40]. The study performed is reported in Chapter 3.4 of the present 
thesis. 
1.3.10 Method of analysis of corticosteroids  
Numerous methods have been developed for the 
determination of endogenous and exogenous corticosteroids in 
different matrices. As recommended by the National Residues 
Plan, urine is the matrix for control a misuse of 
glucocorticosteroids in live animal, while tissues as liver and 
kidney are used for the analysis after slaughter [22, 27]. 
Corticosteroids are chemically similar to the AAS, therefore the 
analytical methods used for the determination of corticosteroids 
are analogous to the ones for AAS. The common pathway 
followed to analyse corticosteroids adopts a preliminary step of 
enzymatic hydrolysis prior of the extraction process in order to 
obtain the free compounds. However, numerous studies reported 
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the possibility to analyse directly the analyte without 
deconjugation step [41,42]. Subsequently, liquid-liquid extraction or 
solid liquid extraction are carried out using different organic 
solvents, i.e. tert-butyl-methyl-ether, diethyl-ether. A step of 
purification is commonly performed in order to obtain 
interference-free samples to analyse. The SPE methods described 
to purify the sample are several, such us the use of simple C18, 
polymeric-based sorbents, HLB Oasis or the more specific 
immunoaffinity columns. The urine, which is the required matrix 
for the monitoring purpose, is traditionally checked, but nowadays 
new kind of matrix are chosen as alternative available matrices due 
to the possibility to have more information  from there and to find 
the analyte more concentrated, for examples hair, plasma and 
serum), faeces, feed, milk, water. Working with solid and more 
complex matrices, a step pf defatting is necessary, such as using n-
hexane.  
Different system of detection are used depending of the 
purpose of the analysis required. A preliminary immune enzymatic 
method (ELISA) is ordinarily done for a screening analysis. 
However, the low specificity of an ELISA test and the possibility 
to obtain false positive results, due to a compounds cross-
reactivity, causes problems regarding the interpretation of the 
results. As confirmatory levels, the techniques used are MS-based 
system of detection, preceded by specific and selective separation 
procedure. In earlier times, the optimization of GC–MS methods 
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was prevalent for the analysis of corticosteroids, but the thermally 
lability and their low volatility cased difficulties on the 
determination and need a long derivatisation step, prior the GC-
MS analysis. Currently, the application of LC-MSn is principally 
preferred, particularly with ion source using electrospray 
ionization (ESI) in negative mode. For the analysis of 
corticosteroids the use of UPLC is now rising. The challenge 
remains for the mass spectrometer analysts is the ability to separate 
isomers as dexamethasone and betamethasone, because with 
common reverse phase columns, it results difficult. Therefore, the 
use of different chromatographic column, characterized by 
different sorbent, are preferred, for example graphite-based 
columns could be used to achieved the separation of the isomers. 
Monolithic and polymeric reversed-phase columns are used, even 
if rarely [43-44]. 
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1.4  Thyreostats 
1.4.1. Thyroid gland 
The bovine thyroid gland is one of the endocrine glands 
and it is constituted by two lobes connected by an isthmus between 
the 2°and 4° tracheal rings, as shown in Figure 17. A normal gland 
weighs between 20-65 grams in a bovine adult while a young cattle 
or calves could have a gland weighing 12-31 grams [1].  
 
Figure I-17. Anatomy structure of the thyroid gland. 
Regarding the microscopically structure, the thyroid 
gland is composed by spherical follicles that are the functional 
units of the gland. (Figure 18) The follicles are lined by a layer of 
epithelial cells, secreting active iodine hormones: triiodothyronine 
(T3) and thyroxine (T4) bound to glycoprotein Thyroglobulin 
(TG). Close to the thyrocytes, the cells parafollicular or C cells 
synthesize calcitonin peptide, involving in the calcium, and 
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phosphate and sodium balance of the organism. The thyroid 
hormones profoundly increase the metabolic rate of the metabolic 
activities of almost all the tissues of the body: increase the oxygen 
consumption and heat production, stimulate the metabolism of 
cholesterol, carbohydrates , stimulate the normal growth and body 
development and have effect on the cardiovascular and nervous 
system [2].  
 
Figure I-18. Microscopically structure of thyroid gland. 
1.4.2. Iodide Pump (Iodide Trapping)  
Iodine is a necessary element for the synthesis of the 
thyroid hormones; therefore, a correct thyroid function essentially 
depends on a proper iodine intake from the diet. From the blood 
circulation, iodine is transported into the thyroid glandular cells 
and follicles, whose basal membrane has the specific pump for 
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taking iodine into the cells. This process is called iodide trapping 
[2].  
The extraction of iodine from the plasma and its 
concentration by the thyroid cells is an active process of 
concentration against an electrochemical gradient, which implies 
a waste of energy ensured by the system ATPase Na / K dependent. 
This is a mechanism saturable, energy-dependent, which produces 
an increase of the intracellular level of iodine from 20 to 40 times 
higher than in plasma. The ability of the thyroid gland to 
concentrate iodine is controlled by the activity of a sodium / iodide 
symporter (NIS), recently identified as a protein located on the 
membrane of the thyrocytes [3].  
1.4.3. Thyroglobulin, and Chemistry of Thyroxine and 
Triiodothyronine Formation  
The iodide ions are converted by the enzyme peroxidase 
to an oxidized form of iodine, either nascent iodine (I0) or I3-, a 
form of iodine capable to link the aminoacid tyrosine.  
The TG, synthesized from the endoplasmic reticulum and 
Golgi apparatus and secreted into the follicles, is bounded to the 
iodine trough the organification. An iodinase enzyme catalyzes the 
binding of the iodine to a tyrosine of the TG. Tyrosine is first 
iodized to monoiodotyrosine (MIT) and then to diiodotyrosine 
(DIT). The coupling of two DIT will form a molecule of 
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triiodothyronine (T4) while the coupling of a MIT and a DIT form 
a molecule of thyroxine (T3), the major hormonal product of the 
coupling reaction that remains part of the thyroglobulin molecule, 
while triiodothyronine represents about one fifteenth of the final 
hormones. The normal thyroid gland produces all the circulating 
T4 and approximately 20% of the entire circulating T3. Many of 
the biological activity of thyroid hormones is due to the effects of 
T3 on the target cells, which has a great affinity for the receptor 
for thyroid hormones and is about from 4 to 10 times more potent 
than T4. Since 80% of the T3 serum is derived from the 
deiodination of T4 in tissues and since the thyroid hormone 
receptor preferentially binds the T3, T4 is considered a 
prohormone. Then, T3 and T4 are released into blood circulation 
[2].  
1.4.4. Storage of Thyroglobulin 
The thyroid gland has ability to store large amount of 
hormones in order to guarantee a supply of thyroid hormones for 
2 or 3 months, depending on the needs of the organism. In fact, 
after the hormone synthesis, each thyroglobulin molecule contains 
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up to 30 thyroxine molecules and a few triiodothyronine 
molecules, a useful form to be stored [2]. 
1.4.5. Release of Thyroxine and Triiodothyronine from 
the Thyroid Gland 
Thyroxine and triiodothyronine has to be cleaved from 
the TG in order to be released into the circulating. Under 
physiological conditions, the TBG binds almost completely T4 and 
T3: the small fraction unbound (free or: F = free) of the activity is 
responsible for a biological hormone. Proteases digest iodinated 
thyroglobulin, releasing the hormones T4 and T3, the biologically-
active agents central to metabolic regulation [2].  
1.4.6. Transport of Thyroxine and Triiodothyronine to 
tissues and transcription 
In the bloodstream, carrier proteins, synthetized from 
liver, form complexes with thyroxine and triiodothyronine. 
Mainly, there are three specific carrier proteins: thyroxine-binding 
globulin (TBG) and thyroxine-binding prealbumin (TBPA), and 
albumin. The hormones are released slowly depending on the high 
affinity of the plasma-binding proteins for the thyroid hormones. 
The catabolism of thyroid hormones occurs in the liver. Most of 
the actions of thyroid hormones are mediated by the interaction of 
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T3 with specific nuclear receptors. The receptors for thyroid 
hormones belong to a family of nuclear transcription factors 
hormone-response elements, which are structurally and 
functionally to steroid hormones. After binding of the nuclear 
thyroid hormone receptor, the complex binds to a regulatory 
region of the gene (thyroid-hormone response elements - TRE) and 
starts a series of events that lead an increased transcription of the 
DNA, translation of the mRNA and protein synthesis. Hence, the 
thyroid hormones increase the metabolic activities of almost all the 
tissues of the body [2]. 
1.4.7. Physiological effects 
The thyroid hormones on the organism are various and 
are briefly summarized [2]: 
 Stimulation of Carbohydrate Metabolism 
 Stimulation of Fat Metabolism: – Decreases the 
concentrations of cholesterol, phospholipids, 
and triglycerides. – Increases numbers of low‐
density lipoprotein receptors on the liver cells, 
leading to rapid removal of low‐density 
lipoproteins from the plasma. – Increases 
significantly the rate of cholesterol secretion in 
the bile and consequent loss in the faeces 
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 Increased metabolism in the tissues causes more 
rapid utilization of oxygen than normal and 
release of greater than normal quantities of 
metabolic products from the tissues. These 
effects cause vasodilation in most body tissues, 
thus increasing blood flow 
  Cardiac output also increases. Thyroid hormone 
has a direct effect on the excitability of the heart, 
which in turn increases the heart rate 
1.4.8. Regulation of Thyroid Hormone Secretion 
Thyroid secretion is primarily controlled by thyroid‐
stimulating hormone (TSH), secreted by the anterior pituitary 
gland in response of the hypothalamus releases hormone (TRH) 
through the Hypothalamic–Pituitary–Thyroid axis. Anterior 
pituitary gland cells produce the thyroid stimulating hormone 
(TSH), a glycoprotein that interacts with specific receptors on the 
cells of the thyroid gland and stimulates the synthesis and secretion 
of thyroid hormones. The synthesis and release of TSH of the 
pituitary gland are influenced by hormones from the thyroid and 
by hypothalamic peptide TRH. The activity of the thyroid gland is 
regulated by a negative feedback, in which the thyroid hormone 
binds to specific receptors on pituitary gland cells inhibiting the 
secretion of TSH and the hypothalamus TRH. The interactions 
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among the hypothalamic-pituitary-thyroid maintain a stable 
amount of circulating thyroid hormones. Therefore, aberrations of 
TSH levels almost always indicate the presence of a pathology 
thyroid hidden. The effects of TSH on the thyroid are numerous 
and complex. It stimulates proliferation mobile and more increases 
the synthesis of thyroid peroxidase, thyroglobulin and uptake 
Iodine all 'inside of the follicular cells and its incorporation in the 
thyroid. Then, the synthesis and release circulating thyroid 
hormone is dependent on factors intrinsic to the gland, such as 
availability of iodine, and factors extrinsic to it, as the negative 
feedback. This is made through different mechanisms [2]: 
1. The hypothalamus by TRH (Thyrotropin Releasing 
Hormone) 
2. The pituitary by TSH (Thyroid Stimulating Hormone) 
3. The same thyroid hormones, or better, their blood level. 
1.4.9. Thyreostats 
Thyreostats are drugs commonly used in human medicine 
as treatment for people with Graves’ disease (autoimmune 
disorder) and in general in the control of hyperthyroidism. The 
consequence of the treatment with thyreostats is a decrease of the 
circulating thyroid hormones (T3 and T4) due to an inhibition of 
the function the thyroid gland [4]. 
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Thyreostats are a complex of synthetic compounds that 
are used in order to interfere with the function of the thyroid gland 
with a following decrease of the production and then inhibition of 
the thyroid hormones T3 and T4, which causes a wide range of 
actions mainly correlated with the growth and the metabolism 
development. In the veterinary field, the administration of the 
thyreostats are made in case of high production of thyroid 
hormones, as in the hyperthyroidism condition, especially for cats 
and dogs [4]. Regarding milk and meat producing animals, 
thyreostats are given with the feed during the last 4-8 weeks before 
the slaughter. The thyreostats are easily and quickly absorbed, are 
able to alter the energetic metabolism by the inhibition of thyroid 
hormones. Despite of the severe legislation regarding the use of 
thyreostats, their illegal administration cannot be excluded. The 
treatment with antithyroid agents is made in order to obtain an 
increase of animal weight due mainly to an increase absorption and 
retention of water in the edible tissue, as well as filling of the 
gastrointestinal tract.  The results is to obtain meat that weighs 
more, but with poor nutritional proprieties [5]. However, 
thyreostatic drugs cause hypertrophy of the thyroid gland, easily 
detectable after slaughter of the animal and a thyroid gland 
weighing more than 60 g was considered as a suspect of fraudulent 
use of the anti-thyroid agents [6]. Furthermore, the presence of 
thyreostats in edible tissues represents a hazard to human health 
related to consumption of contaminated meat from thyreostats [7]. 
 111 
Teratogenic and carcinogenic effects have been reported after 
exposition of edible tissues derived from treated animals, and 
cases of aplasia cutis, characteristic disease of the scalp, were 
registered in Spain due to a contaminated meat ingestion [7-12].  
The main thyreostats used in animal livestock are divided into 
two groups: 
1. Natural source of sulfur compound 
Thiocyanates and oxazolidine-2-thiones 
(OZT’s) are considered not only endogenous but also 
synthetic because they are substances that are capable to 
be synthetized. Cruciferous or Brassicaceae vegetables 
are unique in that they are rich sources of glucosinolates, 
sulfur-containing compounds thyroid inhibiting synthetic 
compounds [13]. 
2. Xenobiotic thyreostats  
The most frequently used thyreostatic drugs 
include the very potent thyroid-inhibiting compounds 2-
thiouracil (TU), 6-methyl-2-thiouracil (MTU), 6-propyl-
2-thiouracil (PTU), 6-phenyl-2-thiouracil (PhTU), and 1-
methyl-2-mercapto-imidazole (tapazole, TAP) [4-6]. The 
chemical structures of these substances are shown in 
Figure 19.  
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Figure I-19. Chemical structure of thyreostats. 
Thyreostats are polar amphoteric thioamide, 
with a low molecular weight (114‐204 Da) a heterocyclic 
tautomeric structure and are mostly derived from 
thiouracil and mercapto-imidazole. The sequence 
consisting in nitrogen–carbon–sulphur known as 
thioamide is considered as accountable for the thyroid-
inhibiting activity (Figure 20). [7]. Especially, the anti-
thyroidal agents include three types of compounds: 
I. Sulfated compounds to 
position 2, aromatic heterocycles containing 
two nitrogen atoms to position 1 and position 3 
(pyrimidine), including the thiouracil (TU) and 
its analogues to which is added a group R at the 
position 6. (ethyl, dimethyl, propyl or phenyl 
group). 
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II. Group of the 2‐
mercaptobenzimidazole (MBI), characterized 
by an aromatic cycling structure with a benzene 
and sulphated imidazole group. 
III. Group of the 1-methyl-2-
mercaptoimidazole, or well known as tapazole 
(TAP), a methylated an sulfated imidazole 
compound. 
  
Figure I-20. Chemical structure of thioamide sequence. 
1.4.10. Endogenous occurrence of thiouracil  
Anti-thyroidal agents could be produced from precursors 
present in Cruciferous or Brassicaceae plants and relative 
analogues. Because of their cheapness and high protein content, 
Brassicaceae are common added in feed. Cabbage, mustard and 
rapes, the most known Brassicaceae, contain glucosinolates, which 
are secondary metabolites involved in the tissues defence system. 
The catabolism of glucosinolates is characterised by the hydrolysis 
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via plant myrosinase, as β-thioglucosidase or by bacterial 
hydrolysis of the microflora of the gut. The hydrolysis of the 
glucosinolates produces oxazolidine-thiones, nitriles, 
epithionitriles, thiocyanates, isothiocyanates, thiourea, that are 
different on the bases of the pH condition of the field production. 
The products of the glucosinolates catabolism express anti-
thyroidal proprieties, as performed by the synthetic thyreostats. 
These metabolites, and particularly the thiocyanate, are able to 
inhibit the thyroid functions and cause a reduction in the 
production of the thyroidal hormones. Other metabolites could 
interfere with different functions of the organism, including motor 
capability; they could have nephrotoxic and mutagenic effects. 
Hence, the presence of glucosinolates in feed should be minimal. 
Furthermore, the presence of TU was found in untreated animal 
(bovine, pigs, and horses) not subject to a diet rich in Brassicaceae. 
A question regarding the non-clear or dual origin of TU raises, as 
well the difficulties in the TU determination on case of fraudulent 
use of endogenous origin. In addition, the thiocyanate could be 
synthetically produced and their characteristic thioamide group, 
that is the corresponding of that in the synthetic drugs, is 
responsible for the inhibition of the thyroid gland activity [14].  
A relationship between presence of Brassicaceae in feed 
and thiouracil in urine has been however demonstrated by Pinel 
[12], Vanden Bussche [15] and Kiebooms [14,16]. The Community 
Reference Laboratories (CRLs) in 2007 proposed a recommended 
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concentration of 10 μg L-1 in urine and 10 μg kg-1 in thyroid for the 
purpose of control [17 ]. 
Recently, Wauters et al. have reported concentrations up 
to 18.2 μg L‐1 in the 99% percentile from 3894 bovines and they 
suggested to increase the recommended concentration to 30 μg L-
1 [18]. Actually, the Italian National Residue Plan already provides 
this level of concentration as the capability of detection for the 
thyreostats in urine [19]. 
1.4.11. Thyreostats and legislation  
Presence of residues of thyreostats in edible tissues are a 
risk for consumer’s health of food of animal origin, and based on 
this risk, the European legislation established the prohibition of the 
illicit use of thyreostats for farm animals [20, 21]. Consequently, the 
method to determinate the presence of thyreostats are rigorously 
regulated. A minimum required performance limit (MRPL) of 10 
μg L-1 in urine is required for the analytical methods. In 1974, 
Belgium forbidden the use of thyreostats and the EU extended the 
prohibition of the use of thyreostats in all Member States seven 
years later, as Council Directive 81/602/EC [21] and, then, revised 
by Council Directive 96/22/EC [22]. Furthermore, it states the ban 
import of meat from third countries hailing from animals treated 
with in the EU prohibited substances. In order to guarantee the 
control of the illicit use of thyreostats, the EU declares specific 
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measures of control have to be observed and realised by each EU 
Member States, as described by Council Directive 96/23/EC [23]. 
The thyreostats are included in in Directive 96/23/EC in Annex I 
as substances belonged to the Group A of the substances having 
anabolic effects and unauthorized substances [23]. Concerning 
thyreostats, a minimum required performance limit (MRPL) has 
been suggested (but not already fixed by the EU authorities) at 100 
μg L−1 or μg kg−1 in urine and thyroid gland, respectively [24]. The 
Community Reference Laboratories (CRLs) in the EURL 
guidance paper in 2007 proposed a recommended concentration 
(RC) for TAP, TU, MTU and PTU of 10 μg L-1 in urine and 10 μg 
kg-1 in thyroid for the purpose of control. RC is considered an up-
to-date reference value for setting analytical requirements to be 
fulfilled by the analytical methods used for the determination of 
thyreostats [17]. Nevertheless, Wauters et al. have recently reported 
concentrations up to 18.2 μg L-1in the 99% percentile from 3894 
bovines and they suggested to increase the recommended 
concentration to 30 μg L-1[18]. Actually, the Italian National 
Residue Plan already provides this level of concentration as the 
capability of detection for the thyreostats in urine, while regarding 
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the thyroid glands, a minimum required performance limit 
(MRPL) of 100 μg.Kg-1is required and set [19]. 
1.4.12. Method of analysis of the thyreostats  
Regard to the importance of the effects that thyreostats 
cause to human health when present as residues in edible matrices, 
different analytical approaches were developed to determine 
thyreostats, as required by European legislation. Prior to the 
development of mass spectrometry techniques, the abuse of 
thyreostatic drugs, causing a condition of hypothyroidism, was 
mainly verified by histological analysis of samples of thyroid, as a 
semi-quantitative parameter and the observation symptoms 
resulting from the administration of these drugs. At the very 
beginning, differentiation (compliant/non-compliant) was based 
on a combination of subjective factors: symptomatology, detection 
of thyroid hormones, thyroid micro- (histological changes) and 
macroscopy (weight, goiter). Eventually, the weight shifted 
towards analytical methodologies for the detection of thyreostats. 
Before the development of the spectrometric system of 
detection, in the early 70s a colorimetric method was firstly 
applied. However, the unsatisfactory performance parameters of 
the limit of detections obtainable through this method and the 
suitability to use the colorimetric method only for the thyroid 
matrix have compelled the researchers to choose another system 
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of detection. Afterwards, thin layer chromatography (TLC) 
improved the level detection and gave the possibility to analyse 
thyreostats in in the order of 10 µg kg-1. 
Nowadays, the evaluation of the thyreostatic residues in 
matrices of animals is mainly performed by gas or liquid 
chromatography as separation methods combined to mass 
spectrometry as detection techniques, able to reach a lower LOD 
in the range of 1-10 µg kg-1 [24]. 
Normally, the extraction of thyreostats is carried out by 
using polar solvents more suitable to their chemical characteristics 
as methanol, acetonitrile or ethyl acetate. Further steps of 
purification or clean up with different kind of solid phase 
extraction (SPE) are reported [24]. Due to the small molecular mass 
and high polarity of the thyreostats, several authors proposed a 
derivatisation before or after the clean-up, mostly made with 3-
iodobenzylbromide (3-IBBr), in case of HPLC-MS/MS analysis 
[24]. This procedure induces the stabilisation of the chemical 
structure of the molecule under a specific and single tautomeric 
form, the reduction of the molecular polarity in order to increase 
the separation characteristics on the reversed-phase column in case 
of HPLC-MS detection and the increase of the molecular mass [25]. 
Nevertheless, its application before the analysis could cause a loss 
of analytes, particularly due to the several evaporation steps 
required. Furthermore, the avoidance of the derivatization 
simplifies and shortens the whole analysis procedure [26].  
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An innovative analytical method based on QuEChERS 
extraction and ultra-high performance liquid chromatography 
coupled to triple quadrupole mass spectrometry detection was 
recently carried out. This technique do not require further SPE 
clean-up or derivatization reactions. The method resulted simple 
and easy to be conducted and able to achieve calculated decision 
limits (CCα) are below the recommended concentration [27].  
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2. Aims 
Problems relating to Food Safety are acquiring 
importance and becoming an increasingly frequent phenomenon. 
Terms as “mad cow disease”, “dioxin-contaminated chickens” are 
getting more familiar and are arising a public interest. Recently in 
2013 the announcement of the horse meat passed off as beef, the 
well known as the horse meat scandal, produced a speeded stir. 
This problem of the horsemeat in frozen beef burgers and in beef 
lasagne has been for the first time reported in United Kingdom and 
subsequently, the analysis have also revealed a widespread 
phenomenon that involved more than 20 countries. In addition to 
commercial fraud, the most troubling aspect of the case concerns 
the use of meat from racehorses, sometimes treated with 
Phenylbutazone, a potent anti-inflammatory drug, for whom 
residues in edible matrices could be a dangerous risk for the 
consumer health [1,2]. These last news reports, including the trade 
and selling of bovine and pigs meat treated with illicit drugs or 
corticosteroids and antibiotics in Italy of the last two years, are 
further evidences of the need to strengthen the capability of the 
control system and increase the levels of increasing levels of 
protection guaranteed to the consumer [3,4]. 
The drugs used in the veterinary field are regulated as 
stated by the European and national legislation. Several veterinary 
drugs do not represent a risk for the consumer. Nevertheless, their 
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use and administration have to be severely controlled, and the 
eventual presence of residues of drugs in edible matrices could be 
a result of illicit treatment or in the case of authorized treatments, 
the inappropriate use of the drugs due to a wrong evaluation of the 
withdrawal times before slaughtering. Therefore, it is necessary to 
develop sophisticated and innovative analytical methods for 
different classes of compounds, whose residues could be present 
in the edible matrices and in the products of animal origin, causing 
a risk to human health. In addition, the monitoring of the consumer 
exposition to the drugs, the impact of the chemicals on the 
environmental and the security in the trade of the animals, result 
further important focal points to be addressed [5].  
Nevertheless, the demands of the market are not always 
in keeping with the available offer and fraudulent use of the drug 
treatment in order to fattening the animals, increasing their growth 
rate and, therefore, to obtain a meat sold at the highest price, it 
cannot be excluded [6]. 
In 1996, the prohibition of the use of beta-agonists and 
the substances having anabolic and thyreostatic actions in 
livestock farming were states with the Directive 96/22/EC, which 
was followed by the Directive 96/23/EC that establishes the 
measures that EU Member States should take to monitor 
substances and their residues in both live animals and animal 
products. In the Annex I of Directive 96/23/EC are listed the 
substances objects of the regulation and they are organised into 
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two groups. Group A or banned substances consist of the growth 
promoters substances subdivided into four groups: r anabolic 
steroids (group A1, A3, A4), Thyreostats (group A2), β-agonists 
or repartitioning agents (group A5) and Annex IV substances. The 
group B comprises veterinary drugs, environmental contaminates, 
and corticosteroids belong to group B2f despite their possible 
abuse to fatten animals [7,8]. 
The anabolic steroids hormones play a role similar to the 
endogenous testosterone, causing an increase of the anabolic 
metabolism, an increase of the thin body mass and a reduction in 
whole body and regional fat mass. 
The monitoring of the use of the growth promoting 
substances registered into the Group A and B2f has a central 
priority, due to their implication in the public health. However, it 
is necessary to improve the scientific knowledge and develop 
analytical methods in order to better understand the presence of 
certain substances having a double identity of endogenous and 
exogenous substances. As well described by Van Thuyne Wim in 
his thesis, these “pseudoendogenous substances” are “situated in 
a grey zone” and characterized by “a urinary threshold level, or 
compounds that are allowed if a proper medical cause justifies 
their use, such as corticosteroids”. These substances have been 
considered for a long time with exogenous origin. Nevertheless, 
thanks to the improvement of the technique and the consequent 
reducing of the limit of detection, they are also discovered as 
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endogenous or pseudoendogenous substances in some animal 
species or in particular conditions, and are “an emerging challenge 
for the future”[9,10] . 
The aim of this thesis is to contribute to the 
comprehension of the possible endogenous or natural origin of 
three borderline or semi-natural substances: boldenone in bovine 
urine, prednisolone in feedstuff for bovine and in porcine urine and 
adrenal glands and the development a new method for the 
detection of thiouracil in bovine urine and thyroid glands.  
 Boldenone in bovine urine 
17β-boldenone (1-dehydrotestosterone) or β-bold is an 
anabolic steroid with androgenic anabolic activity, 
structurally different from 17β-testosterone for the 
dehydrogenation of the carbon in the first position of the 
A ring [11]. The European Directives 96/22/CE and 
96/23/CE ban bold as growth promoter, including it into 
the A3 section as regards the production of animal origin 
and the livestock [7,8]. Until 1996, β-bold has been 
considered only of synthetic origin, but several studies 
confirmed the endogenous production of boldenone in its 
epimer form (17α-boldenone) in urine as a result of the 
involvement of bacteria from faeces or due to the role of 
maggots and moulds on feed, environmental 
contamination. Recently, natural production of traces in 
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urine of 17β-bold is suggested due to the conversions of 
phytosterols precursors [11]. In two studies on evaluation 
of the β-bold metabolism, Le Bizec and Destrez proposed 
β-bold -sulfo conjugate in urine as a useful marker proof 
of illegal treatment [12,13]. At present, α-bold is considered 
as endogenous production in bovine urine if it is detected 
at a concentration lower than 2 ng mL-1 in bovine urine 
[11], where the steroid is present as sulfo or glucuronic-
conjugated form [14]. Regarding bold, the European and 
Italian legislation established the zero tolerance limits 
and state that the only presence of 17β-bold at any form 
of conjugation in urine is a sufficient evidence of illicit 
administration [8,15].  
The determination of conjugated steroids are 
mainly performed after a preliminary step through 
hydrolytic enzymes (glucuronidases and sulfatases) from 
Escherichia coli or Helix Pomatia. Nevertheless, the 
deconjugation may be incomplete and steroid conversion, 
degradation or artefact formation may occur [16, 17]. 
Therefore, one of the aims of the present study is to 
improve the knowledge concerning the origin of 
boldenone in bovine urine, trying to understand if the β-
bold II metabolites could be marker of abuse or naturally 
produced. This purpose was followed in two research 
papers, reported in Chapter 3.1 and 3.2.  
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The first one focused on the improvement of the 
methodological approach to investigate the presence of 
boldenone in urine. Particularly, the development and the 
validation of an innovative method of extraction by using 
immunoaffinity columns (IACs) were carried out. 
Immunoaffinity columns (IACs) are a separation method, 
which permits to obtain a very selective extraction and 
guarantee a purified extract of compounds in only one-
step. Consequently, IACs perform a more reliable 
technique than the common liquid-liquid extraction and 
SPE clean up, optimizing a sensitive, specific, 
reproducible LC-MS/MS technique of analysis. It 
allowed the detection in a single chromatographic run of 
a wide range of steroids, included free forms of α- and β-
bold, as well as α-bold conjugates and 
androstadienedione (ADD). The validation has been 
made according the Decision of Commission 
2002/657/EC [18]. Concerning the second scientific paper, 
the validated method was used to in order to verify the 
possible endogenous origin of β-bold II phase metabolites 
in an extended study in vivo on 56 young bulls. Urine 
samples from 56 animals were collected at different 
intervals at the farm, where the animals were under 
veterinary control, and at the slaughterhouse, where 
histological alterations to the bulbourethral and prostate 
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glands were also investigated. The main variable 
evaluated was the influence of the stress in the eventual 
bold production. Therefore, we evaluated the occurrence 
of β-bold glucuronide and sulfate in young bull urine, 
with the aim of understanding whether they could be of 
endogenous origin, and to check for a possible 
relationship with particular environmental and stress 
condition. 
 Prednisolone in pigs in complementary 
feedstuff for bovine and in urine and adrenal glands 
Prednisolone (Δ14–pragnadiene-11β, 17-triol-3, 
20 dione) is a glucocorticoid with a gluconeogenetic and 
anti-inflammatory activity 3-4 times higher than the 
activity of cortisol, from which structurally differs for the 
presence of a double bond at the position Δ1-2 of the A 
ring, a feature in common with the structure of boldenone 
with respect to the testosterone [19]. In the Commission 
Regulation (EEC) 37/2010 are established maximum 
residues limits (MRLs) of Prednisolone for cattle: 4 µg 
kg-1 in muscle and fat, 10 µg kg-1 in liver and kidney and 
6 µg kg-1 in milk [20]. For urine, no MRLs have been set 
(it is not an edible matrix). Albeit its presence at any 
concentration should not be allowed, a 5 µg L-1 cut-off 
level is recommended, by the Italian Ministry of Health 
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[21]. The only exogenous origin of prednisolone was put 
in doubt through studies that have shown the possibility 
of find prednisolone in urine of untreated cattle. Studies 
suggested poor collection and storage conditions of the 
urine samples could be reasons of the prednisolone 
detections in urine. Besides an endogenous production or 
of ex vivo formation in urine of prednisolone, the 
hypothesis of an accidental ingestion of contaminated 
complementary feedstuff with prednisolone has to be 
taking into account. Considering the complexity of the 
feed composition, we investigated the presence and origin 
of prednisolone plant complementary feed samples for 
cattle. Particularly, we investigated the eventual findings 
of prednisolone in different commercially available 
complementary feedstuffs, stored at the farm and/or in the 
laboratory, with the purpose of understand and verify if 
its presence was due to neo-formation during storage. The 
study id reported in Chapter 3.3. 
Moreover, the role of stress in cortisol 
production and, consequently in the conversion in 
prednisolone is well known. 
 The possibility of the endogenous origin of 
prednisolone has also been described for equine and 
human urine, while there is still a lack of knowledge 
regarding the origin of prednisolone in pigs [22]. Until 
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2014, only one work has been performed about the 
endogenous presence of  prednisolone in pigs (sows). The 
Authors carried out the study on a limited number of 
animals (10), whose urine samples were analysed before 
and after the treatment prednisolone or a synthetic 
analogue of adrenocorticotropic hormone, and at the 
slaughterhouse. The livers were analysed, as well. All 
porcine urine samples collected before the treatment were 
confirmed positive for the presence of prednisolone and 
in most of them after the treatment. Instead, regarding the 
liver, prednisolone was only detected after treatment. The 
prednisolone/cortisol ratio in liver samples was suggested 
as a useful criterion to distinguish a case of fraudulent 
treatment with prednisolone. It has been suggested to 
confirm these observations in a study on a larger number 
of animals [23]. 
In order to clarify the possible endogenous 
origin of prednisolone and the influence of stress on the 
production of this corticosteroid in pigs, the study 
proposed in this thesis (Chapter 3.4) has investigated the 
presence of prednisolone in urine samples collected from 
the same 80 pigs at the farm and at the slaughterhouse. 
Furthermore, their adrenal glands were analysed, 
assuming an endogenous production of prednisolone in 
this organ.  
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A simple liquid-liquid extraction (for urine 
samples) and solid-liquid extraction (for adrenal glands) 
were performed in order to extract the analytes from urine 
and from adrenal glands, and then a LC-MS/MS analysis 
was done. 
 A simple validated method to analyse thyreostats in 
bovine urine and thyroid glands 
The administration of the thyreostats to cattle 
was banned since 1981 following to the severe 
pharmacological activity and the effects given by 
residues of the drugs in the edible matrices for the health 
of consumers [24]. The thyreostats induce an inhibition of 
the synthesis of hormones of the thyroid gland with a 
consequently decrease of the basal metabolism, 
gastrointestinal motility and an increase of the 
extracellular water retention. These effects are 
fraudulently exploited for fattening purposes. At present, 
No Minimum Required Performance Level (MRPL) or 
Maximum Residue Limit (MRL) has been established for 
thyreostats and, in particular the thiouracil [25]. Over 
recent years, the thiouracil was frequently found in 
bovine urine at a lower concentration than 10 μg L-1. 
Several studies confirmed a relationship between 
presence of Brassicaceae containing glucosinolates in 
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feed and thiouracil in urine, so assuming that thiouracil at 
low concentration could have “semi-natural origin” [26,27]. 
In the CRL Guidance paper of December 2007 of the 
Community Reference Laboratories suggested a 
recommended concentration (RC) of 10 μg L-1 in urine 
and 10 μg kg-1 in thyroid were suggested for monitoring 
purposes [28]. Newly, a retrospective study performed by 
six European Member States (France, Poland, the 
Netherlands, United Kingdom, Norway and Belgium) in 
the European Union Reference Laboratory (EURL) on 
the official thiouracil data (2010-2012) collected from 
bovines, pigs and small livestock, suggested to increase 
RC from 10 to 30 μg L-1 [29]. The Italian National Residue 
Plan already provides this level of concentration as the 
capability of detection for the thyreostats in urine [15]. 
Because of their chemical characteristics, the analysis of 
thyreostats is often carried out through a previous 
derivatisation step with 3-iodobenzylbromide to the 
extraction procedure, which might results in a loss in 
terms of recovery of the analytes. Confirmatory methods 
are now mostly perform with GC or LC-MS/MS system 
of detection [25]. In 2011 Vanden Bussche et al. proposed 
a method for direct detection without derivatisation of 
thyreostats in urine [30] . However, unique methods for the 
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direct extraction of the thyreostats from urine and thyroid 
glands from bovine have not yet been reported. 
Therefore, the purpose of the fifth work included 
in this thesis in Chapter 3.5, was to perform a simple, 
sensitive, specific and reproducible method for the 
extraction of five most frequently illegally used 
thyreostats (2-thiouracil, 6-methyl-2-thiouracil, 6-
propyl-2-thiouracil, 6-phenyl-2-thiouracil, 2-
mercaptobenzimidazole or tapazole and 5,6-dimethyl-2-
thiouracil, used as internal) without derivatisation, and by 
HPLC-MS/MS analysis in bovine urine and thyroid 
glands. 
The quantitative method was validated 
following the criteria established in the 2002/657/EC 
Commission Decision and SANCO/2004/2726-revision 
4 [18,31].  
The development of a simple and rapid method 
of analysis not only for the urine, but also for the thyroid 
glands could be a useful tool for studies regarding the 
distinguish between illicit treatment and the natural origin 
of thiouracil in bovine urine and thyroid glands and 
improve the understanding of the current ambiguous 
identity of thiouracil. 
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3.1.1. Abstract 
The debate about the origins of boldenone in bovine urine 
is ongoing for two decades in Europe. Despite the fact that its use 
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as a growth promoter has been banned in the European Union (EU) 
since 1981, its detection in bovine urine, in the form of α-
boldenone conjugate, is considered fully compliant up to 2 ng 
mL−1. The conjugated form of β-boldenone must be absent. In 
recent years, the literature about boldenone has focused on the 
identification of biomarkers that can indicate an illicit treatment. 
β-boldenone sulfate is a candidate molecule, even if the only 
studies currently available have taken place in small populations. 
In this study, a method for the determination of sulfate and 
glucuronate conjugates of β-boldenone was developed and 
validated according to the European Commission Decision 
2002/657/EC and applied to α-boldenone sulfate and glucuronide, 
α- and β-boldenone free forms and androstadienedione (ADD), 
too. The clean-up with immunoaffinity columns enabled the direct 
determination of the conjugates and free forms and allowed 
specific and sensitive analyses of urine samples randomly selected 
to verify this method. The decision limits (CCα) ranged between 
0.07 and 0.08 ng mL−1, the detection capabilities (CCβ) between 
0.08 and 0.1 ng mL−1. Recovery was higher than 92% for all the 
analytes. Intra-day repeatability was between 5.8% and 17.2%, 
and inter-day repeatability was between 6.0% and 21.8% for the 
studied free and conjugated forms. This method has been 
developed as a powerful tool with the aim to study the origin of 
boldenone in a trial on a significant number of animals. 
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3.1.2. Introduction  
The use of substances that have hormonal activity for 
growth promotion in farm animals has been prohibited in the 
European Union (EU) since 1981 [1]. The bans on the use of such 
substances, on the trade of treated animals and their meat within 
the EU, and also on the import from third countries was confirmed 
in 1988 [2, 3]. A typical substance with hormonal action is 17β-
boldenone (1-dehydrotestosterone or androsta-1,4-dien-17β-ol-3-
one) (β-bold), an anabolic steroid that differs from testosterone 
only by the double bond between carbons 1 and 2 of the steroid A 
ring as shown in Figure 1. In 1996, Arts et al. [4] reported the 
natural occurrence in calf urine of 17α-boldenone (α-bold) at 
concentrations ranging from <0.1 to 2.7 ng mL−1. Since then, a 
number of studies and regulations followed, aiming to explain the 
presence of boldenone (bold) in bovine urine, to indicate a 
biomarker metabolite for illicit treatment, and to establish levels 
of the hormonal substance that could exclude administration to the 
animal [5, 6]. In particular, in September 2003, the thesis of the 
natural production of this steroid was proposed by the experts 
within the EU, who stated that scientific knowledge was sufficient 
to conclude that the presence of α-bold in urine and faeces of 
bovine animals has a natural origin. They set the ‘natural 
threshold’ of 2 ng mL−1 in the urine of veal calves below which α-
bold conjugate (boldenone conjugates are water soluble forms of 
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boldenone bound to e.g. glucuronic acid formed by metabolism in 
the animals) come from sources other than illegal treatment. The 
presence of β-bold conjugates at any concentration in the urine of 
veal calves was indicated as the result of an illegal treatment [7]. 
The presence of conjugates of α- and β-bold, without specifying 
the nature of the ionized group (sulphate, glucuronide) is not the 
only option considered by the scientific community. Biddle [8] in 
2005 performed a study on beef cattle treated with three 
preparations of bold: intra-muscular bolus administration of β-
bold, followed by oral administration of the supplement 
androstadienedione (1,4-androstadiene-3,17-dione) (ADD), and 
finally intra-muscular administration of β-bold undecylenate. He 
concluded that highly sensitive methods would be required to 
detect the abuse of bold using β-bold glucuronic acid conjugate as 
a marker; they could not confirm the EU recommended level of 2 
ng mL−1 for α-bold glucuronic acid conjugate due to the lack of the 
reference standard. Finally, two markers, present in the 
glucuronate fraction regardless of route of administration, were 
specially indicated in this study: 6β-hydroxy-17α-bold and 5z-
androst-1-ene-3z-ol-17-one (the letter ‘z’ indicates position α or β, 
due to the lack of the reference standard). Another study [9] 
investigated the metabolites of bold in treated cattle after 
intramuscular and oral treatment with bold, bold esters and ADD. 
The Authors showed that the majority of metabolites, analysed by 
GC-MS, were glucuronide conjugates and that β-bold sulfate was 
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present only in urine from treated animals (this last result obtained 
by LC-MS/MS). They therefore suggested to use β-bold sulfate as 
an indicator of bold administration, after larger scale studies. 
However, the study was conducted in a predominantly qualitative 
way, the analytical limits in the LC-MS/MS were not reported; 
therefore, the question: “Who is to say that as analytical limits 
decrease, (particular steroids) will not be discovered as 
endogenous at a lower concentration?” [6] has a fundamental 
importance. In 2009, Destrez et al. [10] performed a study on treated 
male calves with oral administration of ADD or with intra-
muscular injection of bold undecylenate. The analytical limits for 
β-bold sulfate were set by both LC–MS/MS (negative ESI, SRM 
acquisition, triple quadrupole) and LC-HRMS (negative ESI, R 
30,000, OrbitrapTM): the decision limits (CCα) were 0.2 and 0.1 ng 
mL−1 and detection capability (CCβ) 0.4 and 0.2 ng mL−1, 
respectively. The Authors concluded that once again β-bold sulfate 
demonstrated to be the candidate marker of a treatment. In an effort 
to develop a study on an extended population, deemed necessary 
also by the Authors cited above, we developed an LC-MS/MS 
method with triple quadrupole technology that had the lowest 
analytical limits possible for the detection of β-bold sulfate in 
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bovine urine. The method was also developed for α-bold sulfate, 
α- and β-bold glucuronide, ADD, α-bold and β-bold (Figure 1).  
 
Figure 1. Chemical structures of the seven analytes. 
 
The validation was made according the Decision of 
Commission 2002/657/EC [11]. 
3.1.3. Materials and Methods 
3.1.3.1. Materials 
All solvents were of HPLC or HPLC-MS grade quality 
and supplied by Fluka (Sigma-Aldrich, St.Louis, MO, USA). 
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Formic acid (98–100%) was from Riedel-de Haën (Sigma-
Aldrich, St.Louis, MO, USA). The chemicals for the preparation 
of artificial urine were from Sigma-Aldrich (St.Louis, MO, USA). 
β-bold sulfate (triethylamine salt), β-bold glucuronide, and α-bold 
were from LGC Standards (Teddington, UK), and ADD and β-
bold were from Fluka (Sigma-Aldrich, St.Louis, MO, USA). The 
sulfate and glucuronide forms of α-bold, provided by research 
partners, were prepared by a two-step synthesis: the epimerization 
of β-bold (Steroid SpA, Cologno Monzese, Milan, Italy) using a 
modified Mitsunobu protocol, according to Dodge and Lugar [12]; 
and sulphation, according to Sanaullah and Bowers [13] or 
glucuronation, according to Casati et al. [14], of α-bold. Internal 
standards were β-bold sulfate-d3 for sulfate forms, β-Bold-d3 for 
free forms (LGC Standards, Teddington, UK) and epitestosterone 
(EpiT) glucuronide-d3 for α- and β-bold glucuronide (National 
Measurement Institute, Pymble, NSW, Australia). Stock solutions 
of each analyte and of the internal standards were prepared in 
methanol at a concentration of 1 mg L−1, and stored at −40°C. 
Working solutions were prepared daily by diluting the stock 
solutions. Immunoaffinity columns (IAC) were from Randox. 
Concentrated wash and storage buffers were supplied with the 
columns and diluted following the manufacturer’s instructions 
before use (DM 2185, Randox Laboratories, Antrim, UK).  
 154 
3.1.3.2. Artificial urine preparation 
We were unable to find bovine urine samples in which all 
analytes were totally absent. Artificial urine was prepared in our 
laboratory for the validation studies, as described by Fabregat et 
al. [15]. Briefly, 0.1 g of lactic acid, 0.4 g of citric acid, 2.1 g of 
sodium bicarbonate, 10 g of urea, 0.07 g of uric acid, 0.8 g of 
creatinine, 0.37 g of calcium chloride·2H2O, 5.2 g of sodium 
chloride, 0.0012 g of iron II sulfate·7H2O, 0.49 g of magnesium 
sulfate·7H2O, 3.2 g of sodium sulfate·10H2O, 0.95 g of potassium 
dihydrogen phosphate, 1.2 g of dipotassium hydrogen phosphate, 
and 1.3 g of ammonium chloride were dissolved in 1 L of ultrapure 
water. 
3.1.3.3. Urine sampling and storage 
Urine samples were collected from untreated, under 
veterinary control, Charolaise or Limousine young bulls. Urine 
(about 100 mL) was collected into long-handled sterile containers. 
A visual inspection was made to check the urine clarity, in order 
to exclude the presence of raw materials or faecal contamination 
[16]. Only clear urine was put in 150-mL containers, cooled to 4°C 
and taken to the laboratory for storage at −40°C until extraction 
and analysis. 
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3.1.3.4. Sample preparation, extraction and purification 
Five millilitres of centrifuged urine was added of internal 
standard to a final concentration of 2 ng mL−1. The IAC was 
washed with 5 mL ethanol:water (70:30, v/v) and equilibrated with 
3 × 5 mL wash buffer (flow rate ≤3 mL min−1, i.e. about one drop 
per second). After adjusting the pH to 8 with 0.1 N NaOH, the 
urine was loaded (gravity flow). Wash buffer (2 x 5 mL) and water 
(1 x 5 mL) were used to wash the column. The elution of the bound 
analytes was then made by the application of 4 mL ethanol:water 
(70:30, v/v) (flow rates ≤3 mL min−1) collected in a 15-mL 
polypropylene tube. The eluate was evaporated in a rotary 
evaporator. The dried extract was reconstituted in 500 µL of 
methanol:water (50:50; v/v) and transferred to an autosampler vial. 
The injection volume was 10 µL. The IAC could be again used, 
beginning from the equilibration described above, after a wash 
step with 2 x 5 mL ethanol:water (70:30, v/v).  
3.1.3.5. LC-MS/MS analysis 
LC analysis was carried out with an HPLC system 
(Thermo Fisher Scientific, San Jose, CA, USA), consisting of a 
Surveyor MS quaternary pump with a degasser, a Surveyor AS 
autosampler with a column oven, and a Rheodyne valve with 20-
μl sample loop. Chromatographic separation was achieved by 
using a Synergi Hydro RP reverse-phase HPLC column (150 x 2.0 
mm, i.d. 4µm), with a C18 guard column (4 x 3.0 mm) 
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(Phenomenex, Torrance, CA, USA), kept at 30°C. The flow rate 
was 200 l min−1, and the mobile phase consisted of 0.1% aqueous 
formic acid (solvent A) and methanol (solvent B). The gradient 
program is reported in Table 1. The overall run time was 22 
minutes.  
Table 1. Gradient Timetable. A: 0.1% aqueous formic acid; B: methanol. 
The mass spectrometer was a triple quadrupole TSQ 
Quantum (Thermo Fisher Scientific, San Jose, CA, USA) 
equipped with an electrospray interface (ESI) set both in the 
positive (ESI+) and in the negative (ESI-) ionization mode. 
Acquisition parameters were optimized in the ion spray mode by 
direct continuous pump-syringe infusion of standard solutions of 
the analytes at the concentration of 1 g mL−1, a flow rate of 20 
µL min−1 and flow rate of the MS pump of 100 µL min−1 in the ion 
source of the mass spectrometer. Conditions were as follows: 
capillary voltage 3,5 kV; ion transfer capillary temperature 340°C; 
nitrogen as sheath and auxiliary gas at 30 and 10 arbitrary units, 
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respectively; argon as collision gas at 1.5 mTorr; and peak 
resolution 0.70 Da FWHM. The scan time for each monitored 
transition was 0.1 s, and the scan width was 0.5 amu. Four 
diagnostic product ions were chosen for each analyte and internal 
standard. The acquisition was made in the multiple reaction 
monitoring (MRM). The selected diagnostic ions, one of which 
chosen for the quantification, and collision energies are reported 
in Table 2.  
Table 2. MS/MS condition for the MRM acquisitions of analytes and internal 
standards. Ions for quantification are in bold. CE (eV): collision energy. 
 
In Figure 2, the LC-MS/MS reconstructed chromatogram 
of an artificial urine sample spiked with 0.1 ng mL−1 of each 
analyte is shown together with the ion spectra; on the right the 
internal standards (2 ng mL−1) are also reported. Acquisition data 
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were recorded and elaborated using Xcalibur™ software from 
Thermo. 
 
Figure 2. Reconstructed LC–MS/MS chromatograms of a spiked artificial urine 
sample with the respective ion spectra. Left side: standard analytes (concentration 
= 0.1 ng mL−1). Right side: relative internal standards (concentration = 2 ng 
mL−1). 
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3.1.3.6. Method validation 
The developed method was validated according to 
Commission Decision 2002/657/EC [11]. Parameters taken into 
account were as follows: instrumental linearity, precision, 
recovery, decision limit (CCα), and detection capability (CCβ). 
The instrumental linearity was evaluated by drawing six points 
calibration curves in solvent, containing analytes concentrations 
corresponding to 0.25-0.5-1.0-2.0-3.0-4.0 ng mL−1 and a fixed 
amount of ISTDs corresponding to 20 ng mL−1. The validation 
study was done using artificial urine as explained in 3.2.3.2., so the 
evaluation of specificity could not be made. Matrix calibration 
curves were obtained by spiking urine samples with the seven 
analytes, resulting in three analytical series, each series with three 
concentration levels (0.05-0.1-0.2 ng mL−1) and six samples per 
concentration level (6 samples × 3 concentration levels × 3 series 
= 54 analyses). Method recovery and precision were evaluated 
using these matrix curves results; recovery was expressed in terms 
of percentage of measured concentration-to-fortified 
concentration ratio and precision as the coefficient of variability 
(CV). The same results were used to calculate the decision limit 
(CCα) and detection capability (CCβ) according to the matrix 
calibration curve procedure described in the Commission Decision 
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2002/657/EC as clarified in the document SANCO/2004/2726-
revision 4 [17].  
3.1.3.7. Evaluation of artificial urine suitability 
Three curves were prepared to evaluate the suitability of 
artificial urine. One curve with low doses (0.05; 0.1; 0.2 ng mL−1) 
of the seven analytes in artificial urine, two curves with high doses 
(0.5; 1.0; 2.5 ng mL−1) in artificial and bovine urine, respectively. 
The slopes and the Y-intercepts for each analyte of each curve 
were then compared with the unpaired t-test. 
3.1.4. Results and Discussions 
The presence in bovine urine of α-bold and, primarily, β-
bold in their free forms or as II phase metabolites, is a matter of 
debate in Europe. The need to study the conjugated metabolites 
of boldenone in urine as well as the development of a method that 
can distinguish the different conjugated forms, appears mandatory 
to distinguish between illicit treatment and the natural origin of 
boldenone in bovine urine. The developed method uses a simple 
extraction step with IAC and allows for the determination of 
ADD, sulfate, glucuronate, and free forms of α- and β-boldenone 
in only one chromatographic run at concentration levels suitable 
for research purposes.  
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3.1.4.1 Sample preparation, extraction and purification 
The need for an analysis that directly determined the free 
sulfate and glucuronate forms of bold led us initially to direct our 
efforts on clean-up methods like liquid/liquid extraction. 
Unfortunately, some results were achieved only for bold sulfate 
but not for bold glucuronide, while a different extraction 
altogether had to be made to detect the free forms. Direct 
determination methods of bold sulfate with good analytical limits 
are present in literature, as already stated [10]; a unique method that 
could together determine sulfate, glucuronate and free α- and β-
bold has not been developed even if Buiarelli et al. [18], in 2005 
proposed a method for β-bold free and conjugate forms, free α- 
bold and 5β-androst-1-en-17β-ol-3-one in bovine and human 
urine. The use of the IAC was, at least initially, due to a casual 
occurrence. Briefly, the IACs used in this study are in fact 
intended for the clean-up of urine and serum in order to detect the 
corticosteroids dexamethasone, betamethasone and 
flumethasone. In the course of the development of a method for 
the determination of these corticosteroids with bovine urine 
through IAC extraction and LC-MS/MS analysis with the full 
mass monitoring, we noticed the presence of interfering 
compounds. We hypothesized, because of the m/z values and due 
to the similarities in the chemical structures of anabolic steroids 
to corticosteroids, the compounds were the conjugate forms of 
boldenone. Subsequent trials performed by IAC clean-up of urine 
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fortified with the standards confirmed previous suppositions and 
gave surprising results in terms of analytical limits. Therefore, we 
decided to refine the method as described in 3.1.3.4 and 3.1.3.5 
and to validate it. IAC extraction is considered expensive, so we 
also considered the possibility that not all ten runs recommended 
by the manufacturer could be made, accounting for the different 
use from that indicated. We observed a constant response for the 
first eight runs, a tolerable decline in accuracy in the next two runs 
(that we roughly evaluated lower than 9%) and, subsequently, a 
variable and unpredictable fall in the column performance. Using 
a column for 10 cycles before discarding it is therefore advisable 
and keeps the cost per sample comparable to other techniques. 
3.1.4.2. LC–MS/MS  
Data acquisitions were performed on the pure standard 
compounds in full scan (m/z range 50–500) using the first 
quadrupole to choose the precursor ion. In MS/MS experiments 
m/z product ion scans were recorded between m/z 50 and 500 and 
the four product ions with the higher signal-to-noise ratio (s/n) for 
each analyte or internal standard were then chosen for analysis, 
performed in the MRM mode, because of its high sensitivity and 
specificity. The precursor ions, the four diagnostic product ions 
and the collision energies are reported in Table 2. The four ions 
fulfilled the requirements provided by the Decision of 
Commission 2002/657/EC [11] for the group A substances as 
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defined in Annex I of Directive 96/23/EC [19]. A minimum number 
of 3 ions (the precursor and 2 product ions) and of 4 identification 
points (IPs) are in fact required: as each one of the four product 
ions is equal to 1.5 IPs and the precursor is equal to 1.0 IP, the 
abundant value of 7 IPs was reached. The relative ion intensities 
also always complied with the maximum tolerances permitted. 
The ion for quantification was the most abundant of the four 
diagnostic ions.  
3.1.4.3 Method validation 
The instrumental linearity for the seven analytes was 
evaluated with calibration curves in solvent in a concentration 
range from 0.25 to 4.0 ng mL−1 using standard solutions in 
methanol:water (50:50; v/v), containing a fixed amount of ISTDs 
(20 ng mL−1 each). Regression coefficients of curves indicated a 
good fit for all analytes (α-bold sulfate, r2=0.982; β-bold sulfate, 
r2=0.991; α-bold glucuronide, r2=0.978; β-bold glucuronide, 
r2=0.988; ADD, r2=0.988; α-bold, r2=0.995; β-bold, r2=0.991). 
The matrix calibration curves built for each analyte were 
linear in the range from 0.05-0.2 ng mL−1. The regression lines, 
obtained using the least square method, had good fit for all 
analytes (α-bold sulfate, r2=0.977; β-bold sulfate, r2=0.995; α-
bold glucuronide, r2=0.985; β-bold glucuronide, r2=0.990; ADD, 
r2=0.995; α-bold, r2=0.982; β-bold, r2=0.994). 
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Specificity and matrix effect were not evaluated; the 
presence of at least one of the studied analytes in any bovine urine 
sample required the use of artificial urine, as already specified in 
3.1.3.2. Some bovine urine samples randomly selected were 
however checked, and the presence of one peak at the analyte 
retention times was shown not to be due to an interfering 
substance, i.e. the peak had all the characteristics of the analyte as 
provided by the Decision of Commission 2002/657/EC [11]. 
Precision, calculated by applying the one-way analysis of 
variance (ANOVA), was expressed as CVs, in terms of intra-day 
and inter-day repeatability. The results reported show that the 
intra- and inter-day repeatabilities for all the analytes were below 
17.2% and 21.8%, respectively. These CVs were lower than 22% 
as proposed by Thompson [20]. The high values were probably due 
to the low concentrations used for the method validation: The 
levels chosen were addressed to a subsequent research aimed to 
understand if conjugated bold in bovine urine have a natural or 
endogenous origin of and to eventually set a natural threshold. 
The mean recoveries ranged between 96% and 103% for α-bold 
sulfate, 97% and 102% for β-bold sulfate, 96% and 106% for α-
bold glucuronide, 93% and 109% for β-bold glucuronide, 95% 
and 104% for ADD, 92% and 110 % for α-bold, and 99% and 
100% for β-bold. The data for all the analytes are reported in 
Table 3. 
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Table 3. Method trueness and precision. 
CCα was calculated as described in the document 
SANCO/2004/2726 revision 4 [17] using parallel extrapolation to 
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the x-axis at the lowest experimental concentration. CCα and CCβ 
values are reported in Table 4, which shows the low analytical 
limits obtained.  
 
Table 4. CCα and CCβ validation data. 
3.1.4.4. Evaluation of artificial urine suitability 
After the first preliminary tests, we realized that we 
could not find bovine urine samples where all the studied analytes 
were totally absent. At least one peak for each ‘blank’ bovine 
urine at the retention times of the analytes was found. The 
estimated concentrations were moreover not much lower than 
0.05 ng mL−1, the lowest concentration considered in the 
validation study. In order to avoid errors in the parameter 
calculation, we could not therefore simply subtract the peak areas 
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to the corresponding ones that resulted in the spiked sample 
because of the similar values. The use of artificial urine was thus 
mandatory, even if an evaluation of its suitability was required. In 
a first step, we built two curves with high doses (0.5; 1.0; 2.5 ng 
mL−1) in artificial and bovine urine, respectively. The choice of 
this concentration range was made taking into account the 
estimated concentrations of the peaks found in bovine “blank” 
urine. We therefore considered it satisfactory to use a range the 
minimum concentration of analyte which was at least 10 times 
higher than the estimated concentrations in the “blank” bovine 
urine. The correlation coefficients of all the curves so prepared 
were higher than 0.99. The slopes and Y intercepts of each analyte 
in the two different matrices, compared with an unpaired t-test, 
did not result in significant differences. However, we could not 
yet consider the two matrices similar, as we were using doses 
higher than those used for validation. As a second step, we 
compared the slopes and Y intercepts of the high dose and low 
dose curves of each analyte in artificial urine. In this case, too, no 
difference was found. Therefore, we verified that high and low 
doses of each analyte, if combined, belonged to the same curve 
and subsequently that artificial urine was suitable for method 
validation. Slopes and Y intercepts of this “wide range” curves 
were compared with the slopes and Y intercepts of the high and 
low concentration curves. No difference was found for each 
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analyte. Accordingly, this curves were used as calibration curves 
for quantification of the samples described in 3.1.3.4. 
3.1.4.5. Application of the method 
In order to verify the developed method in real 
conditions, we analysed four urine samples, randomly collected 
from the young bulls under veterinary control, for the detection of 
the seven studied molecules. The reconstructed chromatograms 
and ion spectra relative to one sample are shown in Figure 3. 
 
Figure 3. Reconstructed LC–MS/MS chromatograms and respective ion spectra 
of the analytes detected in a urine sample. 
The concentration values found in the four sample 
ranged from 0.15 to 0.63 ng mL−1 for α-bol sulfate (3 positives); 
from 0.09 to 0.26 ng mL−1 for β-bol sulfate (3 positives); from 
0.12 to 0.58 ng mL−1 for α-bol glucuronide (4 positives); from 
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0.08 to 0.48 ng-mL−1 for β-bol glucuronide (4 positives); and from 
0.47 to 2.1 ng mL−1 for ADD (4 positives); α-bol was found in 
one only sample (0.53 ng mL−1) where β- bol was detected, too, 
at a concentration lower than CCβ. 
For further confirmation of our results, we asked the 
Drug Residue Laboratory of the official organization Istituto 
Zooprofilattico Sperimentale della Lombardia e dell’Emilia 
Romagna (IZSLER) to test five other urine samples already 
analysed by us for the presence of only β-bold conjugates. The 
method used by IZSLER was a fully validated method according 
to the Commission Decision 2002/657/EC with SPE extraction 
[21]. It must be stressed that the method involved deconjugation 
with β-glucuronidase and indirect and non-specific determination 
of conjugate forms by LC-MS/MS: the differences in the sample 
preparation and analysis only permitted a qualitative comparison. 
The method outlined in this paper always detected β-bold 
glucuronide and three times it detected β-bold sulfate, while the 
method used for comparison found β-bold conjugate four times 
out of five. The possibility that incubation with β-glucuronidase 
could cause inter-transformations of steroids [22] and that β-
boldenone could be neo-formed or metabolized cannot be 
discarded. It must be highlighted however that, when the samples 
were ordered by increasing concentrations found by the two 
different methods, the sequence was significantly the same as 
shown in Table 5.  
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Table 5. Results of the comparison between the IAC extraction plus LC-MS/MS 
analysis and the SPE extraction after hydrolysis plus LC-MS/MS analysis. 
3.1.5. Conclusions 
A simple method that uses an IAC extraction and LC-
MS/MS triple quadrupole analysis in the MRM mode, for the 
simultaneous determination of α- and β-bold sulfate, α- and β-
bold glucuronide, α- and β-bold, and ADD in bovine urine was 
developed and validated according to EU Decision 2002/657/EC 
[11]. The method was verified on real samples. A further 
qualitative confirmation by a different laboratory on five urine 
samples that we had already analysed was made just for the 
conjugated forms of β-bold. The results were also satisfying in 
actual conditions and demonstrated that IAC clean up can be used 
for the subsequent direct analysis of α- and β-bold and their 
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sulfate and glucuronate conjugates, and for ADD for research 
purposes. The next step will be the study of the bold II phase 
metabolites as biomarkers of an illicit treatment ‘to 
unambiguously distinguish treated from non-treated animals’ [9] 
on a representative number of animals. 
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3.2.1. Abstract 
The administration of boldenone to bovines, either for 
growth promotion or therapeutic purposes, has been banned in the 
European Union since 1981. It is, however, a pseudoendogenous 
hormone, thus its detection in bovine urine, in the form of α-
boldenone conjugates, is considered fully compliant up to 2 ng 
mL−1. Greater attention has been placed on β-boldenone, the 
anabolic active epimer, whose conjugated form must be absent in 
urine. Recently, the identification of a biomarker representing 
unquestionable evidence of illicit treatment with bold or its 
precursor androstadienedione has been a major topic in the 
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literature regarding the detection of residues in bovine urine, and 
β-boldenone sulfate is a candidate molecule. In this study, we used 
a method previously validated according to the European 
Commission Decision 2002/657/EC for the determination of 
sulfate and glucuronide conjugates of β-boldenone. We assessed 
the occurrence of these molecules in young bull urine, with the aim 
of understanding whether they could be of endogenous origin, and 
to check for a possible relationship with particular environmental 
and stress conditions. Urine samples from 56 young bulls were 
collected after transport stress, under non-stressful conditions and 
after transport and slaughter stress. Histopathological 
investigation of the hormone target organs, i.e. the bulbourethral 
and prostate glands, was also performed. The results indicate an 
inverse relationship between the presence and concentration of β-
boldenone sulfo- and gluco-conjugates in urine, and stress 
conditions, expressed by the absence of detection at the 
slaughterhouse. No significant macroscopic and histologic lesions 
were detected. Our study indicates that β-boldenone sulfate could 
be a biomarker of treatment only at the slaughterhouse, while at 
the farm, in untreated animals, (i.e. after a five-month period under 
the control of Official Veterinarians), sulfate and glucuronide 
metabolites were found with a frequency of 78% and 46%, 
respectively, showing the endogenous origin of boldenone. 
Keywords: β-boldenone sulfate, β-boldenone glucuronide, 
young bull urine, LC-MS/MS analysis. 
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3.2.2. Introduction 
The steroid β-boldenone (β-bold), also called 1-
dehydrotestosterone or androsta-1,4-diene-17β-ol-3-one is an 
anabolic steroid, which differs in structure from testosterone by 
dehydrogenation at the C1-C2 position of the 
cycloperhydrophenanthrene ring as indicated in Figure 1, where 
the conjugated forms of bold are shown. β-bold exhibits strong 
anabolic activity and for this reason can be used by athletes in 
doping preparations (principally as ester form, i.e. as 
undecylenate ester) [1].  
 
 
Figure 1. Chemical structures of the analytes. 
In the veterinary field, β-bold, like other anabolic 
steroids, is among the most important drugs tested for at 
horseracing and equestrian events [2], and is known to be illicitly 
administered as a growth promoter to meat-producing cattle [3,4]. 
Bold belongs to the A group of Council Directive 96/23/EC, which 
includes substances having anabolic effect and unauthorised 
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substances [5]. The presence of β-bold conjugates in veal calf urine 
is considered proof of illicit treatment, while a threshold of 2 ng 
mL-1 has been set for α-bold conjugates in the urine of veal calves, 
under which it could be considered endogenous and not proof of 
illegal administration. A detection capability (CCβ) of screening 
methods or a decision limit (CCα) for confirmatory methods for β-
bold conjugates of 1 ng mL-1 in urine is required for surveillance 
purposes [3, 6, 7]. 
The presence of bold in veal calf urine was first 
demonstrated by Arts et al. [8] who detected α-bold in the urine of 
untreated calves in concentrations ranging from <0.1 to 2.7 ng mL-
1, while β-bold was not observed at levels exceeding 0.1 ng mL-1. 
Sterk et al. confirmed these results on two bovines of unspecified 
gender and age [9]. 
However, it is necessary to elucidate the mechanisms that 
lead to the presence of endogenous bold in cattle urine. Faecal 
contaminations of calf urine could be a source of false positives 
for free α-bold and β-bold, due to the transfer of boldenone and/or 
its precursors from faeces to urine [10-12]. It has therefore been 
recommended to pay particular attention to the procedure of 
bovine urine sampling to prevent faecal contamination in order to 
avoid boldenone false positives [3]. 
The endogenous occurrence of β-bold, α-bold and related 
substances with hormonal activity in cattle urine and faeces could 
be linked to the conversion of phytosterols and other steroid 
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precursors in feed [13-16]. In 2004, Nielen et al. stated the 
importance of investigating the phase II metabolites of bold, 
asserting that the presence of β-bold conjugates (without 
specifying the kind of conjugated moiety) in the urine of calves 
can be considered evidence of illicit treatment [17]. Le Bizec et al. 
[18] and Destrez et al. [19] suggested, in a study carried out on a 
limited number of calves that the presence in urine of the sulfo-
conjugate fraction could be useful to distinguish between natural 
situations and the illegal use of β-bold in cattle.  
The determination of conjugated forms of anabolic 
androgen steroids like β-bold is mainly based on the analysis of 
the free form after a preliminary step of deconjugation, with the 
use of specific hydrolytic enzymes (glucuronidases and 
sulphatase) from Escherichia coli or Helix pomatia. After 
extraction, the analysis of steroids can be performed by GC-
MS/MS or LC-MS/MS. However, the enzymatic hydrolysis may 
be incomplete. Moreover, steroid conversion or degradation and 
artefact formation may occur [20, 21]. 
As an alternative to the indirect detection (i.e. after 
enzymatic hydrolysis) of β-bold conjugates, we have developed 
and validated a method which uses immunoaffinity purification 
coupled to LC-MS/MS in order to perform direct analysis of the 
glucuronide and sulfate forms of β-bold [22, 23]. In contrast to the 
present study, in that study the free forms of α- and β-bold, as well 
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as α-bold conjugates and androstadienedione (ADD) were also 
considered. 
In order to verify the possible endogenous origin of β-
bold II phase metabolites in young bulls, we carried out a study on 
urine samples from 56 animals collected at different times at the 
farm, where the animals were under veterinary control, and at the 
slaughterhouse. As already shown for the relationship between 
prednisolone and cortisol [24], we hypothesised that an increase in 
the release of androstenedione (AED) by the adrenal glands, 
stimulated by pituitary adrenocorticotropic hormone (ACTH), 
could lead to the production of bold through the formation of 
ADD.  
Additionally, we performed a histological examination of 
the accessory sex glands of each animal, a screening test 
introduced in Italy in 2009 by the Ministry of Health to control the 
illegal use of sex hormones [25]. This strategy is based on the 
biological effects of the different steroid classes in target organs. 
Groot and Biolatti [26] and Cannizzo et al. [27] reported 
morphological alterations to the accessory sex glands of 
boldenone-treated animals. The official monitoring of residues in 
cattle throughout the European Union in 2012 found 0.25% non-
compliance for the use of illegal growth promoters, including sex 
steroids, corticosteroids and β-agonists. In particular, in the group 
of steroids (A3), there were 0.09% non-compliant samples in all 
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animal and product categories. These figures may underestimate 
the real incidence of steroid abuse in meat cattle breeding. 
The conditions that could lead to the detectable presence 
of β-bold glucuronide and sulfate in the urine were hence 
considered: uncontrolled, stressed animals upon arrival at the 
farm, animals in non-stressful conditions after an adequate period 
of adaptation, and animals stressed by transport and slaughtering 
operations. In this last case, histological alterations to the 
bulbourethral and prostate glands were also studied. 
3.2.3. Materials and methods 
3.2.3.1. Chemicals and reagents  
Methanol (HPLC-MS grade), ethanol (HPLC grade) were 
purchased from Fluka (Sigma-Aldrich, St. Louis, MO, USA). 
Formic acid 98-100% was from Riedel-de-Haën (Sigma-Aldrich, 
St. Louis, MO, USA). Ultrapure water was prepared with a Milli-
Q Plus apparatus (Millipore, Molsheim, France).  
β-bold sulfate (triethylamine salt) and β-bold glucuronide 
were procured from LGC Standards (Teddington, UK). Internal 
standards were β-bold sulfate-d3 for the sulfate form and 
epitestosterone (EpiT) glucuronide-d3 for β-bold glucuronide 
(National Measurement Institute, Pymble, NSW, Australia). Stock 
solutions of each analyte and of the internal standards were 
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prepared in methanol at a concentration of 1 mg L−1, and stored at 
−40°C. Working solutions were prepared daily by diluting the 
stock solutions. Immunoaffinity columns (IAC) were from 
Randox. Concentrated wash and storage buffers were supplied 
with the columns and diluted following the manufacturer’s 
instructions before use (DM 2185, Randox Laboratories, Antrim, 
UK).  
3.2.3.2. Animal housing and urine collection 
The study was performed on 56 young Charolaise and 
Limousine bulls, initially weighing 300 to 350 kg; animals were 
reared in France, transported to the farm and slaughtered in an 
abattoir, both located in Piedmont. The young bulls were fed with 
a diet usually employed in zootechnical practice. Ad libitum 
access to water was allowed to the animals. Throughout the 
experimental period, the animals were under the control of Official 
Veterinarians of the National Health Service, who also collected 
urine at different times. The first collection was performed upon 
arrival (T1) at the farm. The second urine collection was 
performed at the farm after a five-month adaptation period (T2) in 
order to assess untreated, unstressed animals. The first and the 
second urine samples at the farm were collected into long-handled 
sterile container and collection was performed in the morning 
hours under conditions of natural micturition, as recommended by 
the Italian National Residues Plan  [28]. The third urine sampling 
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was performed at the slaughterhouse after a period of seven 
months (T3) of residence at the farm and when the weight of the 
animals was about 550-600 kg. This last urine sample was 
collected directly from the urinary bladder immediately after 
slaughter. A visual inspection was made to check the turbidity or 
the presence of raw materials. Only clean urine was sampled, 
frozen and taken to the laboratory for storage at -40°C until 
extraction and analysis. 
3.2.3.4. Tissue collection 
The bulbourethral and prostate glands of each animal 
were collected after slaughter. Tissue samples were fixed in 10% 
neutral buffered formalin overnight at room temperature and 
paraffin embedded according to routine histological procedures. 
Representative sections of each sample were stained with 
haematoxylin-eosin (HE). 
3.2.3.5. Sample preparation, extraction, LC-MS/MS 
analysis and method validation 
Urine extraction and analysis were performed as 
previously described by Chiesa et al..[23]. Briefly, a 5 mL 
centrifuged urine sample spiked with internal standards (2 ng mL-
1) and adjusted to pH 8 with 0.1 N NaOH was loaded into a 
previously washed IAC column (5 mL ethanol: water; 70:30, v/v) 
and equilibrated (3 x 5 mL wash buffer). The column was then 
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washed (wash buffer, 2 x 5 mL and water, 1 x 5 mL). The elution 
was performed with 4 mL ethanol:water (70:30, v/v) (all the flow 
rates were ≤ 3 mL min-1). The eluate was evaporated until dry in a 
rotary evaporator, reconstituted in 500 µL of methanol:water 
(50:50; v/v) and transferred to an autosampler vial. A volume of 
10 µL was analysed by LC-MS/MS. The LC apparatus and 
chromatographic conditions were: Surveyor AS autosampler and 
Surveyor MS quaternary pump (ThermoFisher Scientific, San 
Jose, CA, USA), Synergi Hydro RP reverse-phase HPLC column 
150 x 2.0 mm, i.d. 4µm, with a C18 4 x 3.0 mm guard column 
(Phenomenex, Torrance, CA, USA), kept at 30°C. The mobile 
phase consisted of 0.1% aqueous formic acid (solvent A) and 
methanol (solvent B) with a flow rate of 200 L min−1. The 
gradient program was: from 0 to 1 minutes A was kept at 40%, 
then decreased to 5% in 11 minutes, and maintained for 1 minute, 
then A was increased again to 40% from 13 to 15 minutes; the last 
7 minutes were in isocratic elution (A=40% and B=60%). The run 
length was 22 minutes. The MS/MS apparatus and conditions 
were: triple quadrupole TSQ Quantum (Thermo Fisher Scientific, 
San Jose, CA, USA) equipped with an electrospray interface (ESI) 
set both in positive and negative ionisation mode; capillary voltage 
3.5 kV; ion transfer capillary temperature 340°C; nitrogen as the 
sheath and auxiliary gas at 30 and 10 arbitrary units, respectively; 
argon as the collision gas at 1.5 mTorr and peak resolution 0.70 
Da FWHM; the scan time for each monitored transition was 
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0.1 s and the scan width was 0.5 amu. The acquisition was 
performed in multiple reaction monitoring (MRM) after 
selecting, for each analyte and internal standard, four 
diagnostic product ions, one of which used for quantification 
(Table 1).Data were acquired and elaborated by Xcalibur™ 
software from Thermo. Figure 2 shows the reconstructed 
chromatograms with the ion spectra of β-bold glucuronide and 
sulfate in the solvent. The validation protocol, performed 
according to the European Commission Decision 2002/657/EC [22], 
is described by Chiesa et al. [23]. 
 
Table 1. MS/MS conditions for the MRM acquisitions of analytes and 
internal standards. Ions for quantification are in bold. CE (eV): collision energy 
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Figure 2. Reconstructed LC–MS/MS chromatograms with ion spectra of β-bold 
sulfate and β-bold glucuronate in solvent at a concentration of 0.5 ng mL-1. 
 
3.2.3.6. Statistical analysis 
All statistical analyses were performed by taking into 
account only the samples in which β-bold sulfate and glucuronate 
were found. The Kolmogorov–Smirnov test was performed to 
check the normality of the positive results from each dataset and 
the non-parametric Spearman correlation test was used to verify 
the effective pairing of the datasets. The differences in the results 
obtained from the analysis were checked using the Wilcoxon 
matched-pairs signed-rank test. The null hypothesis was set at 
P>0.05. GraphPad InStat version 3.10 for Windows (GraphPad 
Software, San Diego, CA, USA) was used to perform these 
calculations. 
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3.2.4. Results and Discussion 
3.2.4.1. Method validation 
The parameters of the validation are reported here in a 
summarised way: linear matrix calibration curves for each analyte 
were in the range from 0.05-0.2 ng mL−1 (r2= 0.99 for both 
analytes) (6 samples×3 concentration levels×3 series = 54 
analyses). Intra-day and inter-day repeatability, representing the 
precision, were calculated by one-way analysis of variance 
(ANOVA), expressed as CVs, and were below 14.7% and 17.0%, 
respectively. The mean recoveries ranged between 93% and 109%. 
The CCα value, calculated as described in the document 
SANCO/2004/2726 revision 4[29], was 0.07 ng mL-1 and the CCβ 
value was 0.09 ng mL-1 for both analytes. The values of the 
decision limit (CCα) and detection capability (CCβ) were 
significantly lower than the actual recommended concentration set 
at 1 ng mL-1 for β-bold [7]. 
3.2.4.2. Urine analyses 
The reconstructed chromatograms with ion spectra of β-
bold sulfate and β-bold glucuronate in a urine sample at the three 
different times of collection are shown in Figure 3. The results of 
this study are reported in Table 2. 
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Figure 3. Reconstructed LC–MS/MS chromatograms with ion spectra of β-bold 
sulfate and β-bold glucuronide in a urine sample at different steps of collection T1 
(A), T2 (B) and T3 (3).The internal standard is at a concentration of 2 ng mL-1. 
The concentrations of β-bold sulfate at T1 and T2 were 0.16 and 0.32 ng mL-1, 
respectively. The concentrations of β-bold glucuronide at T1 and T2 were 0.61 
and 0.92 ng mL-1, respectively. 
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Table 2. Number of young bull urine samples analysed and found positive for β-
boldenone sulfate and glucuronide at different times on the farm (T1=arrival; 
T2=after five months) and after slaughtering (T3=7 months); mean, minimum and 
maximum concentrations of the two conjugated forms. 
The most evident datum is the lack of detection of both β-
bold conjugates in urine samples collected at the slaughterhouse. 
Moreover, the II phase metabolites were found with a lower 
frequency at the collection time T1 than T2, i.e. 32% and 78% for 
β-bold sulfate, and 18% and 46% for β-bold glucuronide, 
respectively. The three collection times were chosen due to their 
correspondence to different stress conditions: the collection at T1 
occurred after transport stress, at T2 there were no stressors, at T3 
the animal had transport and slaughter stresses. The cause of stress 
can be psychological (restraint, handling, unfamiliar smell, 
breakdown of social groupings, crowding) or physical (hunger, 
thirst, noise, etc.) [30-32], and animals respond to stressful challenges 
in their environment through interacting mechanisms that include 
 192 
neuro-hormonal parameters [33]. It can be supposed that, even if the 
listed causes of stress are related to both transport and 
slaughtering, the cattle perceives with greater intensity the stimuli 
at the slaughterhouse (i.e. the smell of blood). In addition, the 
young bulls underwent a long period of transport, with grouping 
in assembly centres and subsequent transfer to the farm where the 
first urine collection was performed on the day of arrival. An 
adaptive response to stressors as a function of their duration can 
be expected [34]. Due to these considerations, a ranking can be 
made based on the stress suffered at different sample collection 
times: T3 (higher stress conditions) >T1 (lower stress conditions) 
>T2 (presumable absence of stress). If the frequencies in detection 
of β-bold sulfate and glucuronate are considered, an inverse 
relationship was found. It is therefore conceivable that the starting 
hypothesis expressed in the introduction, i.e. a positive correlation 
between stress and ACTH-induced boldenone release, has to be 
turned upside down. In the urine collected at T2, when the animals 
were under control for five months, we found more positive 
samples, demonstrating the production of endogenous bold and, 
by the comparison with T1 and T3 samples, an inhibitory role of 
stress on bold production. The detected concentrations of β-bold 
sulfate were to the frequencies, i.e. they were statistically higher 
when the frequencies of detection were higher. A similar 
observation does not seem feasible for the glucuronide metabolite, 
as there was no statistical difference. The high standard deviations, 
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however, did not allow for finding a difference between the 
average values at T2 and T1. The means per se and the maximum 
values were higher at T2, as for β-bold sulfate. The T2 
concentrations of β-bold sulfate were higher than the T1 maximum 
concentration in 11 out of 44 samples i.e. in about 25% of the 
samples, while the T2 concentrations of β-bold glucuronide were 
above the T1 maximum concentration in 9 out of 26 samples, i.e. 
in about 35% of the samples. This higher percentage seems to 
indicate an actual difference between the concentrations of β-bold 
glucuronide at the first two time points. Also for the 
concentrations, a negative correlation between stress and β-bold 
endogenous production was suggested; this hypothesis is 
strengthened by the consideration that the animals at T1 had just 
been put under veterinary control for bold treatment, thus we 
cannot exclude a lower frequency of detection and concentration 
of β-bold conjugates of endogenous origin at the first sampling. 
The concentration of the sulfate form found in our study 
was higher than has been described in literature. In a study in 2004, 
performed using GC-MS, Sterk et al. stated that almost all 
boldenone excreted in urine is present as the glucuronic acid 
conjugate. In 2009, Destrez et al. proposed β-bold sulfate as a 
candidate marker of treatment.[19].Both studies were performed on 
treated (bold or ADD) bovines. Particularly the second study, 
performed using LC-MS/MS, showed a CCα value of 0.2 ng mL−1 
and a CCβ of 0.4 ng mL−1. These higher analytical limits could 
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have caused misleading conclusions, considering that we found β-
bold sulfate in 37 urine samples at a concentration lower than the 
CCα indicated in the previous study, and 21 out of these 37 
samples were collected in the absence of stress.  
Finally, even if determining the endogenous presence of 
α-bold sulfate and glucuronate was not the aim of the study, 
because of their nature as conjugates of the epimer of β-bold, the 
LC-MS/MS method detected their eventual presence. α-bold 
sulfate was found just once at T2; α-bold glucuronate was found 
at the three collection time points, generally together with β-bold 
glucuronate. 
3.2.4.3. Gross pathology and histopathology  
No macroscopic alterations were detected in the genital 
tracts and accessory sex glands of the examined subjects. In 18.1% 
(n=10) of cases, slight prostate ectasia was detected, but 
sometimes this lesions were associated with other changes, such 
as slight hypersecretion, which was observed in 5.5% (n=3) of the 
examined animals. Slight hypersecretion of the bulbourethral 
glands was observed in 16.4% (n=9) of cases, and slight ectasia 
was detected in 3.6% of the examined glands. 
3.2.5. Conclusions 
The analyses performed on urine samples from 56 young 
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bulls at three collection times showed that β-boldenone conjugates, 
both the sulfate and glucuronide forms, can be naturally present 
with variable concentrations in urine collected at the farm. 
The finding that β-boldenone conjugates were not found 
at the slaughterhouse is of note. A negative influence of stress on 
bold endogenous production is conceivable. The results obtained 
from urine collected at the farm confirm this hypothesis. This 
study indicates that β-bold sulfate presence is not per se a 
biomarker of treatment when urine sample collection is performed 
at the farm; it still needs to be ascertained if a cut-off level can be 
set for both β-bold conjugates. The presence β-bold sulfate and 
glucuronide in urine at the slaughterhouse could contrariwise 
represent a useful parameter for the control of illicit treatments. To 
this aim, a study on urine collected at the slaughterhouse from 
treated animals should be performed. No relevant morphological 
alterations to the sexual organs and associated glands were 
detected in these animals. These results are compatible with the 
physiological findings typical of untreated animals. 
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3.3.1. Abstract 
BACKGROUND: According to European Union 
legislation, prednisolone, a steroid that belongs to the 
glucocorticosteroid group, is banned as a growth promoter in cattle 
husbandry and therefore should not be present in bovine 
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feedstuffs. As our preliminary investigations detected 
prednisolone in this matrix, we performed a study on different 
commercially available complementary feedstuffs, stored at the 
farm and/or in the laboratory, in order to verify whether its 
presence was due to neo-formation during storage.  
RESULTS: Prednisolone was detected in almost all 
(95%) feedstuffs collected at the farm. When the feedstuffs were 
stored at the laboratory, the frequency (31%) and the concentration 
of prednisolone-positives were lower. This difference, likely due 
to different environmental conditions, implies the possibility of its 
neo-formation. 
CONCLUSION: Our data indicate that the neo-
formation of prednisolone can occur in feedstuff, and that the 
frequency and concentration could be related to the storage 
conditions. The individuation of an objective parameter that is 
useful for the identification of the compliance of feed is therefore 
mandatory.  
Keywords: pigs urine, pigs adrenal glands, endogenous 
prednisolone, cortisol, LC-MS2. 
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3.3.2. Introduction 
The intensive production of food animals has triggered 
the development of minutely elaborated diets and has induced 
increased utilisation of veterinary drugs for therapeutic or 
preventive purposes. 
The ban of any growth-promoter in the EU, accomplished 
on January 1st 2006 with the last four antimicrobial agents - 
Monensin sodium, Salinomycin sodium, Avilamycin and 
Flavophospholipol [1] set moreover very precise limits to the use 
of drugs or medicated feeds in animal husbandry, with the aim of 
ensuring “a high level of consumer protection with regard to food 
and feed safety”, and “animal health and animal welfare”[2] as well 
as limiting anti-microbial resistance.[3] The concern of the EU 
legislator was the control of the use of veterinary drugs in food 
producing animals,[4-6] the enactment of regulation on feedstuff 
hygiene,[2] on the use of additives in animal nutrition,1 and on the 
presence of undesirable substances such as inorganic 
contaminants, nitrogenous compounds, dioxins and 
polychlorobiphenyls in animal feed, as stated by the Directive 
2002/32/EC and its subsequent amendments.[7,8] The monitoring of 
residues in feed and food of banned or undesirable substances 
requires a heavy effort by Official Control Organisations, whose 
investigations are regulated by the National Animal Feed Plan and 
the National Residues Plan in each EU Member State. The work 
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of these Organisations is however made more difficult by the 
possible presence of active principle of drugs, which may be 
included in the category of pseudoendogenous substances, i.e. 
synthetically produced hormones that are also known to be 
endogenous under certain conditions, due to their dual 
synthetic/endogenous nature.[9] This is the case for thiouracil, a 
thyreostatic drug that was banned in the EU in 1981 for use in 
livestock for fattening purposes; this drug, and other naturally 
goitrogen substances, may originate from the ingestion of 
Brassicaceae, glucosinolate-rich plants. Myrosinase, an 
endogenous enzyme of these plants freed from the cell vacuoles 
after disruption, or myrosinase-like intestinal bacterial activity 
during digestion, causing glucosinolate hydrolysis, can induce the 
presence of thiouracil in the urine of livestock.[10] 
Also, the anabolic steroid boldenone has been heavily 
studied since Arts et al.[11] showed its possible endogenous origin 
in calves. Some Authors hypothesised an ex vivo neoformation in 
contaminated urine.[12] A study on human athletes who tested 
positive for boldenone showed, through GC/C/IRMS (gas 
chromatography/combustion/isotope ratio mass spectrometry), its 
endogenous presence in urine, and suggested its formation in the 
gut, defined as an ‘‘endocrine active side organ’’.[13] The role of 
phytosterols in the diet was studied on veal calves:[14] it was shown 
that these sterols do not significantly increase the urinary level of 
17α-boldenone, nor induce the formation of 17β-boldenone, both 
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in their conjugate forms. The EU regulations require the presence 
of the total conjugate fraction in bovine urine as an unambiguous 
demonstration of boldenone administration [15] and, to demonstrate 
the difficulties experienced by Control Laboratories, more recent 
studies have shown that the detection of only the sulfo-conjugate 
fraction of 17β-boldenone should unequivocally demonstrate 
treatment with the anabolic steroid ester.[16, 17] 
In these pseudoendogenous substances, prednisolone 
must be mentioned. This corticosteroid was demonstrated to be 
produced by cattle under stress conditions, [18,19] was found in 612 
out of 780 racehorse urine samples at concentrations around 1 ng 
mL-1,[20] in all urine samples of 34 untreated human volunteers of 
both genders [21] and, finally a possible ex vivo neoformation in 
human urine [22] and in bovine faeces [23] was demonstrated. 
Besides its endogenous origin, it was recently suggested that 
exogenous prednisolone administrated in bovine, could influence 
the metabolism of some natural corticosteroids. [24] 
Currently, studies of the natural presence of prednisolone 
in feed are not available in the literature: although the possibility 
of an endogenous production or of ex vivo formation in the urine 
cannot be excluded, the involuntary administration of 
prednisolone with complementary feed should be accounted for. 
The term “complementary feed” is precisely described in Article 
3, Paragraph 1 of the Regulation (EC) No 767/200925 as: 
“compound feed which has a high content of certain substances 
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but which, by reason of its composition, is sufficient for a daily 
ration only if used in combination with other feed”. Therefore, 
specific, “dense” composition of complementary plant feedstuffs 
can serve as a good basis to start with the examination of the 
presence of corticosteroids in this milieu.  
Bearing this in mind, we undertook an investigation of the 
presence and origin of prednisolone in complementary plant 
feedstuff samples.  
3.3.3. Experimental  
3.3.3.1. Reagents and Chemicals  
Cortisol and prednisolone were purchased from Sigma-
Aldrich (St. Louis, MO,USA). The Internal Standard 
prednisolone-d6 was from CDN Isotope (Pointe-Claire, Quebec, 
Canada). All other chemicals were from Fluka ChemieGmbH 
(Buchs, Switzerland). Standard stock solutions were prepared in 
ethanol (1 mg mL-1) and stored at −18°C. Working solutions were 
prepared daily by diluting the stock solutions with methanol:water 
(50:50, v/v). 
3.3.3.2. Sample selection 
The experiment was designed according to available feed 
samples. Initially, feeds were collected at the farms (FARM group) 
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and included into two samples sets. The first set included five feed 
samples that were randomly collected in farms during hot summer 
months. After collection, the samples were stored in the 
laboratory, without any consideration of storage temperature. In 
the late autumn, the samples were analysed. The second set 
consisted of 15 samples of cattle feed of four different 
compositions. These samples were stored at the farm in the 
summer and autumn, collected in the late autumn, taken to the 
laboratory and, unlike the first set, immediately analysed. A 
second analysis was carried out after a month of storage at room 
temperature.  
On the bases of preliminary results obtained for the 
FARM group, a new experimental group was formed, which 
included feeds stored in the laboratory (LAB group). The LAB 
group included 18 samples of cattle feed of different compositions, 
which were collected in the spring. These samples taken to the 
laboratory before their delivery to the farm. Upon their arrival in 
the laboratory, these samples were and immediately analysed. A 
five weeks storage period at room temperature followed, with 
sampling on every 7th day. 
3.3.3.3. Complementary feed composition 
We used commercially available, vegetable 
complementary feeds. All of the information about the feedstuff 
compositions came from the manufacturer’s certificates. The total 
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number of feeds considered in the experiment was 38. The types 
of feed were 16, named with the letters of the English alphabet 
from A to P, as some samples came from different batches of the 
same feed type. Feed A was for veal calves weaning, feed B was 
for veal calves weaning and young beef, feeds C to G were for 
young beef, feeds H to O for adult beef and feed P for dairy cows. 
Feeds A, B, C, D and F came from different farms, the remaining 
were obtained directly from the manufacturer. 
All feeds contained calcium carbonate, sodium chloride, 
sodium bicarbonate, magnesium oxide and calcium salts of fatty 
acids. Feeds G and M also contained dicalcium phosphate and feed 
H calcium sulphate. 
All feeds, except K and N, contained wheat as flour 
middling (B, D, E, O, P), bran (A, C, E-G, I, J, L, M, P) or middling 
(H). 
Corn was present in all feeds except J, K and N; in B, C, 
E and F this was present as gluten feed, in E and G as germ, in I 
and L as bran, in A and E as corncob. In the remaining feeds, the 
presence of corn was generically indicated. In O, corn was 
genetically modified (GM). 
All feeds but M contained soy as dehulled soybean flour 
(A- D, F-L, N and P), soybeans (E, P), soybean oil (G), and 
soybean hulls (A). In O, soy was GM.  
Sunflower meal was present in all feeds except D. Feeds 
K and O contained barley flour; GM canola flour (O) and rice bran 
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were also present. Sugarcane or beet molasses were in B, D, E, G, 
I, J, M-O; sugar beet pulp was in A, E, F, H, L and N. 
Streptomyces cerevisae was in I and L-N; wheat distillers 
in I; sulphur bloom and saponified vegetable oil in L; Yucca 
schidigera, brewers grain, linseeds and carob in M.  
The analytical constituents were: proteins from 14.5% 
(O) to 35.0% (K); lipids from 1% (K) to 9% (M); cellulose from 
5.10% (D) to 12.0% (L); ashes from 6.20% (A) to 35.0% (K); 
calcium from 0.9% (A, D, E) to 3.5% (M); phosphorus from 0.40% 
(E) to 0.80% (G); sodium from 0.30% (E) to 4.8% (K); magnesium 
from 0.30% (A) to 0.90% (M); methionine from 0.20% (A) to 
0.60% (P). Feed H was supplemented with selenomethionine 
(22.75 mg kg-1). 
Vitamins A, D3 and E were present as additives in all 
complementary feeds (from 6500 to 125000 UI kg-1, from 750 to 
25000 UI kg-1 and from 25 to 1400 mg kg-1, respectively). B 
vitamins were present at different concentrations in feeds H, I, K-
N and P. Choline was present in feeds H, L and M. In L, vitamin 
K was also reported. Feeds B, H, J and K contained urea (from 
18000 to 40000 mg kg-1). Selenium, zinc, manganese, iron, 
copper, and iodine were present. Feed L contained sorbent and 
binding materials, while flavourings were present in feed N.  
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3.3.3.4. Sample extraction  
A 2 g portion of cattle feed (pellets or flour), transferred 
to a 50 mL polypropylene tube, was spiked with 40 μL of a 100 ng 
mL−1 internal standard solution. After the addition of 20 mL water, 
the sample was shaken for 1 minute until complete dispersion was 
achieved. A solution (4 mL) of 80/20 tert-buthylmethylether:ethyl 
acetate (v/v) was added, and the resulting mixture was shaken in a 
vertical rotary shaker for 20 min and centrifuged for 15 min at 
3000 g. The tube was kept at -18°C for about 1 h, until freezing of 
the aqueous phase and lipid solidification. The organic liquid 
supernatant was then transferred into a glass 10 mL tube. The 
sample was dried under vacuum in a centrifugal evaporator. The 
residue was dissolved in 200 μL of a mixture of methanol:aqueous 
formic acid 0.1% (50:50 v/v), 800 μL of petroleum ether was 
added, and then the solution was vortexed for 30 s and centrifuged 
for 2 min at 3000 g. The lower aqueous phase was collected with 
a disposable 1 mL syringe and transferred to the autosampler vial. 
3.3.3.5. LC–MS3 analysis 
Analysis conditions have been previously described 
elsewhere. [18] Briefly, the HPLC system comprised a quaternary 
pump equipped with a degasser and a Surveyor AS autosampler 
(Thermo Electron, San Jose, CA, USA). The chromatographic 
separation was performed using a HPLC column (100mm×2.1mm 
i.d., 3 µm particle size Allure Biphenyl) (Restek Corporation, 
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Bellefonte, PA, USA) in an oven set at 30°C with an isocratic 
elution [40% aqueous formic acid (0.1%) and 60% methanol at a 
flow rate of 0.2 mL min-1]. An LCQDecaXpMax ion trap mass 
spectrometer (Thermo Electron, San Jose, CA, USA) was operated 
in negative electrospray ionisation (ESI-) mode with the following 
conditions: sheath and auxiliary gas (nitrogen) flow rates of 40 and 
18 arbitrary units, respectively; a spray voltage of 5.50 kV; an ion 
transfer capillary temperature of 245°C; a capillary voltage of −23 
V; and a tube lens offset of −77 V. Helium was used for collision-
induced dissociation. All of the investigated compounds showed, 
in full scan MS, very abundant formiate adducts ([M+HCOO]−). 
Consequently, these ions were used as precursor ions for the MS2 
fragmentation: for each analyte, the most abundant ion detected 
after collision was then used as a precursor for the MS3 
fragmentation. The analysis was performed in consecutive 
reaction monitoring (CRM). The precursor ions were the formiate 
adducts of the studied compounds ([M+HCOO]−), and are shown 
in Table 1 together with the product ions and collision energies.  
 
Table 1. Ions for prednisolone, cortisol and the internal standard 
prednisolone-d6 detected by LC-MS3 in consecutive reaction monitoring mode 
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The quantifications were made on one ion. 
Representative chromatograms and mass spectra of a spiked feed 
sample are reported in Figure 1. 
 
Figure 1. Reconstructed chromatogram and consecutive reaction 
monitoring (CRM) mass spectra of a blank feed sample spiked with 2 ng g−1 
prednisolone and cortisol. The concentration of the internal standard 
prednisolone-d6 is 2 ng g−1. 
3.3.3.6. LC/HRMS analysis  
The presence of prednisolone was qualitatively 
confirmed by High Resolution Mass Spectrometry (HRMS) in 
four samples in full MS scan mode; all data were processed with a 
mass tolerance of 5 ppm. The exact mass of the prednisolone 
formiate adduct is 405.19187 Da. The chromatographic separation 
was performed on a reversed-phase SunfireW column (150 2.1 
mm, 3.5 mm; Waters, Milford, MA, USA), with a mobile phase 
consisting of a mixture of 75% water with 0.1% formic acid and 
25% acetonitrile at a flow rate of 0.3 mL min-1. The HRMS 
instrumentation was an Exactive™ Benchtop high-resolution mass 
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spectrometer equipped with an HESI-II source (Thermo Fisher, 
San José, CA, USA) operating in negative mode. The method is 
exhaustively described elsewhere.20 
3.3.3.7. LC–MS3 method validation  
The presence of the studied corticosteroids in feed 
samples was checked by the analytical method described above. A 
calibration curve was thus prepared with blank samples, which 
were spiked to give known concentrations of prednisolone and 
cortisol (0.10, 0.2, 0.3, 0.4, 0.5, 1.0, 2.0, 5.0 and 10 ng g-1 feed). 
Three replicates were measured on three different days after 
liquid–liquid extraction. The following parameters were 
calculated: precision, expressed as intra- and interday coefficient 
of variations (CV%), on four blank feed samples, spiked with 0.6 
ng g-1 feed, roughly corresponding to twice the detection capability 
(CCβ); recovery (%), on the same four samples, expressed as the 
percentage of measured concentration to a fortified concentration 
ratio; decision limit (CCα) and detection capability (CCβ); 
between-run accuracy, on three different days using four different 
samples spiked with 0.6ng g-1 feed (twice the CCβ). 
The method used was validated following the 
Commission Decision 2002/657/EC,26 with modifications 
proposed by Galarini et al.,27 who calculated CCα and CCβ, 
starting with the determination of the “minimum required 
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performance level” (mrpl), which indicates the concentration 
above which the curves must be built. 
3.3.3.8. Statistical analysis  
Means, medians and standard deviations were calculated 
for every set/group of feeds. In order to determine if a difference 
existed in prednisolone concentrations, we compared the different 
sets/groups of feeds. The Kolmogorov and Smirnov method was 
used to verify the normality of the value distribution. When a 
comparison was made between two sets/groups, we always used 
the Mann-Whitney test as at least one of the populations did not 
pass the normality test. To compare three sets of values, we 
performed the ordinary Analysis of Variance (ANOVA) if the 
normality test was passed by all sets, or the Kruskal-Wallis test 
(non-parametric ANOVA) in all other cases. The software used 
was GraphPad InStat™ version 3.00 (GraphPad Software, San 
Diego, California USA; www.graphpad.com). 
3.3.4. Results And Discussion 
Although there is a need for sensitive, accurate and quick 
analytical methods to monitor the abuse of corticosteroids, only a 
limited number of analytical methods have been published for 
feedstuff. Animal feed is a very complex matrix; not only does the 
composition differ for each type but starting materials also differ 
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for each production batch, leading to each sample of feed having 
its own characteristics. This means that the interfering compounds 
differ from sample to sample, which makes method development 
challenging. Therefore, we paid special attention to the sample 
handling and extraction procedure. The parameters calculated for 
method validation are reported in Table 2. All validation data for 
prednisolone and cortisol determination in feedstuff were adequate 
and indicated good performance of the developed analytical 
procedure. The level of cortisol was below the decision limit in all 
of the analysed samples.  
 
Table 2. Validation performance characteristics of prednisolone and 
cortisol 
Prednisolone was detected in all samples from the 
preliminary study (first set, FARM group) and could be quantified 
in four. The mean ± SD value was 1.6±1.5 ng g-1 (Table 3). The 
unexpected presence of prednisolone in these samples strongly 
suggested the possibility of its neo-formation, similarly to the 
faecal matter as we already observed.23 The samples were 
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randomly collected from farms, and then transferred in the 
laboratory. The time and temperature of their storage at the farm 
were neither uniform nor exactly monitored; the period was from 
1 to 2 months. The storage period in the laboratory was 2 months, 
also without any caution to the storage temperature. Therefore, 
neo-formation could occur during both of the indicated intervals. 
In order to gain a clearer picture of where and when 
prednisolone was formed, a new approach was designed; the 
results are given as a second set of the FARM group. As the values 
obtained for this set were not normally distributed, the Mann-
Whitney test was used to compare them to the first set. The 15 
samples showed a prednisolone concentration value of 1.6±1.3 ng 
g-1 (mean±SD), which did not differ significantly from the first set 
(table 3). The second set of the FARM group seemed to confirm 
the initial hypothesis. Prednisolone was in fact detected in 14 out 
of 15 samples independent of the variable environmental 
conditions (temperature, humidity, etc.). It has to be noted that the 
samples of this set had been stored only at the farm when the first 
analysis was undertaken. The second analysis on the presence of 
prednisolone was performed after a 1-month storage period in the 
laboratory at room temperature: all samples were negative except 
No. 15 (Table 3). The extremely high concentration found in this 
feed specimen could not be interpreted by the simple addition of 
the corticosteroid to the feed, as its concentration in the first 
analysis was about 74-fold lower. A possible explanation for this 
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could be a high level of precursors or more presumably high 
microbiological activity due to the particular conditions in the jar. 
More profound studies should be conducted to clarify why other 
samples of the same composition did not behave in the same 
manner (Table 3).  
 
 
Table 3. Concentrations of prednisolone detected in the feed samples 
of the FARM group: first set (1 to 5) and of the second set (6 to 20), after a 
storage period at the farm (first analysis) and at the laboratory (second analysis). 
 
In order to compare feed samples according to their stay 
in farm, the samples were merged (samples 1 to 5, 6 to 10, 11 to 
17 and 18 to 20, respectively) and ANOVA test was performed; 
no significant difference was observed (P = 0.81). On the other 
hand, the Kruskal-Wallis test was performed to evaluate the 
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prednisolone concentration in the feed samples merged according 
to their composition. When the mean prednisolone concentrations 
of feedstuffs B to E were compared, no significant difference was 
shown. Feed A could not be considered due to the presence of one 
only sample.  
Because of the lack of a significant difference between 
the prednisolone concentrations in feedstuffs studied in the FARM 
group, a second experiment was undertaken. Commercially 
available vegetable feedstuffs (n=18) were randomly chosen, 
regardless of their composition. The results obtained for this group 
are shown in Table 4.  
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Table 4. Concentrations (ng g-1) of prednisolone detected at different 
collection times in the feed samples of LAB group during the storage period at the 
laboratory. 
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Only one sample showed the presence of prednisolone 
upon arrival at the laboratory. A total of 108 analyses were 
performed and prednisolone was found on 34 occasions. Only one 
sample (No. 22) was always negative. In the other samples, no 
relationship was found between the collection time and the 
presence of prednisolone: the corticosteroid was in fact detected 
between one and four times in each sample. The concentration was 
either roughly constant, raising, decreasing or with a bell-shaped 
profile. The mean±SD prednisolone concentrations ranged from 
0.74±0.26 ng g-1 (day 28) to 1.13±1.07 ng g-1 (day 14), with no 
difference shown between the collection days. The positives were 
1 upon arrival, 2 on the 7th day and, even if the distribution was 
random, 7 at any further collection time (Figure 2). 
 
 
Figure 2. Mean ± SD concentrations ( ) and number of positives ( ) to 
prednisolone in samples of laboratory (LAB) group, related to the collection 
day. 
The Kruskal-Wallis test was performed to compare 
prednisolone-positive samples, merged by collection day, but no 
significant statistical relationship was found again.  
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Beyond this, the integrated data from positive samples of 
the FARM group were compared to the corresponding data from 
the LAB group. The mean±SD values were 1.66±1.28 and 
0.95±0.76 ng g-1, respectively, and the Mann-Whitney test 
(P=0.024) demonstrated a difference in prednisolone 
concentration between the samples stored at the farm and in the 
laboratory. Nevertheless, apart from this statistical significance, 
one fact remains: prednisolone is formed either at the farm or in 
the laboratory. In the LAB group, in contrast to the FARM group, 
the sample storage after production was performed only in the 
laboratory: the neo-formation of prednisolone occurred in this 
environment as well. However, the frequency was lower, as only 
31% of analyses were positive for prednisolone, versus 95% of 
samples stored at the farm, at least for the short-term. These data 
suggest that different storage conditions differently evoke 
prednisolone neo-formation. Also, the variability observed did not 
exclude the possibility of its degradation. In the second set of the 
FARM group, 14 samples out of 15 were found to be negative after 
1-month of storage in the laboratory. In the LAB group, the higher 
frequency of prednisolone detection was seen in 7 out of 18 
samples, observed from day 14 to day 35. Hence, most of the 
samples (about 60%) were negative for these collection days and 
when prednisolone was observed early, it generally disappeared. 
The poor stability of the corticosteroids has recently been shown 
by De Clercq et al.,[28] who, to preserve glucocorticoids in bovine 
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urine for a long period (20 weeks), recommended filter-sterilising 
and storage under acidic conditions, preferentially at pH 3 and at a 
temperature of −80◦C (or at least −20◦C). This last observation, 
made on a different matrix, shows the real possibility of the 
microbiological transformation of corticosteroids. Currently, the 
only explanation for the higher frequency of prednisone–positive 
samples in the FARM group in respect to the LAB group could be 
found in the different sanitary-hygienic storage conditions. 
Conservation in closed jars, which is performed in the laboratory, 
preserves the possibility of contamination; while, on the farm, the 
hygienic conditions are objectively different and obviously more 
favourable for prednisolone neo-formation. The appearance of 
prednisolone in a very high concentration in sample No. 15, 
collected after one month storage in the laboratory, could represent 
indirect, although controversial, evidence of this observation: in 
fact, it took place in a closed container where the conditions could 
have been different compared to all other samples that were stored 
in closed jars.  
Finally, the identification of prednisolone with a low 
mass resolution spectrometer was fully confirmed in four 
randomly selected samples, through the accuracy of the measured 
mass of the formiate precursor ([M+HCOO]−) in HRMS analysis, 
as shown in Fig. 4. 
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Figure 3. Total ion spectra of the prednisolone peak acquired by HRMS. (A) 
Standard solution (1 ng mL−1), (B) a positive feed sample. The exact mass of 
prednisolone formiate ([M +HCOO]−) is 405.19187 Da. 
3.3.5. Conclusions 
Based on the results obtained, we hypothesise that 
feedstuffs without the addition of drugs may be noncompliant for 
prednisolone presence upon inspection by the Health Authorities. 
Due to the low possibility of affecting the storage conditions at the 
farms, the studies that would indicate objective parameters, e.g. a 
cut-off level or metabolite markers, are essential. To this aim, 
special attention must be paid to the definition of the prednisolone 
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metabolic precursors in the feedstuffs and the nature of their 
origin. All of this would allow the official control organisations to 
make the most possible accurate decisions about the cause and 
importance of the presence of prednisolone in complementary 
feedstuff.  
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3.4.1. Abstract 
The debate about the origin of prednisolone in animal 
organisms has lasted for five years. The bovine species has been 
the most studied, but studies on humans and horses are also present 
in the literature. Even if prednisolone in pigs does not yet represent 
a problem for control agencies, recently interest has risen with 
regard to this species. To date there has been just a single study in 
the literature about this topic, performed on ten sows treated with 
prednisolone or a synthetic analogue of adrenocorticotropic 
hormone. We therefore initiated a study on 80 pigs, a number 
considered representative in relation to the expected frequency 
(prevalence) of prednisolone detection in urine collected at 
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slaughter. Prednisolone was detected in urine both at the farm and 
at the slaughterhouse, with a concentration and frequency higher 
at slaughter. The presence of prednisolone was also studied in 
adrenal glands, where the corticosteroids are produced in response 
to stress, and it was detected in 89% of the samples. These results, 
together with the similar behaviours of prednisolone and cortisol, 
i.e. a mutual rise in the two corticosteroids in urine collected at the 
slaughterhouse and the correlation between the concentrations of 
the two corticosteroids in the adrenal glands, seem to indicate an 
endogenous origin of prednisolone in pigs. 
Keywords: pigs urine, pigs adrenal glands, endogenous 
prednisolone, cortisol, LC-MS2. 
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3.4.2. Introduction 
Cortisol is a steroid hormone produced and released by 
the adrenal cortex. Cortisol is involved in physiological processes 
such as immune reactions, the regulation of inflammatory states, 
and carbohydrate metabolism [1, 2]. 
Prednisolone is a glucocorticosteroid whose anti-
inflammatory activity is 3-4 times higher than cortisol. The 
therapeutic use of prednisolone in bovine is regulated by 
Commission Regulation (EU) N°37/2010 [3] which sets maximum 
residue limits (MRLs), even if its illicit use as growth promoter 
agent cannot be discarded [4]. For urine, no MRLs have been set 
but a 5 ng mL-1 cut-off level has been recommended, e.g. by the 
Italian Ministry of Health [5], following the indications of the 
European Union Reference Laboratory (RIKILT) of Wageningen 
and the National Institute for Public Health and the Environment 
(RIVM) of Bilthoven [6]. 
Corticosteroids are allocated to group B2f (other 
pharmacologically active substances) by EU Council Directive 
96/23/EC [7] and monitoring of their administration to livestock is 
carried out both on urine collected at the farm and urine or liver at 
the slaughterhouse [3, 8]. 
In recent years, an increase in cases positive for 
prednisolone, reported by some European Union Member States, 
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has been observed in bovine urine, particularly when sampled at 
the slaughterhouse [9]. 
The possibility of in vitro formation of prednisolone from 
cortisol has been reported, possibly due to poor collection and 
storage conditions of the urine samples [10-12]. Pompa et al. [13] 
investigated the relation of stress to the formation of prednisolone 
from cortisol in dairy cows. The role of stress in cortisol 
production is well-known. The cortex of the adrenal glands is 
stimulated by the adrenocorticotropic hormone (ACTH) secreted 
from the anterior pituitary in response to corticotropin-releasing 
hormone (CRH) from the hypothalamus. Under unstressed 
conditions, prednisolone was found sporadically in urine. When 
the cows were stressed with intramuscularly administered 
tetracosactide hexaacetate, a synthetic analogue of ACTH, or 
physically by transport and slaughter, cortisol concentration 
increased and prednisolone was consistently found in urine, 
demonstrating the possibility of its endogenous formation. 
The possibility of the endogenous origin of prednisolone 
has also been described for equine and human urine [14, 15]. 
Finally, Delahaut et al. [16] reported that the Belgian 
Federal Agency for the Safety on the Food Chain (FASFC) found 
prednisolone at a mean concentration of 0.96 ng mL-1 in 73% of 
393 samples of porcine urine collected at the slaughterhouse. The 
same Authors described the results of a preliminary study 
concerning the presence of prednisolone in sows before and after 
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i.m. administration of prednisolone or tetracosactide hexaacetate. 
The urine collection was performed at the farm before and after 
the treatment and at the slaughterhouse, where the liver was 
collected as well. The presence of prednisolone in porcine urine 
was confirmed in all samples prior to the treatment and in most of 
them after the treatment, but, in liver, prednisolone was only found 
after administration of prednisolone or tetracosactide hexaacetate. 
The Authors proposed the prednisolone/cortisol ratio in liver 
samples as an indicator for detecting illicit prednisolone 
administration to pigs and suggested confirming these 
observations in a study on a larger number of animals [16]. 
In order to clarify the possible endogenous origin of 
prednisolone and the influence of stress on the production of this 
corticosteroid in pigs, the present study investigated the presence 
of prednisolone in urine samples collected from the same eighty 
pigs at the farm and at the slaughterhouse; we also analyzed the 
adrenergic glands of the same animals, supposing an endogenous 
production of prednisolone in this organ. 
3.4.3. Materials and methods 
3.4.3.1. Chemicals and reagents  
Cortisol and prednisolone were purchased from Sigma–
Aldrich (St.Louis, MO, USA). The internal standard prednisolone-
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d6 was from CDN Isotopes (Pointe-Claire, Quebec, Canada). All 
other chemicals were from Fluka Chemie GmbH (Buchs, 
Switzerland). Ultrapure water was obtained through a Milli-Q 
system (Millipore, Molsheim, France). Standard stock solutions 
were prepared in methanol (1 mg mL−1) and stored at −40∘C. 
Working solutions were prepared daily by diluting the stock 
solutions with methanol/water (50:50, v/v). 
3.4.3.2. Animals and sampling procedure 
The study was carried out on 80 pigs of both genders 
weighing 100 to 150 kg, coming from northern Italy farms and 
slaughtered in different abattoirs of Lombardy. Official 
Veterinarians of Lombard Veterinary Services collected urine and 
adrenal gland samples, not used for routine analyses. They also 
verified the lack of treatments in the 90 days before slaughter, by 
checking the records of purchase, possession and administration of 
veterinary medicinal products of the animal treatments, 
maintained by the owners of food producing animals as required 
by the Directive 2001/82/EC [17]. Urine samples were collected for 
the first time at the farm into long-handled sterile containers, 
approximately one week before transport of the animals to the 
slaughterhouse. 
Only clean urine, i.e. clear ad without raw materials, was 
sampled, frozen and taken to the laboratory for storage at -40°C 
until extraction and analysis. 
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A second collection was made at the slaughterhouse: 
urine samples were collected directly from the urinary bladder 
immediately after slaughter, as well as the adrenal glands. All 
samples were immediately frozen and taken to the laboratory for 
storage at –40 °C. Each pig, randomly selected and followed from 
farm to slaughterhouse, provided three different samples (urine at 
the farm, urine at the slaughterhouse and adrenal glands) in order 
to have matched data.  
3.4.3.3 Sample size 
The urine and adrenal glands investigated in this work 
came from pigs that were under the veterinarian control for 90 days 
before slaughter. The sampling therefore had to be made on an 
appropriate number of animals that would assure detection of the 
predicted prevalence, i.e. the expected frequency of endogenous 
prednisolone detection in urine and adrenal glands. The sample 
size calculation was made according to Bottarelli et al. [18] using 
the following equation: n=𝑍2 × [𝑃(1 − 𝑃)]/𝐷2, where n is the 
sample size, Z is the Student’s t value (1.96, when the level of 
significance is 5%), P the expected prevalence and D the required 
precision. At the time the experimental protocol was designed, we 
had no data on the frequency of prednisolone detection in pig 
urine, but only from bovines (cows at slaughter = 71% positive) 
[19] and race horses (78.5%) [14]. Based on these frequencies, on 
their difference between cows and horses, and because the pigs, 
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i.e. a different species, are studied in this work, we supposed a 
prevalence for prednisolone detection in pig urine collected at the 
slaughterhouse of 70% (P=0.7); and a precision of ± 10% (D=0.1). 
The necessary sample size predicted was 80 animals. 
3.4.3.4. Pig urine sample extraction 
Sample preparation was conducted as previously reported 
in Arioli et al. with slight modifications [20]. An aliquot of 2 mL of 
each urine sample was spiked with prednisolone-d6 as internal 
standard to a concentration of 2 ng mL-1. A 4 mL mixture of tert-
butyl methylether: ethyl acetate (4:1, v/v) was then added. After 
shaking in a vertical rotary shaker for 20 min, the sample was 
centrifuged at 1300 g for 15 min. The upper organic layer was 
collected and dried under vacuum in a centrifugal evaporator at a 
temperature of 30°C. The residue was dissolved in 200 μL of the 
mixture of methanol/aqueous formic acid 0.1%, 50:50 v/v and 
transferred to an autosampler vial for the LC–MS2 analysis. The 
injection volume was 10 μL. 
3.4.3.5. Pig adrenal gland sample extraction 
Sample preparation was conducted as previously reported 
in Bertocchi et al. (2013) [19]. A 5 g portion of the adrenal gland 
was transferred to a 50 mL tube and spiked to a concentration of 
10 ng mL−1 with the internal standard prednisolone-d6. After the 
addition of 10 ml water, the sample was homogenized in a 
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dispersing machine operating at a speed of 13500 rpm for 1 min. 
A 4 mL mixture of tert-butyl methyl ether: ethyl acetate (4:1, v/v) 
was then added. After shaking in a vertical rotary shaker for 20 
min, the sample was centrifuged at 3000 g for 15 min. The tube 
was then put in a freezer for about 1 h until lipid solidification. The 
organic liquid supernatant was transferred to a glass 10 mL tube; 
the solid lipid layer was placed in a polypropylene 15 mL tube and 
centrifuged again to recover residual liquid, which was transferred 
to the glass tube. The aqueous phase was then re-extracted (as 
described above) and the supernatant liquid was added to the two 
portions already placed in the glass tube. The sample was then 
dried under vacuum in a centrifugal evaporator. The residue was 
dissolved in 250 μL of methanol/aqueous formic acid 0.1%, 50:50 
v/v, 1.5 mL of petroleum ether were added, and then the sample 
was vortexed for 30 s and centrifuged for 5 min at 3000 g. The 
lower aqueous phase was then quantitatively (200 μL) transferred 
to an autosampler vial. The injection volume was 20 μL. 
3.4.3.6. LC-MS2 analysis 
Chromatographic separation was performed with a 
Thermo Finnigan LC system consisting of a Surveyor MS 
quaternary pump (Thermo Fisher Scientific, San Jose, CA, USA) 
operating at flow rate of 250 L min−1 and a Synergi Hydro RP 
column 150 x 2.0 mm, internal diameter 4 µm (Phenomenex, 
Torrance, CA, USA), kept at 30°C. The mobile phase was aqueous 
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formic acid 0.1% (eluent A) and methanol (eluent B). The gradient 
program, lasting 31 minutes, was as follows: A was at 75% at 
minute 0, decreased to 20% over 20 minutes, then to 5% for one 
minute, maintained for 3 minutes, and increased again to 75% 
from the 24th to 26th minute; the last 5 minutes were in an isocratic 
elution (A=75%). The mass spectrometer was a TSQ Quantum 
(Thermo Fisher Scientific, San Jose, CA, USA) equipped with an 
electrospray interface (ESI) set in the negative ionisation mode. 
The capillary voltage was 3.2 kV, ion transfer capillary 
temperature was 340°C, while the sheath and auxiliary gas 
(nitrogen) had arbitrary units of 30 and 10, respectively. The 
collision gas was argon at 1.5 mTorr. Three diagnostic transitions 
were monitored, in multiple reaction monitoring (MRM), for the 
analytes and internal standard. The quantification was performed 
on transition with the higher signal-to-noise ratio. Table 1 shows 
the precursor ions, i.e. the formiate adducts ([M+HCOO]−), the 
product ions and the collision energies. Data were acquired using 
Xcalibur™ software from Thermo. 
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Table 1. MS2 conditions for the MRM acquisitions of analytes and the internal 
standard. Ions for quantification are in bold. CE: collision energy expressed in 
electron volts (eV). 
 
3.4.3.7. Method Validation 
The method was validated for prednisolone and cortisol, 
according to Commission Decision 2002/657/EC requirements [21]. 
The instrumental linearity was evaluated by preparing eight point 
calibration curves in the mobile phase containing a fixed amount 
of internal standard prednisolone-d6 (2 ng mL-1) and analytes at 
concentrations corresponding to 0.01-0.05-0.1-0.2-0.5-1-2-5 ng 
mL−1. 
Matrix calibration curves were obtained by spiking urine 
samples and adrenal glands with the analytes, resulting in three 
analytical series, each with three concentration levels (0.05-0.1-
0.2 ng mL−1 for urine and 0.1-0.2-0.3 ng g−1 for adrenal glands) and 
six samples per concentration level (6 samples × 3 concentration 
levels × 3 series = 54 analyses for each matrix). Method recovery 
and precision were evaluated using these matrix curve results; 
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recovery was expressed in terms of percentage of measured 
concentration to fortified concentration and precision as the 
coefficient of variation (CV) calculated by applying one-way 
analysis of variance (ANOVA) for the intra-day and inter-day 
repeatability. The decision limit (CCα) and detection capability 
(CCβ) were calculated according to the procedure described in the 
Commission Decision 2002/657/EC as clarified in the document 
SANCO/2004/2726-revision 4 [22]. 
Specificity identification was achieved by detecting the 
peaks in the blank matrix chromatograms matching the relative 
retention time observed for the spiked analytes, compared to 
standard analytes in methanol, with a tolerance of ±2.5% . 
3.4.3.8. Statistical analysis  
The Kolmogorov–Smirnov test was performed to check 
the normality of datasets: depending on whether this test was 
positive or negative, the correlation of the datasets was verified 
through the Pearson or the non-parametric Spearman test. The 
results obtained from farm and slaughterhouse urine were 
compared using one of the following tests depending on 
correlation, standard deviation (equal or different), and normality 
of the datasets: the unpaired t-test; the Wilcoxon matched-pairs 
signed-ranks test; and the Mann-Whitney test. When three datasets 
were compared, the non-parametric analysis of variance (Kruskal-
Wallis test for unpaired data and non-normal distributions) with 
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Dunn’s Multiple Comparisons post-test was used. The null 
hypothesis was set at P>0.05. GraphPad InStat version 3.10 for 
Windows (GraphPad Software, San Diego, CA, USA) was used. 
3.4.4. Results and Discussion 
3.4.4.1. Method validation 
The instrumental linearity for prednisolone (r2= 0.991) 
and cortisol (r2= 0.994) were both satisfactory. The validation 
parameters, shown in Table 2, demonstrated the good performance 
of the analytical methods in urine and adrenal glands. As regards 
specificity, blank and spiked samples did not show any 
interference (signals, peaks, ion traces) in the region of interest 
where peaks for cortisol and prednisolone were expected. 
 
Table 2. Validation parameters of the analytical method. CCα and CCβ 
are expressed in ng mL-1 for urine and ng g-1 for adrenal glands. 
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3.4.4.2. Sample analysis 
The hypothesis made by Delahaut et al. [16] that 
prednisolone can be endogenously produced was checked on 80 
pigs, a number calculated as already described in the “Sample 
size” section. In Figure 1, a representative chromatogram and the 
relative ion spectra of cortisol and prednisolone in a urine sample 
are shown. 
 
Figure 1. Reconstructed LC-MS2 chromatograms and respective ion spectra of 
the analytes detected in a urine sample. The calculated concentration of cortisol 
and prednisolone are 9.2 and 0.11 ng mL-1, respectively. 
The overall results obtained in this study are reported in 
Table 3 and 4.  
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Table 3. Overall analytical results. 
 
 
Table 4. Relationship between prednisolone detection and the place of urine 
collection for the same pig. 
Cortisol was always detected in urine and its 
concentration was significantly different (higher) when the sample 
was collected at the slaughterhouse (P<0.0001). Despite the wide 
variability (relative standard deviations greater than 80%), the 
difference was extremely significant, making the data even more 
meaningful for the influence of stress due to transport and 
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slaughter on cortisol release. The observed variability could be 
explained by the circadian rhythm of cortisol secretion in pigs [23] 
and by inter-individual variability in its urinary excretion. The 
selection of pigs and the time at which urine samples were 
collected at the farm and slaughterhouse followed the Official 
Collection Schedule, so we could not control these factors. As 
regards prednisolone, the concentration of this corticosteroid in 
urine from the farm was different with respect to urine from the 
slaughterhouse (P<0.0001), as well as the frequency of its 
detection. For both parameters, the value at the farm was lower 
than that at the slaughterhouse, so demonstrating the influence of 
stress as for cortisol. Based on the positivity of urine for 
prednisolone at the farm or slaughterhouse, the data were divided 
into four groups as shown in Table 4. Group 1 consisted of 10 
animals negative both at the farm and at the slaughterhouse; Group 
2 consisted of 26 pigs negative at the farm but positive at the 
slaughterhouse; Group 3 consisted of 42 pigs positive in both 
cases; Group 4 consisted of just two animals positive at the farm 
and negative at the slaughterhouse. Table 5 shows the mean ± SD 
of urine and adrenal concentrations of cortisol and prednisolone in 
these groups. Group 4 was not considered due to the very small 
number of values.  
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Table 5. Cortisol and prednisolone urinary (ng mL-1) and adrenal (ng g-1) levels 
expressed as mean±SD values considering 3 Groups, partitioned accounting for 
prednisolone detection in urine and place of urine collection for the same animal. 
In Table 6 the normality, correlation and comparison tests 
are reported. Either the Pearson or Spearman test was performed 
to check the correlation between different datasets, in the first case 
between datasets that included the results from the same urinary 
corticosteroid collected at the farm or at the slaughterhouse, 
respectively (table 6A); in the second case, between datasets that 
included the results from the two different urinary corticosteroids 
collected at the same place (Table 6B), in the third case, between 
datasets that included the results from the two different 
corticosteroids in the adrenal glands (Table 6C). A comparison of 
means or medians (depending on the result of the Kolmogorov 
Smirnov normality test) was made only between datasets for the 
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same urinary corticosteroid collected at the farm and at the 
slaughterhouse (Table 6A).  
 
Table 6. Statistical analyses, performed on Groups. A): normality, correlation and 
comparison of the urinary concentration of the same corticosteroid at the farm and 
at the slaughterhouse, B): normality and correlation of the urinary concentrations 
of the two distinct corticosteroids at the farm and or the slaughterhouse C): 
normality and correlation of the concentration of the same corticosteroid in 
adrenal glands. The Groups considered are related to prednisolone detection in 
urine collected at the farm and at the slaughterhouse as shown in Table 4 in the 
manuscript. 
A difference between urinary cortisol collected at the 
farm or at the slaughterhouse was always found, independent of 
the group. Urinary cortisol concentrations in the three groups at 
the farm ranged between 7.7±4.9 and 9.4±7.9 ng mL-1 and were 
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not significantly different by the Kruskal-Wallis test. However, 
when the same test was made for urinary cortisol at the 
slaughterhouse a difference was found (P<0.05) between groups: 
Group 1 differed from Groups 2 and 3 (P<0.05) (Table 5). It must 
be noted that in Group 1 urine, prednisolone was never detected, 
while in Group 2 it was found at the slaughterhouse (0.37±0.24 ng 
mL-1) and in Group 3 a significant rise (P<0.0001) in prednisolone 
concentration was observed between farm (0.24±0.49 ng mL-1) 
and slaughterhouse (0.46±0.31 ng mL-1) urine. Also in Group 2, a 
rise in prednisolone concentration was actually observed, from 
“not detected” to 0.37±0.24 ng mL-1. The similar behaviour of 
prednisolone in Groups 2 and 3 could be related to their similar 
urinary cortisol concentrations at the slaughterhouse: this could be 
interpreted as further evidence for the relationship between 
prednisolone and cortisol. A difference between the urinary levels 
of each corticosteroid collected at the different places is also 
observable within the same group (table 6A). 
As regards the adrenal glands, no difference was observed 
between Groups 1 to 3 for both cortisol and prednisolone levels, 
as the P value of the Kruskal-Wallis test was higher than 0.05. It 
is worthy of note that in the three groups the Spearman and Pearson 
tests evidenced significant correlations between cortisol and 
prednisolone levels in the adrenal glands, so demonstrating an 
endogenous origin of prednisolone. (Table 6C). Our data on urine 
collected at the farm do not completely agree with Delahaut et al. 
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[16], who found a very good correlation coefficient value of 0.81 
between prednisolone and cortisol levels in untreated pigs. We 
could not find this correlation at the farm, but only at the 
slaughterhouse (Tables 3 and 6B). The positive correlation 
between prednisolone and cortisol at the slaughterhouse seems to 
demonstrate a mutual rise in their concentrations, a condition that 
should exclude treatment with prednisolone, as checked by 
Official Veterinarians. A doubt about one sample out of 80 could 
arise: the concentration of prednisolone in urine collected at the 
farm was 3.3 ng mL-1 and that of cortisol at the slaughter was 0.69 
ng mL-1. However, the levels of cortisol and prednisolone in the 
adrenal glands were 3691 and 2.6 ng g-1, respectively, quite a bit 
higher than the mean values found in this study, showing no 
inhibition due to treatment with corticosteroids. Confirmation of 
the presence of prednisolone in the adrenal glands was made by 
LC-MS3 on 8 samples already analysed by LC-MS2. The analysis, 
already used for bovine adrenal glands by Bertocchi et al. [19] was 
performed with an ion trap in the negative ESI mode. The results, 
performed only through qualitative determination, fully confirmed 
the ones reported in this work. A reconstructed chromatogram with 
the relative ion spectra is shown in Figure 2.  
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Figure 2. Reconstructed LC-MS3 chromatograms and respective ion spectra of 
the analytes detected in an adrenal gland sample. The calculated concentration of 
cortisol and prednisolone are 4.4 µg g-1and 1.4 ng g-1, respectively. 
Finally, the possibility of setting a cut-off level, 
calculated in an analogous way to the one proposed by de Rijke et 
al. for cattle should not be discarded [6]. The threshold level for a 
finding of prednisolone in pig urine would be equal to the mean 
value of 80 urine samples + 3 x SD. Accounting for both urine at 
the farm and at the slaughterhouse, the average concentration is 
0.35 ng mL-1 and the standard deviation is 0.38 ng mL-1. The cut-
off value would be 1.51 ng mL-1 (0.35 + 3 x 0.38). 
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3.4.5. Conclusions 
The possibility that prednisolone is endogenously 
produced in pigs was directly demonstrated by its presence in 
adrenal glands, the organ in which cortisol is produced. Indirect 
evidence was also provided about the origin of prednisolone that 
considered its relationship to cortisol levels under different 
conditions. First, both prednisolone and cortisol urinary 
concentrations were higher at the slaughterhouse than at the farm 
because of the stress the animals underwent. Second, Groups 2 and 
3, in which a rise in prednisolone urinary concentration was 
observed at the slaughterhouse, showed a higher concentration of 
cortisol with respect to Group 1, in which prednisolone was never 
found. Third, in the adrenal glands, cortisol and prednisolone 
levels were positively correlated in the three groups. The similar 
trends in their concentrations and the positive correlation 
demonstrate the endogenous nature of prednisolone.  
In order to understand the mechanism leading to the 
formation of this corticosteroid in pigs further  studies on the 
metabolites of prednisolone, like 6β-hydroxyprednisolone, 20α-
hydroxyprednisolone, and 20β-hydroxyprednisolone, must be 
carried out.  
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3.5.1. Abstract 
The use of thyreostats in livestock is strictly forbidden by 
European legislation since 1981. The investigation of thyreostats 
is commonly performed by their detection as derivatives with 3-
iodobenzylbromide. However, the derivatisation procedure could 
lead to a decrease in analyte concentrations. With the aim of 
simplifying the analysis of five thyreostats in both bovine urine 
and in thyroid glands, two methods were developed without the 
derivatisation step. Salting-out assisted liquid–liquid extraction 
was carried out for both matrices, followed by high-performance 
liquid chromatography coupled with triple-quadrupole mass 
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spectrometry analysis. The methods were validated in agreement 
with the guidelines of Commission Decision 2002/657/EC. For all 
the thyreostats evaluated, satisfactory results were achieved; the 
recovery was within 96% to 104% for both the matrices, while 
precision (coefficient of variation) was less than 20% for urine and 
21% for thyroid glands. The limits of decision and capacities of 
detection for all the compounds were lower than the recommended 
values of 10 μg L-1and 10 μg kg-1, respectively. In urine, the limits 
of decision ranged from 6.9 to 7.3 μg L-1, and the capacities of 
detection ranged from 8.5 to 9.7 μg L-1, while in thyroid glands 
these values varied from 6.6 μg kg-1to 7.4 μg kg-1and from 8.0 μg 
kg-1to 9.7 μg kg-1, respectively. The results obtained show that the 
methods described are suitable for the direct detection of 
thyreostats in bovine urine and thyroid glands.  
Keywords: thyreostats, bovine urine, bovine thyroid gland, 
method validation, HPLC-MS/MS 
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3.5.2. Introduction 
Thyreostats are drugs that interfere with the mechanism involved 
in the synthesis of thyroid hormones and cause a condition of 
deficiency of circulating thyroxine (T4) and triiodothyronine (T3) 
[1,2], whose production and release are controlled by the 
hypothalamus–anterior pituitary axis. The hypothalamus secretes 
thyrotropin-releasing hormone (TRH), which in turn stimulates the 
anterior pituitary gland to release thyroid-stimulating hormone 
(TSH) that induces the production of T3 and T4 by the thyroid, 
which releases them into the bloodstream. These hormones 
activate the nuclear transcription of a large number of genes, thus 
causing the synthesis of enzymes, as well as structural and 
transport proteins. This leads to an increase in metabolism and 
maintains the physical and psychological development of the 
organism [3]. The illicit administration of thyreostats causes an 
improvement in bodyweight gain mainly due to increased 
absorption and extracellular retention of water in the edible tissues 
and in the gastrointestinal tract. The most frequently used 
thyreostatic drugs include the very potent thyroid-inhibiting 
compounds 2-thiouracil (TU), 6-methyl-2-thiouracil (MTU), 6-
propyl-2-thiouracil (PTU), 6-phenyl-2-thiouracil (PhTU) and 1-
methyl-2-mercapto-imidazole (tapazole, TAP) [4-6]. The chemical 
structures of these substances are shown in Figure 1. 
 265 
The fraudulent use of thyreostats produces low quality 
meat. Moreover, the edible tissues derived from treated animals 
might represent a potential risk to the consumer’s health due to the 
presence of residues and their teratogenic and carcinogenic effects 
[7-11]. 
In 1981, the European Union banned their use in animal 
production both as growth promoters and therapeutic agents [12] 
and classified them as “substances having anabolic effects and 
unauthorized substances” belonging to the group A2 as described 
by the Council Directive 96/23/CE [13]. However, a relationship 
between the presence of Brassicaceae in feed and thiouracil in 
urine has been demonstrated by Pinel et al. [9], Vanden Bussche et 
al. [14] and Kiebooms et al. [15,16]. The Community Reference 
Laboratories (CRLs) in 2007 proposed a recommended 
concentration of 10 μg L-1 in urine and 10 μg kg-1in thyroid tissue 
for the purpose of control, as “low concentrations of thiouracil 
have been detected in bovine animals fed with cruciferous plants, 
however there is scientific evidence showing that levels above 10 
ppb in urine cannot be linked to natural origin due to this 
contamination” [17]. Recently, Wauters et al. reported 
concentrations of up to 18.2 μg L-1 in the 99% percentile from 3894 
bovines and they suggested that the recommended concentration 
should be increased to 30 μg L-1 [18]. In fact, the 2015 Italian 
National Residue Plan already provides this concentration as the 
limit of detection for thyreostats in urine [19].Thyreostats are polar 
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amphoteric thionamides with a heterocyclic tautomeric structure, 
and are mostly derived from thiouracil and mercapto-imidazole. 
The sequence consisting of nitrogen–carbon–sulphur, known as 
thioamide, is considered responsible for the thyroid-inhibiting 
activity (Fig. 1).  
 
 
Thyreostats analyses typically consist of separation 
methods based on gas or liquid chromatography associated with a 
mass spectrometry system of detection. Normally, the extraction 
of the substances is carried out by using polar solvents more 
suitable to the chemical characteristics of the thyreostats, such as 
methanol, acetonitrile or ethyl acetate. Further steps of purification 
or clean-up with different kinds of solid-phase extraction (SPE) 
have been reported. Due to the low molecular mass and high 
polarity of the thyreostats, several authors have proposed a 
derivatisation step before or after the clean-up, mainly by using 3-
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iodobenzylbromide (3-IBBr) in the case of HPLC-MS/MS 
analysis [6]. This procedure induces the stabilisation of the 
chemical structure of the molecule in a specific and single 
tautomeric form, the reduction of the molecular polarity in order 
to increase the separation characteristics on the reversed-phase 
column in the case of HPLC-MS detection, and an increase in the 
molecular mass [20]. However, its application before the analysis 
could cause a loss of analytes, particularly due to the multiple 
evaporation steps required. Furthermore, removing derivatisation 
step simplifies and shortens the whole analysis procedure [21,22]. In 
this paper, we describe the extraction without derivatisation of the 
five above-mentioned thyreostats in bovine urine and thyroid 
glands followed by a sensitive, specific and reproducible HPLC-
MS/MS analysis. For the full identification and quantification of 
the analytes, the criteria established in the 2002/657/EC 
Commission Decision were followed [23] and the decision limit 
(CCα) and the detection capability (CCβ) were calculated 
according to the matrix calibration curve procedure as clarified in 
the document SANCO/2004/2726 rev. 4 [24]. 
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3.5.3. Materials and methods 
3.5.3.1. Reagents and chemicals 
All solvents were of HPLC-MS grade quality and 
purchased from Fluka (Sigma-Aldrich, St. Louis, MO, USA). 
Formic acid (98–100%) was from Riedel-de Haën (Sigma-
Aldrich). Ultrapure water was obtained through a Milli-Q system 
(Millipore, Merck KGaA, Darmstadt, Germany). KH2PO4 and 
NaCl were from Sigma-Aldrich. The analytes 2-thiouracil (TU), 
6-methyl-2-thiouracil (MTU), 6-propyl-2-thiouracil (PTU), 6-
phenyl-2-thiouracil (PhTU), 2-mercaptobenzimidazole or tapazole 
(TAP) were acquired from Sigma-Aldrich, as well as 5,6-
dimethyl-2-thiouracil (DMTU), used as internal standard (I.S.). A 
stock solution of 1 mg/mL was prepared by dissolving the 
compounds in methanol. Serial dilutions were prepared by diluting 
the stock solution in the mobile phase, which were then stored at 
−40°C.  
Phosphate buffer, prepared by dissolving 0.25 M 
KH2PO4 in ultrapure water, was adjusted to pH 7 and then 
saturated with 0.1% DL‐dithiothreitol (DTT; Sigma‐Aldrich) as 
in Vanden Bussche et al. [11]. 
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3.5.3.2. Sample collection 
Urine and thyroid gland samples from Friesian Cows 
aged 32 to 63 months were collected in a Lombard abattoir after 
slaughtering, immediately frozen and taken to the laboratory for 
storage at –40°C until analysis.  
3.5.3.3. Sample extraction  
Urine  
One millilitre of bovine urine was transferred to a 15-mL 
glass tube and spiked with 10 ng of internal standard (DMTU) in 
order to give a final concentration of 10 μg L-1, then vortexed and 
left for 5 minutes to equilibrate. The samples then underwent 
denaturation conditions at 65°C for 30 min, after the addiction of 
1 mL of PBS buffer with 0.1% DTT at pH 7. NaCl (2 g) was added 
to the solution to mixture as a salting-out reagent.  
The extraction was performed by twice repeating these 
steps: addition of 5 mL tert-butyl methyl ether, centrifugation at 
2000 x g for 5 min at 4°C, and collection and transfer of the upper 
organic layer to a 10-mL polypropylene tube. The extract was 
dried under vacuum in a rotary evaporator apparatus (Heidolph 
Instruments GmbH & Co., Schwabach, Germany) at a temperature 
of 40°C. The residue was dissolved in 200 µL of the mobile phase 
(methanol: 0.1% aqueous formic acid, v/v 50:50) and transferred 
to vials for HPLC. The injection volume was 10 µL. 
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Thyroid gland  
The thyroid gland samples were minced with surgical 
scissors and homogenised. The sample (1 g) was weighed in a 
polypropylene tube and 10 ng of internal standard (DMTU) were 
added, and then the sample was vortexed and left for 5 minutes to 
equilibrate, then 5 mL of methanol was added. The samples were 
vortexed, placed in an ultrasonic bath for 10 min and then 
centrifuged at 2000 x g at 4°C for 10 min. The organic liquid 
supernatant was then filtrated and transferred to a 15-mL glass 
tube and 5 mL of PBS buffer with 0.1% DTT at pH 7 were added. 
The samples underwent denaturation conditions at 65°C for 30 
min. NaCl (4 g) was added to the solution as a salting-out reagent. 
Tert-butyl methyl ether (2 x 10 mL) was added. The sample was 
centrifuged at 2000 x g for 5 min at 4°C. The upper organic layer 
was collected and transferred to a 50-mL glass evaporating flask. 
Lastly, the extracts were combined and dried under vacuum in a 
rotary evaporator apparatus at 40°C. The residue was dissolved in 
200 µL of the mobile phase and transferred to vials for the 
autosampler. The injection volume was 10 µL. 
3.5.3.4. HPLC-MS/MS analysis 
A Synergi Hydro RP reverse-phase HPLC column C18 
(150 x 2.0 mm, i.d. 4 µm) with a C18 4 x 3.0 mm guard column 
(Phenomenex, Torrance, CA, USA) at a column oven temperature 
of 30oC was used for the separation, which was performed by an 
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HPLC system that included a Surveyor MS quaternary pump with 
a degasser, a Surveyor AS autosampler with a column oven, and a 
Rheodyne valve with a 20-μl sample loop (Thermo Fisher 
Scientific, San Jose, CA, USA). The mobile phase consisted of 
0.1% aqueous formic acid (solvent A) and methanol (solvent B), 
and the flow rate was set at 200 L/min. The gradient program is 
shown in Table 1. The overall run time was 30 minutes.  
 
Table 1. Gradient table for HPLC method 
 
The HPLC system was connected to a TSQ Quantum 
(Thermo Fisher Scientific, San Jose, CA, USA) triple-quadrupole 
mass spectrometer with an electrospray interface (ESI) set in the 
positive (ESI+) ionization mode. The acquisition was made in the 
multiple reaction-monitoring (MRM) mode. The specific 
acquisition parameters of all the analytes were optimised by means 
of direct infusion of standard solutions of the analytes at a 
concentration of 1 g/mL, a flow rate of 50 g/mL and a flow rate 
of the MS pump of 100 g/mL. The capillary voltage was 3.2 kV; 
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the capillary temperature was 340°C; nitrogen was used as the 
sheath and auxiliary gas at 30 and 10 arbitrary units, respectively, 
and argon as the collision gas at 1.5 mTorr; peak resolution was 
0.70 Da FWHM. The parent ions, product ions, and collision 
energy values for each analyte are shown in Table 2. The scan time 
for each monitored transition was 0.1 s and the scan width was 0.5 
amu. The mass spectrometer data acquisition and processing were 
carried out using Xcalibur™ 2.0.7 SP1 software from Thermo 
Fisher Scientific Inc. 
 
 
Table 2. MS/MS conditions for the MRM acquisitions of analytes and 
the internal standard. Ions for quantification are in bold. 
 
3.5.3.5. Method validation  
The HPLC-MS/MS method was validated according to 
the guidelines of Commission Decision 2002/657/EC [23]. 
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Specificity, instrumental linearity, precision (intra-day and inter-
day repeatability), recovery (accuracy), measurement of 
uncertainty, decision limit (CCα) and detection capability (CCβ) 
were assessed.  
MS identification criteria were verified throughout the 
validation study by monitoring relative retention times, signal-to-
noise ratios (S/N) and ion ratios. The instrumental linearity was 
evaluated through calibration curves in solvent at six levels, (1.0, 
5.0, 10, 20, 50, 80, 100 μg L-1) and 10 μg L-1 of DMTU as I.S. 
The method validation parameters were determined with 
fortified blank urine and thyroid gland samples at three 
concentration levels (5.0 , 10, 15 μg L-1 and μg kg-1) in six 
replicates on three different days (6 samples × 3 concentration 
levels × 3 series = 54 analyses). Method recovery and precision 
were evaluated using the matrix curves; recovery is calculated as 
ratio between the measured concentration to fortified 
concentration and expressed in percentage, and precision in terms 
of intra- and inter-day repeatability expressed as the coefficient of 
variability (CV). The same data from the matrix calibration curves 
were used to calculate the decision limit (CCα) and the detection 
capability (CCβ) according to the matrix validation curve 
procedure described in the Commission Decision 2002/657/EC 
and clarified in the document SANCO/2004/2726-rev. 4 [23,24].  
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3.5.4. Results and Discussion 
Thiouracil may be considered a semi-endogenous 
compound, and its ‘natural’ presence at concentrations lower than 
10 μg L-1 in urine of untreated animals is associated with a 
cruciferous-based diet [6,14]. The development of a simple, rapid 
and sensitive method for the detection of thyreostats in matrices of 
bovine origin is required and mandatory, particularly to 
discriminate between illicit treatment and the natural origin of 
thiouracil in bovine urine and thyroid glands. The performed 
method uses a simple liquid–liquid extraction, preceded by a 
deconjugation step, and allows for the determination of TAP, TU, 
MTU, PTU, PhTU and DMTU in only one chromatographic run 
at concentration levels suitable for monitoring purposes. 
3.5.4.1. Sample preparation 
Despite the diversity of the matrices analysed, we carried 
out two similar methods to prepare urine and thyroid glands in 
order to have the same steps for each matrix.  
Regarding the denaturation step, as reported by Vanden 
Bussche et al. [11], the cleavage of the disulfide bonds of the 
proteins in urine can be performed by the addition of a reducing 
agent, such as DTT. The protocol developed in the present work 
follows this suggestion for both urine and thyroid glands.  
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The polarity of the thyreostats requires the use of an 
organic polar solvent to extract them from the matrices: we 
evaluated the applicability of different solvents by several tests 
using ethyl acetate, chloroform and tert-butyl methyl ether. 
Comparing the signal intensity of the analytes extracted with the 
three different solvents, tert-butyl methyl ether was chosen as the 
best solvent for the extraction. The poorest results were obtained 
by the extraction performed with ethyl acetate by which we could 
not extract most of the thyreostats. 
In order to facilitate the phase separation and to reduce 
the miscibility of the analytes in the aqueous phase, this protocol 
adopted the approach of salting-out-assisted liquid–liquid 
extraction (SALLE), adding salt (NaCl) prior to the liquid–liquid 
extraction to favour the transfer of the analytes into the organic 
solvent [25-27]. 
3.5.4.2. Method validation 
The analytical procedures developed were subjected to 
the validation process according to the Commission Decision 
2002/657/EC and clarified in the document SANCO/2004/2726-
rev. 4 [23,24]. 
The HPLC–MS/MS-reconstructed chromatograms 
together with the ion spectra of the thyreostats in solvent (10 μg L-
1) and of the thyreostats in urine and thyroid glands are shown in 
Figures 2 and 3, respectively. DMTU as the internal standard (10 
μg L-1) is also reported. The chromatograms show the absence of 
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interference peaks at the expected retention times of the 
thyreostats, hence illustrating a good specificity and selectivity of 
the method. The analytes were detected and confirmed based on 
their proper relative retention times and their ion ratios. The 
relative retention times were within a tolerance limit of 2.5% and 
the relative ion intensities were within the maximum permitted 
tolerances [28]. 
 
 
LC-MS/MS chromatograms and ion spectra of thyreostats in solvents at a final 
concentration of 10 μg L-1. 
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LC-MS/MS chromatograms and ion spectra of a blank urine (A) and thyroid 
gland (B) sample spiked with thyreostats at a final concentration of 5 
μg L-1 and μg kg-1, respectively. 
 
For the HPLC-MS/MS confirmation of substances listed 
in Group A of Annex I of Directive 96/23/EC [13], a minimum of 
four identification points (IPs) is required. In the present work, we 
monitored five products ions with the highest intensity [23]. Each 
one of the five product ions is equal to 1.5 IPs, making a total of 
7.5 IPs. The ion giving the highest signal-to-noise ratio was 
selected for the quantification. The MRM transition intensities 
were compliant with the maximum tolerances permitted. The 
parameters obtained for the method validations are given in Tables 
3, 4 and 5. Linearity was verified by using squared correlation 
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coefficients (r2): The regression coefficients of the curves that 
were built to check the instrumental linearity were higher than 
0.982, which indicates a satisfactory linearity for all the analytes. 
Good linearities were also achieved in urine and in thyroid glands 
and showed values higher than 0.978 and 0.973, respectively, thus 
demonstrating a suitable and adequate correlation between the 
concentration and the acquired response in the sample for both 
matrices. The precision of the method, which was calculated by 
applying one-way analysis of variance (ANOVA), was evaluated 
in terms of intra- and inter-day repeatability, and is expressed as 
the coefficients of variation (CV) from the replicate samples. Their 
values were lower than 22%, as proposed by Thompson [28], 
demonstrating an acceptable precision for the method. The 
recoveries showed good values ranging from 96% to 104% in 
urine and from 96% to 104% in thyroid glands. The results 
regarding the precision and recovery of TAP are noteworthy both 
in urine and the thyroid glands. The CV values are better than those 
reported in the literature, as are the recovery values. In particular, 
the highest values of the recovery could be due to the decrease in 
the number of the evaporation steps that may cause of considerable 
losses of TAP, as suggested by Abuìn et al. [21]. 
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Table 3. Analytical performance (method trueness and precision) data for 
thyreostat determination in urine. 
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Table 4. Analytical performance (method trueness and precision) data for 
thyreostat determination in thyroid glands. 
 
The decision limit (CCα) and detection capability (CCβ) 
are very important, debated and decisive points to evaluate. For the 
estimation of these values, the document of the Commission 
Decision 2002/657/EC (2002) explains both the definition and 
procedure. However, the approach proposed in the document to 
evaluate these limits – based on the extrapolation of the calibration 
curve procedure according to ISO 11843 – may lead to an 
underestimation of the parameters, as already explained by 
Galarini et al. [29] and other Authors [31-32]. 
 
 281 
 
Table 5. Decision limits (CCα) and detection capabilities (CCβ) calculated for 
thyreostats in urine and in thyroid glands. 
 
Therefore, CCα (and, consequently, CCβ) was 
determined using a parallel extrapolation to the x-axis at the lowest 
experimental concentration as clarified in the document 
SANCO/2004/2726-rev. 4 [24]. Decision limits achieved with this 
approach were thus experimentally determined, and therefore not 
underestimated. A comparison with previously published data 
concerning the detection of non-derivatised thyreostats should 
consider the differences in the method of CCα determination. 
Table 5 shows the obtained CCα and CCβ values, which are lower 
than the minimum required performance limits (MRPLs) proposed 
in the CRL guidance document of 2007 in urine and in thyroid 
glands [17]. Moreover, the TAP analytical limits are lower than 
those reported in literature for the two matrices, such as MTU in 
the thyroid gland [11,21,22,31]. Finally, it is worth noting that the 
validation parameters obtained with our method are comparable 
between the two different matrices. 
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3.5.5. Conclusion 
The methods for the simultaneous direct identification 
and quantification of five thyreostats without derivatisation in both 
urine and thyroid gland samples were specific and sensitive. 
Moreover, the validated methods guarantee a better performance 
for TAP in both matrices than those reported in the literature. The 
choice to develop a method without derivatisation and clean-up 
steps was made due to the advantages in terms of costs and the 
time of analysis. The simultaneous determination of five 
thyreostats in two matrices using similar methods could be useful 
to make comparative analyses more reliable, because the process 
variables are the same for urine and thyroid glands.  
Furthermore, the measurement of the endogenous TU in 
urine and thyroid is possible as the analytical limits are all below 
10 μg L-1  and 10 μg kg-1, and particularly considering that the CCα 
– which was determined as clarified by the document 
SANCO/2004/2726-rev. 4 [24] – is not an estimate, but an 
experimentally verified concentration with all the characteristics 
required by the Commission Decision 2002/657/EC [23]for a 
substance to be quantified.  
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General conclusion and research 
prospective 
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4. General conclusions and research perspective 
Boldenone, prednisolone and thiouracil (as main 
representative of the thyreostats) are substances well known to be 
fraudulently used in livestock for fattening purposes. Despite their 
different chemical classes, hormones (boldenone and 
prednisolone) and thyreostats, these substances share a common 
feature: a double identity, both exogenous and endogenous, as to 
be considered pseudoendogenous or with semi-natural origin [1-3].  
Nowadays, the approaches to investigate the illicit use of 
a substance are qualitative, by the identification of the substance 
or its metabolites of interest in the analysed matrix, and 
quantitative, based on a cut-off level of concentration for the 
detection of an eventual abuse. However, the detection of the illicit 
treatment of the so-called pseudoendogenous and semi-natural 
substances is challenging and represents a problem for official 
control, because the approach of the “zero tolerance” appears to 
not be valid for these substances. Additionally, a continuous 
improvement of the techniques to detect the presence of drug 
residues that leads to a decreasing of the detection limits has to 
deal with the difficulty to understand when a sample should be 
considered compliant or non-compliant under a certain 
concentration. 
During the three years of doctoral fellowship, my whole 
research has been dedicated to a better comprehension of these 
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substances, trying to give a contribution to the development of new 
methods to analyse them, and to understand their nature. 
In particular, we have dealt with the problem of the 
origins of these substances considering the following questions: 
I. “Where particular steroids are 
believed not to be endogenous in an 
animal at a particular limit of 
detection (LOD), who is to say that 
as analytical limits decrease, they 
will not be discovered as 
endogenous at a lower 
concentration? [4]”  
II. Is it still valid the “zero tolerance” 
for the pseudoendogenous and 
semi-natural substances? 
III. Based on literature, a proper 
sampling procedure allows a 
decrease of the probability of false‐
positive results to boldenone and 
prednisolone. The sampling 
procedure as well as the all the 
events associated to the 
slaughtering (transport, blood 
smell, fear) are now thought as 
essential factors to take into 
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account in case of monitoring and 
official control. In the context of 
steroids analysis, one of the main 
element to study seems to be the 
stress. Therefore, a question arises: 
has the stress always a positive 
influence in the eventual presence 
of these substances in urine?  
1)  The improvement of the analytical methods requires a 
constant research of the best technique and 
methodologies to perform in each step of the analysis. 
Very clear extracts, without any interferences due to 
the matrix, combined with a sophisticated and specific 
chromatographic separation, and sensitive system of 
detection, as a triple quadrupole, are all elements 
necessary to achieve optimal analytical performances. 
The application of new methods allows to obtain 
higher sensitivity and specificity values and, 
consequently, a reducing of the decision limits (CCα). 
Considered the chemical proprieties of our analytes of 
interest and the techniques described in scientific 
literature, we have developed and optimized new 
analytical methods that gave advantages in terms of 
time of execution, cost, and very satisfactory 
analytical performances. The detection capabilities 
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(CCα) calculated for the research of β-bold sulfate and 
β-bold glucuronide were for both metabolites 0.07 ng 
mL-1. In the chapter 3.1. our purpose was to improve 
the analytical techniques in order to carry out a further 
study on the investigation of boldenone II phase 
metabolites in urine of young bulls. The ability to 
detect low concentrations, as a result of the 
methodological advancement, allowed to observe 
significant presence of β-bold sulfate and glucuronide 
in urine samples of bovine in different conditions and 
degree of stress.  
A technical improvement was also realised for the 
detection of prednisolone (CCα calculated of 0.07 ng 
mL-1) in the study included in the chapter 3.4., 
regarding its possible endogenous origin in urine of 
pigs. While concerning the CCα of prednisolone for 
adrenal glands of pigs was of 0.12 ng g-1.  
The development of new simple method for the 
detection of thyreostats has been carried out 
considering the chemical properties, chromatographic 
behaviour of the analytes, and the characteristics of 
the two matrices studied (urine and thyroid glands) in 
order to detect them without the most common 
derivatisation procedure that is generally performed 
(Chapter 3.5.). Therefore, all thyreostats showed CCα, 
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both in urine and in thyroid glands, below the 
recommended concentration of 10 ng mL-1 in urine 
and 10 ng g-1 in thyroid glands. The decision to avoid 
the step of derivatisation led to CCα not extremely 
low, if compared to the values already reported in 
literature. However, it is worth of note that the method 
to calculate the decision limit is not homogenous in 
all laboratory. We chose to determine the CCα as 
explained by the document SANCO/2004/2726-rev. 4 
[5]. Therefore, our limits were experimentally verified, 
already useful for an eventual quantification of the 
substances. 
 
2)  During the early years of this decade, several EU 
Member States reported an increase in the frequency 
of detection of boldenone (mainly as α-bold) in urine 
of cattle [6]. In particular, the so-called “boldenone 
problem” was deeply felt in Italy. In the course of the 
biennium, 2001 and 2002, within the framework of 
the Italian National Residues Plan, a considerable 
number of urine samples of calves was confirmed 
positive to α-bold and, less, to β-bold [7]. 
Then, data provided by the Italian National Residue 
Plan between the years 2008-2008, stated an alarming 
rise in the occurrence of prednisolone residues in 
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cattle [8]. Afterward, the probably endogenous nature 
of prednisolone has been also proposed for horse and 
human. In the Belgian Residue Control Plan in 2011 
and 2012 urines of pigs were found positive for 
prednisolone, and a study performed by the Belgian 
Federal Agency for the Safety of the Food Chain 
(FASFC) revealed that out of 393 porcine urine 
samples taken at the slaughterhouse, a percentage of 
73% was found positive for prednisolone[9].  
Recently, low levels of thiouracil in urine of cattle 
were frequently registered in the ordinary frameworks 
of different EU Member States [10,11]. 
Based on data reported, threshold levels for α-bold 
and prednisolone in urine of cattle, and thiouracil in 
urine and thyroid gland of bovine were proposed, 
apparently violating the politics of zero tolerance 
limits regarding banned substances as boldenone and 
thiouracil.  
As described in chapter 3.1 and 3.2., a technical 
development and a resultant reduction of the 
analytical limits, allowed to found a significant 
naturally presence of β-bold sulfate and glucuronide 
in urine samples of bovine, suggesting that β-bold 
sulfate is not an indicator of treatment at the farm. 
Further study could establish cut-off levels for β-bold 
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II phase metabolites. The zero tolerance for a 
pseudoendogenous substance as boldenone is 
probably to re-evaluate because of its natural origin. 
By the other hand, there are no data in literature 
regarding eventual promoting effects of these 
substances at the “natural “levels. Our study, reported 
in the chapter 3.2. on 56 calves, revealed that no 
significant morphological alterations to the sexual 
organs and associated glands were detected in the 
examined animals. Therefore, it could be concluded 
that the content in steroid may be so low as not to be 
sufficient to determine a fattening effect. 
A neo-formation of prednisolone can occur in 
feedstuff for cattle, as discussed in chapter 3.3. 
Therefore, eventual ingestion of feedstuff rich of the 
prednisolone may be a reason of non-compliant 
response for the investigation of prednisolone. Due to 
the low possibility of modifying the storage 
conditions at the farms, the studies that would indicate 
objective parameters, e.g. a cut-off level or metabolite 
markers, highlighting the need for the definition of the 
prednisolone metabolic precursors in the feedstuffs 
and the nature of their origin. 
In chapter 3.4, the high frequency of detection of 
prednisolone in urine samples and, mainly, in the 
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adrenal glands permitted to confirm the endogenous 
presence of prednisolone in pigs and its positive 
relationship with cortisol, explained with several 
statistically considerations. Additionally, based on the 
significant sample size of the animals and following 
the calculations proposed for cattle, a cut-off value 
equal to 1.51 ng mL-1 for prednisolone in porcine 
urine was also suggested.  
 
3)  The most interesting element of our researches was 
the opposite influence of the stress in the behaviour of 
boldenone in bovine and prednisolone in pigs. 
In Chapter 3.2., the endogenous presence of β-bold 
sulfate and glucuronide was demonstrated in urine 
from young calves collected in two different times of 
sampling corresponding to different degree of stress: 
medium and low levels of stress. No sample positive 
for boldenone has been found in the most intense 
moment of stress, which is at the slaughterhouse. 
Surprisingly, our preliminary hypothesis, that 
proposed the stress as a positive factor for the 
occurrence of boldenone in urine, has been 
completely overturned and a negative influence of 
stress on boldenone endogenous production may be 
now more plausible. 
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Based on the results obtained in our study, the 
presence β-bold sulfate and glucuronide in urine 
collected at the slaughterhouse may be used as marker 
of fraudulently use of boldenone with the purpose to 
distinguish treated and untreated animals. This study 
could suggest a different parameter to evaluate a case 
of abuse of boldenone contrary to what Le Bizec and 
Destrez reported, who indicated β-bold sulfate as a 
candidate marker of unequivocally evidence of abuse 
of boldenone [12, 13].  
Hence, it is necessary to formulate a hypothesis 
explaining the absence of the detection of boldenone 
in urine collected at the slaughterhouse.  
More studies should be performed to investigate the 
relationship between cortisol and boldenone in order 
to understand if an eventual ratio between the two 
steroids might be useful to define a condition of illicit 
use of boldenone. 
While, regarding prednisolone occurrence in pigs, the 
results obtained in the study reported in Chapter 3.4. 
confirmed the positive role of stress in the excretion 
of prednisolone, as already see in cattle [2]. 
 
Further studies could be also carried out on non-conventional 
matrices as hair, which is now considered worth of note for the 
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advantages that it offers: easily sampling, possibility to detect the 
administrated compound, large window of time of detection of 
substances to be monitored after administration. The segmental 
analysis of the hair could permit to define the timing of the 
administration [14]. Other matrices are now very interesting to 
evaluate, as bile that was recently studied for the investigation of 
steroids in bovine because of the ease of sampling and for the 
accumulation of residues of drugs occurring [15,16]. 
At present, the “omics” technologies, comprising the analysis of 
the metabolic pathways in order to obtain the entire metabolic 
profile of the steroid and the analysis carried out with gas 
chromatography coupled to combustion/isotope ratio mass 
spectrometry (GC-C/IRMS) would seem as a promising approach 
for tracing the abuse of boldenone and evaluate its endogenous 
nature. Besides, a great contribute to the understanding of the 
metabolism, biochemical reactions and nature of the molecules, is 
given by the study of the metabolomics untargeted fingerprinting 
of biological matrices depending on several mass spectrometric 
techniques (MS–MS, HRMS, and hybrid HRMS systems). This 
approach as well may be significantly advisable in order to 
evaluate a useful marker to discriminate between the endogenous 
occurrence and exogenous administration of a compound [17].  
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